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THE UNIVERSITY OF MANCHESTER 
 
Abstract of thesis submitted by Jemima Lois Whyte for the degree of Doctor of 
Philosophy entitled ‘Density dependent differentiation of mesenchymal stem cells 
to endothelial cells’ September 2010. 
 
The differentiation of mesenchymal stem cells (MSCs) to endothelium is a critical but 
poorly understood feature of tissue vascularisation and considerable scepticism still 
remains surrounding this important differentiation event. Defining features of endothelial 
cells (ECs) are their ability to exist as contact-inhibited polarised monolayers that are 
stabilised by intercellular junctions, and the expression and activity of endothelial 
markers.  
 
During vasculogenesis, communication between MSCs and differentiated ECs or 
vascular smooth muscle cells, or between MSCs themselves is likely to influence MSC 
differentiation. In this study, the possibility that cell density can influence MSC 
differentiation along the EC lineage was examined. High density plating of human bone 
marrow-derived MSCs induced prominent endothelial characteristics including 
cobblestone-like morphology, enhanced endothelial networks, acetylated-low density 
lipoprotein uptake, vascular growth and stimulated expression of characteristic 
endothelial markers.  
 
Mechanistically, this density-dependent process has been defined. Cell-cell contact-
induced Notch signalling was a key initiating step regulating commitment towards an EC 
lineage, whilst VEGF-A stimulation was required to consolidate the EC fate. Thus, this 
study not only provides evidence that MSC density is an essential microenvironmental 
factor stimulating the in vitro differentiation of MSCs to ECs but also demonstrates that 
MSCs can be differentiated to a functional EC. Taken together, defining how these crucial 
MSC differentiation events are regulated in vitro, provides an insight into how MSCs 
differentiate to ECs during postnatal neovascularisation and an opportunity for the 
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therapeutic manipulation of MSCs in vivo, enabling targeted modulation of 
neovascularisation in ischaemia, wound healing and tumourigenesis. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Adult stem cells 
 
Stem cells are generally defined as clonogenic, undifferentiated cells capable of self-
renewal and able to give rise to one or more types of differentiated cell progeny (Barry et 
al  2003). Embryonic stem cells (ESCs) are pluripotent, that is, they have the ability to 
give rise to cell types and tissues of all three germ layers of the body (ectodermal, 
mesodermal and endodermal origins) and they are capable of unlimited proliferation in 
an undifferentiated state (Stojkovic et al ., 2004). Adult mesenchymal stem cells (MSCs) 
however are much more committed, persisting throughout life and capable of 
differentiating into a more restricted number of cell lineages and subsequent tissues of 
predominantly mesodermal origin (Kolf et al., 2007). Such tissues include bone 
(Friedman et al ., 2007), cartilage (Baksh et al ., 2004; Tuan et al ., 2003; Hardingham et 
al ., 2006; Oldershaw et al., 2008), fat (Hong et al ., 2005; Jakkaraju et al ., 2005; 
McBeath et al ., 2004), tendon (Altman et al ., 2002) and muscle, for example vascular 
smooth muscle (Dezawa et al ., 2005; Li et al ., 2006). More recently however, MSCs 
were shown to be capable of differentiating along neural (ectodermal) (Dezawa et al ., 
2004) and endothelial  lineages (Al-Khaldi et al ., 2003; Alviano et al ., 2007; Bai et al ., 
2009; Chen et al ., 2009; Chung et al ., 2009; Lozito et al ., 2009a; b; Ohata et al., 2009;  
Oswald et al ., 2004; Silva et al ., 2005;  Wu et al ., 2005; Xu et al ., 2009; Yue et al ., 
2008; Zhang et al ., 2008) (Figure 1.1).  
 
Adult stem cells have been shown to occupy specific niches within most human tissues 
and organs, including bone marrow (BM), heart, brain, adipose tissues, muscles, skin, 
eyes, kidneys, lungs, liver, gastrointestinal tract, pancreas, breast, ovaries, prostate, 
testis, umbilical cord and vascular walls (Baksh et al ., 2004; Chen et al ., 2009; Crisan 
et al ., 2008; Mimeault et al ., 2006; 2007). The best characterised adult stem cells are 
the BM-derived stem cells, which mainly comprise haematopoietic stem cells (HSCs) 
and MSCs, as well as cardiac stem cells  and neural stem cells that are localised in 
heart and brain, respectively (Mimeault et al ., 2006). This introduction focuses on  
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Figure 1.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Bone marrow MSCs can be induced to a number of different cell lineages in vitro 
(A) Schematic showing how MSCs can be isolated from a number of different cell types within the 
bone marrow stroma (black arrow) and induced either chemically or following exposure to vascular 
growth factors to differentiate to a number of different cell types in vitro. A micrograph of red bone 
marrow containing haematopoietic tissue is depicted in B and is taken from 
www.aamdsglossary.co.uk. 
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current understanding of the differentiation of adult MSCs along vascular cell lineages. 
 
1.2. Mesenchymal stem cells (MSCs) 
 
1.2.1. Tissue origin of MSCs 
 
Considerable inconsistency has occurred between the nomenclature and biological 
properties of MSCs. Recently the terms multipotent mesenchymal stromal cells and 
mesenchymal progenitor cells have also been coined as alternative nomenclature for 
MSCs. (Erices et al, 2000; Horwitz et al, 2005). In this thesis, MSCs refers to the plastic-
adherent cells isolated from BM with multipotent differentiation capacity in vitro as 
defined by Caplan et al, 1991 and Dominici et al, 2006.  
 
MSCs have been located in BM, umbilical vein, muscle, trabecular bone, adipose tissue, 
dermis, periosteum, adult peripheral blood, synovial membrane, periodontal ligament, 
liver, lung, deciduous teeth and vascular walls (van Vliet et al ., 2007; Schaffler et al ., 
2007; Dhawan et al ., 2005; Peault et al ., 2007; Beltrami et al., 2003; Leri et al ., 2005; 
Kim et al ., 2005a; Brittan et al ., 2002; Griffiths et al ., 2005; Bussolati et al ., 2005; 
Herrera et al ., 2006; Koblas et al ., 2007). MSCs are typically isolated from the stromal 
fraction of adult BM, and most insights into their biological properties and characteristics 
have been obtained from BM-derived MSCs. Aside from being one of the first 
documented sources of MSCs, BM is considered to be one of the most enriched and 
accessible stem cell sources. Murine MSCs are obtained from the femurs and tibias of 
mice by flushing the marrow out of these bones with culture medium, then selecting and 
expanding the MSC population by cell culture techniques. Human MSCs can similarly be 
obtained by taking aspirates of BM from the iliac crest of donors (Barry et al, 2003). 
 
BM is the flexible tissue found in the hollow interior of bones. There are two types of BM: 
yellow BM (a complex heterogeneous cellular milieu forming a niche comprising HSCs, 
adipocytes, osteoblasts, endothelial cells (ECs), endothelial progenitor cells (EPCs), 
vascular smooth muscle cells (vSMCs), and MSCs) and red BM (comprising red blood 
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cells, platelets and most white blood cells). Both types of BM contain numerous blood 
vessels and capillaries (see Figure 1.1). The stroma of the BM is all tissue not directly 
involved in haematopoiesis (The formation of blood cell components) which includes the 
yellow BM, in addition to stromal cells located in the red BM (Wilson et al ., 2006). In 
fresh BM, MSCs account for only 0.01-0.0001% of nucleated marrow cells (Barry et al, 
2003). However the BM is still considered the most accessible and enriched source of 
MSCs. Although rare, MSCs serve many important functions within the BM, including 
providing mechanical support for the differentiating HSCs in marrow, and regulating the 
maturation of haematopoietic cells. In addition, MSCs also play a role in the 
maintenance of tissues in the adult organism, being involved in the repair of 
microfractures of bone that occur on a daily basis, as well as repairing more occasional 
bone fractures (Shanti et al., 2007). In response to injury, a number of studies have 
shown how MSCs can be mobilised from the BM leading to subsequent migration, 
engraftment and differentiation at sites of postnatal neovascularisation. Growth factors 
and cytokines such as vascular endothelial growth factor (VEGF) have been strongly 
implicated as signals that mediate this response (Figure 1.2) (Mace et al ., 2009; Moore 
et al ., 2001; Raafi et al ., 2002) 
 
1.2.2. Characterisation of MSCs 
 
The cellular heterogeneity of the BM means that, in order to isolate populations of 
MSCs, other contaminating cell types must be removed. One simple method of isolating 
MSCs relies on the fact that MSCs selectively adhere to plastic surfaces, whereas 
haematopoietic cells do not adhere and can therefore be removed through culture 
medium changes. Alternatively, mononuclear cells can be sorted based on their density 
and enriched by centrifugation over a Percoll gradient (Barry et al, 2003). However these 
methods are relatively crude; and more specific methodologies employ antibodies 
directed against defined cell surface expressed antigens to isolate selected populations 
of MSCs. These techniques may involve sorting BM populations by fluorescence 
activated cell sorting, or magnetic bead based sorting applications, either by positively 
  
 - 21 - 
Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. MSCs are recuited from the bone marrow to sites of neovascularisation. 
Schematic diagram showing MSC recruitment from the bone marrow to sites of postnatal 
neovascularisation. Once MSCs reach these sites it is thought that they differentiate to ECs and 
such differentiation events are largely controlled by microenvironmental factors present within 
these environments including vascular growth factors. 
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selecting for MSC cell surface antigens and/or by immuno-depletion of cells expressing 
haematopoietic and/or other lineage antigens (Baksh et al ., 2004). Typically, cell 
surface markers used to identify the MSC fraction include CD13, CD29, CD44, CD54, 
CD63, CD73, CD105, CD106, CD140b, CD166 and Stro-1 (Dominici et al ., 2006; 
Delorme et al ., 2008). However, none of these epitopes individually is considered a 
specific marker for MSCs since they have also been detected in a range of differentiated 
mesenchymal cell types. To date, no single marker that definitively designates MSCs in 
vivo or in vitro has been identified, leading to significant difficulties in identifying MSCs 
during their isolation and purification. Many groups have reported varying degrees of 
heterogeneity in their MSC cultures after isolation and purification, resulting in different 
expansion and differentiation capabilities (Ho et al ., 2008; Shanti et al ., 2007; Phinney 
et al ., 2007b).  
 
1.2.3. Differentiation potential of MSCs 
 
As previously mentioned, MSCs have the potential to differentiate into a restricted 
number of cell lineages of mesodermal origin including bone, cartilage, fat and muscle 
(Figure 1.1). It is important to note that different populations of MSCs are heterogenous 
in terms of their multilineage differentiation potential. For instance, it has been reported 
(Baksh et al ., 2004) that only one-third of BM-derived MSC clones are multipotent, 
having the capacity to differentiate to osteogenic, chondrogenic and adipogenic 
lineages, whilst the remainder displayed a bi-lineage (osteogenic/chondrogenic) or uni-
lineage osteogenic potential (Figure 1.3). In addition, a subset of MSCs has been 
identified which appeared to possess pluripotency, giving rise to adipocytes, osteoblasts, 
chondrocytes, endothelial cells, skeletal and cardiac muscle cells, neural cells, 
hepatocytes and epithelial cells (Baksh et al ., 2004; Charbord et al., 2010). However, 
these cells are extremely rare and may arise from fusion with cells in contact with MSCs, 
cell reprogramming or the selection of rare vestigial embryonic stem cells that have 
homed to the bone marrow (Charbord et al., 2010). Recent data indicates that 
proliferating MSCs may be primed to the adipogenic, osteogenic, chondrogenic and 
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Figure 1.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. MSCs are heterogenous in terms of their multilineage differentiation potential. 
 MSCs comprise cell populations which have different differentiation potentials (i.e., 
quadrapotential, tripotential, bipotential or uni-potential) (Baksh et al ., 2004). Using appropriate in 
vitro differentiation culture conditions, all or a subset of these MSCs may be isolated.  
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 vascular lineages, endogenously expressing a subset of genes associated to the 
differentiation pathways to which they can commit (Delorme et al., 2009). The 
differentiation potential of MSCs can vary throughout life, with older cells generally 
having a more limited differentiation potential. In addition, species differences, such as 
human cells compared to murine cells, the tissue source of the cells, such as BM 
compared to umbilical vein, and variations in isolation and culture techniques can all 
contribute to differences in MSC differentiation capacity. There are currently no culture 
conditions that have been described which can maintain MSC multipotency over time. 
Because of the lack of ability to distinguish and separate multi, bi and unipotent cells, directed 
differentiation currently is unlikely to give homogenous populations for regenerative purposes 
(Kaltz et al., 2010). Recently, genome wide gene expression analysis identified novel 
markers enriched in unipotent MSCs capable of differentiating only to osteoblasts 
(integrin subunit alpha II) or in bipotent MSCs capable of differentiating to both 
adipocytes and osteoblasts (Notch3). These studies may facilitate the development of 
more homogenous MSC populations for cell therapy (Kaltz et al., 2010). The intrinsic 
ability of MSCs to self-renew or to differentiate into different cell types, has generated 
much excitement and promise as a potential source of cells for cell-based therapeutic 
strategies. Stem cell therapy can be defined as the treatment of disease by the 
mobilisation or transplantation of autologous (donor and host (recipient) are the same) or 
allogeneic (donor and host are different) stem cells into a host. It is noteworthy that 
neither autologous nor allogeneic MSCs induce any significant immunoreactivity in the 
host upon local transplantation or systemic administration, since studies indicate that 
MSCs are immune-privileged with low major Histocompatibility Complex I and no major 
Histocompatibility Complex II (Uccelli et al., 2007). Some striking examples of the 
therapeutic use of MSCs have been reported, both in mammals and in humans covering 
a broad spectrum of disorders (Mimeault et al ., 2006; Li et al., 2009a; Sasaki et al ., 
2008; Shoji et al., 2010; Xu et al ., 2010; Wakabayashi et al ., 2010; Zhang et al ., 
2010)). 
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1.2.3.1. Osteogenic differentiation of MSCs 
 
Bone formation (osteogenesis) is a complex process involving three main steps: the 
production of the extracellular organic matrix (osteoid); mineralisation of the matrix to 
form bone; and bone remodelling by resorption and reformation. The cellular activities of 
osteoblasts, osteoblasts, and osteoclasts are essential to the process. Osteoblasts 
synthesise the collagenous precursors of bone matrix and also regulate its 
mineralisation (Caplan et al ., 2001). Osteogenic differentiation of MSCs can be induced 
in vitro by treating a monolayer culture with osteogenic differentiation media, standardly 
composed of dexamethasone, ascorbic acid-2-phosphate and β-glycerophosphate. 
Mineralised deposits and an osteoblastic morphology can appear after a week, 
accompanied by an increase in bone-specific alkaline phosphatase (ALKP) activity and 
the activation of bone-specific genes such as osterix, core binding factor α1, 
osteopontin, osteocalcin and bone sialoprotein (Barry et al, 2003). Recently, osteogenic 
differentiation has also shown to be regulated by the bone morphogenetic proteins 
(BMPs) 2 and 6 (Caplan et al ., 2001; Friedman et al ., 2006), as well as environmental 
factors including morphogenetic signals from chondrocytes, (Zachos et al ., 2006; 
Solursh et al ., 1975; Gerstenfeld et al ., 2002; 2003) exposure to hypoxia (1% oxygen) 
(Potier et al ., 2007) and collagen types I and III (Kundu et al ., 2006; Jager ., 2005). 
Osteogenic differentiation can be demonstrated by von Kossa staining, a stain for 
calcium in mineralised tissue which utilises silver nitrate solution followed by sodium 
thiosulphate. Calcified bone but not osteoid is stained brown to black. Alternatively 
alizarin red staining can be utilised to detect calcium deposits (Zachos et al ., 2006).  
 
1.2.3.2. Chondrogenic differentiation of MSCs 
 
The formation of cartilage, or chondrogenesis, is an orchestrated molecular and cellular 
process that shapes musculoskeletal tissues during embryogenesis (Goldring et al ., 
2006). This complex process is controlled by cellular interactions with the surrounding 
matrix, growth and morphogenetic factors, and other environmental cues that modulate 
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cellular signalling pathways and transcription of specific genes in a temporal-spatial 
manner. Chondrogenesis can be chemically induced by forcing aggregation of 200,000 
to 300,000 MSCs in chondrogenic medium, usually containing the presence of 
dexamethasone, ascorbic acid phosphate, bovine insulin, transferrin, selenous acid, 
linoleic acid and bovine serum albumin (Barry et al, 2003). Further additives to the 
medium include sodium pyruvate, proline, L-glutamine and transforming growth factor 
(TGF-β) 1 (Goessler et al ., 2005; Mauck et al ., 2006). The TGF-β superfamily such as 
TGF-β1, TGF-β2, insulin-like growth factor-1 (Longobardi et al ., 2003) and the BMPs 
seem to play a crucial role in inducing and maintaining chondrogenic differentiation 
(Reddi et al, 1994; Hunziker et al, 2000; Worster et al ., 2000). Environmental factors 
such as morphogenetic signals from chondrocytes (Hwang et al ., 2007) and hyaluronan 
(Grigolo et al ., 2003) have also been shown to be involved in chondrogenic 
differentiation. In the majority of these studies, chondrogenic differentiation has been 
characterised by the emergence of cartilage-specific markers, such as the expression 
and deposition of collagen type II (Col2A1), collagen type IX (Col9A2), aggrecan, and 
other sulphated proteoglycans (Mauck et al ., 2006).  
 
1.2.3.3. Adipogenic differentiation of MSCs 
 
Adipogenesis can be chemically induced by treating MSCs twice weekly for three weeks, 
with a medium supplemented with dexamethasone, isobutylmethylxanthine, insulin and 
a peroxisome proliferation activated receptor gamma (PPARγ) agonist. Alternatively, 
adipogenesis can be stimulated by three cycles of three days in culture with induction 
medium (contains indomethacin), followed by three days in maintenance media 
(contains insulin) (Jackson et al ., 2007). BMP7 has also been shown to stimulate 
adipogenesis using a serum-free high-density micro-mass culture, a differentiation 
system that favours chondrogenic development (Neumann et al ., 2007). Adipogenic 
differentiation can be determined by screening for a series of genes shown to increase 
with adipogenic differentiation, including PPARγ, CCAAT enhancer-binding protein-α, 
acylCoA synthetase, lipoprotein lipase, and Adipocyte protein 4 and 2 (AP2/AP4). The 
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formation of lipid droplets can also be specifically stained with fresh Oil Red-O solution 
or Sudan Red. Alternatively, staining can be performed for Bodipy493/503 which stains 
lipid droplets green and immunostaining for fatty acid binding protein 4 (FABP-4) (Sekiya 
et al ., 2004). 
 
1.2.3.4. Myogenic and neural differentiation of MSCs 
 
MSC differentiation towards muscle and neural cells has been less well characterised, 
however, MSCs can be chemically differentiated in vitro to a cardiomyocyte-like 
phenotype by treatment with medium containing 5-azacytidine (10 µmol/l), basic 
fibroblast growth factor (10 µg/l), and amphotericin (0.25 mg/l) for two weeks (Barry et al, 
2003). In addition, Wnt3a (Shang et al ., 2007) and a muscle-specific micro-RNA, 
miRNA206 (Kim et al ., 2006), have also been shown to be sufficient to induce myogenic 
differentiation in MSCs by activating the muscular regulatory genes Pax3, Pax7, MyoD, 
Myf5, myogenin and the major Histocompatibility Complex. Damaged rat skeletal muscle 
is endowed with the capacity to induce myogenic differentiation of BM-derived 
mesenchymal progenitors. Conditioned medium prepared from skeletal muscle 
previously damaged by a barium chloride injection, resulted in a time-dependent change 
from fibroblast-like into elongated multinucleated cells. A transient increase in the 
number of MyoD positive cells, and the subsequent onset of myogenin, α-actinin, and 
myosin heavy chain expression occurred (Santa Maria et al ., 2004). Direct cell-cell 
contact of rat MSCs with either cardiomyocytes or SMCs also invoked MSC 
differentiation, as judged by their expression of a panel of cardiomyocyte markers 
including α-actin, desmin and cardiac Troponin T (Wang et al ., 2006; Xu et al., 2004). 
These findings indicate that either physical contact or soluble chemical factors can 
determine the differentiation fate of MSCs. 
 
Mesenchymal-like cells from umbilical cord blood have been shown to be capable of 
differentiation towards neural cells, with this capability being mediated through the 
protein kinase A signal transduction pathway. Whilst activation of protein kinase A via 
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experimental cyclic adenosine monophosphate-activated protein up-regulation led to 
outgrowth of neurite-like structures as well as expression of neural marker genes, 
blocking protein kinase A activity completely abolished all these features (Wang et al ., 
2007a). Neuron-like morphologic changes and neuronal markers (growth-associated 
protein-43, neuron-specific nuclear protein and neurofilament 200 kDa) have also been 
shown in MSCs cultured for ten days with different neurotrophic factors, including brain-
derived neurotrophic factor, epidermal growth factor and neural growth factor (Choong et 
al ., 2007).   
 
1.2.3.5. Vascular differentiation of MSCs 
 
MSC differentiation towards vascular cell lineages is controversial and the mechanisms 
regulating MSC differentiation to vascular cells are ill defined, however it is becoming 
increasingly recognised that MSCs make an important contribution to promoting 
postnatal vascularisation during ischaemic myocardial tissue regeneration, wound 
healing and tumour vasculogenesis. It is therefore crucial to understand mechanisms 
controlling MSC differentiation into vascular cells to enable their therapeutic 
manipulation. The vasculature and its resident cells will be described (see Chapter 1: 
Introduction; section 1.4), followed by the current understanding of the vascular 
differentiation potential of MSCs.  
 
1.3. Biological roles of MSCs 
 
1.3.1. Involvement of MSCs during tissue repair 
 
It has been well documented that MSCs are involved in revascularisation of injured 
tissues such as in a wound site, during ischaemic myocardial tissue regeneration and 
also during pathological situations such as in tumour neovascularisation (Liechty et al., 
2000; Toma et al., 2002; Nagaya et al., 2004). Myocardial infarction or coronary artery 
occlusion induces tissue ischaemia, resulting in the permanent loss of a proportion of 
cardiomyocytes and a compromised contractile function of the remaining cells. Several 
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studies have shown that local administration of human MSCs into the infarcted 
myocardium resulted in their differentiation towards cardiomyocytes, mediated by 
platelet derived growth factors (PDGFs) signalling through the PDGF receptors 
(PDGFRs), (PDGF-AB induced PDGFRαα and/or PDGFRαβ), which improved cardiac 
function (Liechty et al ., 2000; Toma et al ., 2002). Furthermore, MSC administration also 
stimulated revascularisation of the injured myocardium, presumably influenced by 
VEGF-A released from the ischaemic tissue (Nagaya et al ., 2004). Thus VEGF-A 
signalling is a crucial determinant in regulating the recruitment and incorporation of 
MSCs into new blood vessel walls, which may also subsequently control the 
differentiation of MSC into ECs. As well as MSCs being regulated by VEGF-A, MSCs 
may also be an important source of VEGF-A during neovascularisation. MSCs can 
secrete several arteriogenic factors, such as VEGF, which may stimulate 
neovascularisation from pre-existing arterial vessels (Kinnaird et al ., 2004).  
 
During pathological situations such as tumour vasculogenesis, the formation of tumour 
blood vessels and associated connective tissue stroma is regulated by VEGF-A, which is 
expressed by the majority of human tumours. As the tumour enlarges above one to two 
millimetres in size, an increase in the level of hypoxia leads to increased VEGF-A 
expression, which stimulates blood vessel formation to provide nutrients and oxygen for 
growth. Several studies have documented that MSCs are involved in tumour 
vasculogenesis, being actively recruited to areas of blood vessel growth 
(neovascularisation), and differentiating into platelet endothelial adhesion molecule-1 
(PECAM-1) positive, von Willebrand factor (vWF) positive endothelial-like cells (Annabi 
et al ., 2004). MSCs have been shown to significantly enhance vascularisation in a 
murine tumour models, engrafting into tumour lesions and becoming incorporated into 
the tumour stroma (Studeny et al ., 2002; Hung et al ., 2005). 
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1.3.2. Contribution of MSCs to vasculogenesis  
 
In the adult, two separate mechanisms are responsible for driving neovascularisation. In 
the first, differentiated vascular cells derived from pre-existing vessels are utilised, a 
process known an angiogenesis. The second involves the recruitment of undifferentiated 
BM-derived cells and is known as vasculogenesis. During angiogenesis, ECs in pre-
existing blood vessels are activated by VEGF, and such activation leads to local EC 
proliferation and migration to form new vessel sprouts, then primitive tubular vascular 
structures. These immature vascular structures subsequently secrete PDGF-BB, 
inducing proliferation and recruitment of PDGFRβ-positive mural cells (vSMCs or 
pericytes), from vessel walls (Ball et al ., 2007a). These mural cells surround and coat 
the immature endothelial tubes, promoting EC survival, stability and maturation 
(Hellstrom et al ., 1999). 
 
Adult vasculogenesis in contrast is driven by local tissue hypoxia and this is presumed to 
be mediated by increased VEGF release (Tepper et al., 2005). Local VEGF release 
creates a chemoattractive gradient, which has been shown to mobilise BM-derived 
EPCs into the circulation, where they form tubular vessels and connect to the existing 
vasculature (Asahara et al., 1999). During severe hypoxia, such as at a wound site, 
within a tumour environment or in ischaemic tissue disease, it is proposed that a 
proportion of neovascularisation occurs by vasculogenesis and may involve MSCs.  
 
During vasculogenesis, MSC recruitment and differentiation has been demonstrated to be 
mediated by VEGF-induced signalling. However as previously reported, MSCs may not 
express cell surface VEGF receptors (VEGFRs) (Asahara et al ., 1999), therefore such 
signalling is likely to occur by VEGF-induced PDGFR signalling (Ball et al ., 2007c). 
 
1.4. The vasculature  
 
The adult vascular system is composed of arterial, venous and lymphatic compartments, 
which together provide oxygen and nutrients to peripheral organs, remove carbon 
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dioxide and waste products and maintain an immune barrier to defend the host against 
foreign organisms. The vascular system comprises an organised hierarchical structure of 
arteries, capillaries and veins. The capillary bed is composed solely of ECs, occasionally 
associated with an outer covering of pericytes. These simple capillary tubes are 
surrounded by a basement membrane. Larger blood vessels such as arteries have three 
distinct cellular layers (Figure 1.4). ECs and the subendothelial extracellular matrix 
(ECM) form the intimal layer (tunica intima), which is surrounded by an outer ring of 
vSMCs interspersed with elastic fibres that is known as the medial layer (tunica media). 
An outer adventitial layer (tunica adventitia) encases the blood vessel and is composed 
primarily of fibroblasts and collagen-rich connective tissue (Eichmann et al ., 2005). The 
size of the vessel wall varies according to the location and function, for example the 
aorta is subject to high intra-vessel pressures hence there is a need for elastic recoil and 
thick vessel walls. In comparison, veins are subject to low intra-vessel pressure and 
therefore have thin vessel walls. 
 
1.4.1. Endothelial cells (ECs) 
 
All blood vessels are lined with ECs and these cells are thought to derive from a 
common Flk-1 +ve/ E-cadherin +ve mesodermal precursor (Figure 1.5). Haemogenic 
endothelial cells are specified from cells already expressing endothelial markers, which in turn 
generate blood cells (Eilken et al., 2009). EPCs are thought to derive from a non 
haematopoietic origin (Urbich et al ., 2004; Khakoo et al ., 2005; Ribatti et al ., 2007). 
However, controversy exists with respect to the identification and the origin of ECPs, 
which are isolated from peripheral blood mononuclear cells by cultivation in medium 
favouring endothelial differentiation (Urbich et al ., 2004; Khakoo et al ., 2005). Overall, 
there is consensus that EPCs can derive from the BM and that CD133/VEGFR2 cells 
represent a population with endothelial progenitor capacity. However, evidence suggest 
that there are additional BM-derived cell populations (e.g. myeloid cells) within the blood, 
which also can give rise to ECs (Schmeisser ., 2001). Moreover, non-bone marrow-
derived cells with endothelial characteristic were isolated from the peripheral blood. This  
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Figure 1.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Schematic diagram of the structure of blood vessels. 
ECs form a lumen in blood vessels. They can either exist in a simple organisation surrounded by a 
basal lamina as in a vein (examples include the human umbilical vein endothelial cells (HUVECs) 
or as a relatively more complex organisation surrounded by layers of mural cells as in an artery 
(examples include the human coronary artery endothelial cells (HCAECs). The ECs and basement 
membrane constitute the tunica intima, the thick ring of vSMCs encasing the endothelial layer 
constitutes the tunica media while the outer layer of fibroblasts and connective tissue constitutes 
the tunica adventitia. The black box depicts ECs. The lower panels depict two different cross 
sectional images of arteries, one at low magnification (taken from http://blog.lib.umn.edu) and one 
at high magnification (taken from http://cccla.hostrocket.com) depicting the different intimal, medial 
and adventitial layers.  
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Figure 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Specification pathways during generation of endothelium and blood cells 
Upon appropriate cytokine stimulation, Flk1 +ve/ E-cadherin +ve mesodermal cells differentiate 
into endothelium. Haemogenic endothelial cells are specified from cells already expressing 
endothelial markers, which in turn generate blood cells (Adapted from Eilken et al.,  2009) 
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might represent shed mature ECs or other ECs deriving from other progenitor cell 
populations (Urbich 2004; Ribatti ., 2007).The functions of ECs are diverse; they do not 
just form a passive barrier. They can actively transport small molecules, macromolecules 
and hormones such as insulin, and degrade lipoprotein particles (Bouis ., 2001; Pinkney 
., 1997). Furthermore, ECs play major roles in blood pressure regulation, blood 
coagulation and fibrinolysis (Cines ., 1998), adhesion and transmigration of inflammatory 
cells out of the vessel into the target tissue. Additionally, ECs are the primary cell type 
responsible for angiogenesis, the formation of new blood vessels from pre-existing 
vasculature, during physiological and pathological neovascularisation. EC functions can 
vary considerably depending on their localisation and the size of the blood vessels they 
constitute. Human umbilical vein endothelial cells (HUVECs) found in a venous 
environment will differ considerably from human coronary artery endothelial cells 
(HCAECs) found in an arterial environment, in their morphology, expression of markers 
and ability to perform endothelial functional tests. 
 
Whilst ECs may have heterogeneous characteristics, they also display a “typical” 
phenotype and function (Figure 1.6). Firstly, most form monolayers that are stablilised by 
cell-cell junctions giving them a characteristic ‘cobble-stone’ morpology (Bazzoni et al., 
2004). They contain Weibel-Palade bodies, which are large rod-shaped organelles 
specific to ECs. Weibel-Palade bodies store large amounts of vWF, also known as factor 
VIII related antigen; that can quickly be released upon activation of the cells. vWF is a 
large adhesive glycoprotein specific to ECs, which serves as a stabilising carrier for 
factor VIII with which it circulates as a complex. vWF secretion can be constitutive or 
regulated, and may occur in the absence of Weibel Palade bodies. Secretion of vWF is a 
key characteristic of ECs (Weibel et al ., 1964; Ewenstein et al ., 1987; Edgell et al . 
1983). Secondly, the expression of intracellular adhesion molecules (ICAMs), vascular 
cell adhesion molecule (VCAM) and E-selectin are also up-regulated upon EC activation, 
and vascular endothelial cadherin (VE-cadherin) and PECAM-1 are expressed at the 
cellular junctions (Pober et al ., 1986; Dejana et al, 2004). In addition, the expression of 
specific cell surface receptor tyrosine kinase (RTK) receptors can serve to identify ECs.  
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Figure 1.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Organisation of endothelial cell–cell junctions. 
(A) ECs adhesion is mediated by transmembrane proteins that promote homophilic interactions 
and form a pericellular zipper-like structure along the cell border. ECs express cell-type-specific 
transmembrane adhesion proteins, such as VE-cadherin at adherens junctions, shown by red 
immunostaning in B and claudin-5 at tight junctions, the glycoprotein vWF involved in factor VIII 
binding is depicted in green. Outside specialised junctional structures, ECs express other cell-
specific homophilic adhesion proteins including PECAM-1, shown by green immunostaining in C. 
Scale bar = 7μm. PECAM-1 is also present in leukocytes and platelets and mediates leukocyte 
diapedesis. Together these cell-cell contacts stabilise ECs forming monolayers displaying a typical 
cobblestone morphology shown in D. Scale bar = 100μm. Images were taken using a Nikon 
upright C1 confocal microscope (60× objective) or an Olympus (CK X41 microscope (10× 
objective). 
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For instance, the receptor Tie2 is expressed by ECs as well as HSCs and, together with 
its ligand angiopoietin-1, is essential for both angiogenesis and EC survival (Claesson-
Welsh., 2003). ECs also express three different VEGFRs, named VEGFR1 (Flt-1), 
VEGFR2 (KDR/Flk-1) and VEGFR3 (Flt-4). The expression of the VEGFRs is almost 
exclusively restricted to ECs, but VEGFR1 can also be expressed on many other cells 
including monocytes (Salmonsson et al ., 2003), humal dermal fibroblasts (HDFs) as 
well as some populations of vSMCs (Ishida ., 2001). Specific functions which may serve 
to identify ECs include binding of the Ulex europaeus lectin agglutinin 1 (Holthofer et al ., 
1982), uptake of acetylated low-density lipoprotein (ac-LDL) (Voyta et al ., 1984), 
histamine induced release of vWF, angiotensin converting enzyme activity, induction of 
VCAM-1 in response to tumour necrosis factor α (TNFα) and nitric oxide release 
(Johnson et al ., 1977). 
 
1.4.2. Vascular smooth muscle cells (vSMCs) 
 
Vascular smooth muscle refers to a specific type of smooth muscle found within blood 
vessels and the gut. In blood vessels, SMCs comprise the major cell type within the 
medial layer. vSMCs maintain blood vessel tone by pulsatile contraction, to both change 
the volume of blood vessels and the local blood pressure, a mechanism that is 
responsible for redistributing blood within the body to areas where it is needed (i.e. areas 
with temporarily enhanced oxygen consumption) (Conway et al., 2001). Thus the main 
function of vascular smooth muscle tonus is to regulate the calibre of the blood vessels 
in the body. Excessive vasoconstriction leads to hypertension, while excessive 
vasodilation leads to hypotension. Unlike most other adult cells, vSMCs are not 
terminally differentiated, but exist as a continuum of phenotypes ranging from synthetic 
to contractile. Synthetic vSMCs are proliferative, migratory and express abundant ECM 
molecules, but few contractile proteins, representing an immature phenotype commonly 
found in pathology (Ball et al ., 2007a; Owens et al, 1995). In contrast, contractile 
vSMCs are quiescent, contractile and express few ECM molecules but abundant 
contractile proteins, representing a more differentiated phenotype as found in the medial 
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layer of adult blood vessels (Ball et al ., 2004). Vascular smooth muscle profoundly 
differs from SMCs of digestive, respiratory and urogenital tract, in that it contains a 
number of different SMC contractile proteins, such as smooth muscle alpha actin (α-
SMA), vascular smooth muscle-myosin heavy chain 1 (SM-MHC-1) and smoothelin-B 
(Ball et al ., 2004; Stephan et al ., 2006). Whilst there is no individual protein that defines 
vSMCs, the complement of contractile proteins characterises the vSMC phenotype. As 
the cell becomes more differentiated, it acquires an increasingly complex array of 
contractile components (Ball et al ., 2007a). 
 
1.4.3. Vascular extracellular matrix 
 
The ECM is a highly organised structural network of proteins and polysaccharides, that 
provides a set of instructive molecular signals to cells that are attached to it. Much of the 
information content of the vascular ECM resides in the insoluble collagenous and non-
collagenous glycoproteins (e.g., collagens VIII, VI, XV, elastin, vitronectin, proteoglycans 
and fibronectin) and together with the basement membrane is known as the 
subendothelial extracellular matrix. ECs reside on basement membranes in which the 
primary components are laminin, collagen type IV and perlecan, a heparan sulphate 
proteoglycan, whilst vSMCs interact with elastic fibers in the medial layer indicating 
these ECM molecules may be important in mediating MSC differentiation towards 
vascular cells (Hayden et al ., 2005). 
 
Cellular interactions with ECM molecules are primarily mediated by integrins, a family of 
heterodimeric cell adhesion receptors that provide both a physical bridge and a 
biochemical link integrating the outside and inside of the cell. Integrins are composed of 
an α and β chain, and different α and β chain combinations facilitate selective binding to 
different ECM ligands. The level of integrin-mediated receptor signalling regulation will 
depend on the local ECM composition, together with the abundance and type of cell 
surface integrins expressed. Specific ECM-integrin interactions have been shown to 
modulate RTK signalling. For instance, vitronectin induced αvβ3/PDGFRβ and 
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αvβ3/PDGFRα complexes (Woodard et al ., 1998; Baron et al ., 2002), whilst collagen 
type I induced a α2β1/PDGFRβ complex (Hollenbeck ., 2004), all of which increased 
PDGF stimulated responses. In addition, membrane associated proteins such as 
sphingosine-1-phosphate (Tanimoto et al .,2004) and membrane-type 1 matrix 
metalloproteinase 14 (Lehti et al ., 2005) have been shown to modulate PDGF/PDGFR 
signalling. It is therefore possible for a particular RTK, such as PDGFR, to transmodulate 
its signalling by forming different complexes with other membrane associated proteins. 
Furthermore, ligand stimulation of either PDGFRα or PDGFRβ can induce the 
recruitment, activation and interaction with different complements of intracellular 
signalling molecules (Klinghoffer et al ., 2001). Thus, different vascular ECM molecules 
can modulate RTK signalling and may regulate the activity of effectors such as 
intracellular enzymes and transcription factors, resulting in distinct cellular responses. 
 
1.5. Differentiation of MSCs along vascular lineages 
 
Several studies have indicated that MSCs are involved in revascularisation of tissues 
after vascular injury. MSCs have been documented to be involved in revascularisation of 
the injured myocardium in myocardial ischaemia (Tang et al, 2005a), wound healing 
(Satoh et al ., 2004), and to contribute to tumour neovascularisation, where they may 
also engraft into tumour lesions and become incorporated into the tumour stroma (Ball et 
al ., 2007a).  Many of these studies have suggested that, at these sites of injury, MSC 
differentiation is regulated by local microenvironmental factors such as the composition 
of the ECM, the bioavailability of growth factors and cytokines, and local mechanical 
forces. 
 
1.5.1. Differentiation of MSCs towards ECs 
 
The contribution of BM-derived cells to tumour neovascularisation in animal models is 
highly variable, ranging from near to 100% to virtually negligible (Annabi et al., 2004). In 
a murine tumour model, VEGFR2-negative MSCs were shown to be actively recruited to 
  
 - 39 - 
areas of neovascularisation, where they differentiated into PECAM-1-positive 
endothelial-like cells and increased vascularisation (Annabi et al ., 2004). In addition, 
MSCs systemically administered into a murine tumour model were shown to localise and 
engraft into tumor lesions, where they proliferated, differentiated into vWF and PECAM-
1-positive endothelial-like cells, and formed a significant fraction of the tumour stroma 
(Hung et al ., 2005). 
 
Previous studies have reported that differentiation can be induced by cultivation of 
confluent human MSCs following exposure to VEGF (Al-Khaldi et al ., 2003; Alviano et al 
., 2007; Bai et al ., 2009; Chen et al ., 2009; Chung et al ., 2009;  Oswald et al., 2004;  
Wu et al ., 2005; Xu et al., 2009; Zhang et al ., 2008). One group demonstrated that 
human BM-derived MSCs positive for CD105, CD73, CD166, CD90 and CD44, but 
negative for CD34, CD133, VEGFR1, VEGFR2, VE-cadherin, VCAM-1 and vWF could 
be induced to differentiate towards ECs after seven days culture in 2% fetal calf serum 
supplemented with VEGF-A (Oswald et al ., 2004). A second study using human term 
amniotic membrane MSCs positive for CD105, CD73, CD29, CD44, CD166 and 
negative for CD14, CD34, CD45, demonstrated a spontaneous differentiation into 
endothelial-like cells induced by in vitro culture on Matrigel, a basement membrane 
extract derived from the Engelbreth-Holm-Swarm mouse tumour on which MSCs 
spontaneously form networks and this differentiation was enhanced by VEGF-A 
exposure (Alviano et al ., 2007). Similarly, in a third study, human BM-derived MSCs, 
positive for CD105, CD166, but negative for CD34, VEGFR2 and vWF, expressed the 
endothelial marker vWF following five days culture in 10% fetal calf serum supplemented 
with VEGF-A (Wu et al ., 2005). However, these in vitro studies have not convincingly 
demonstrated MSC differentiation to ECs only analysing the expression of a limited 
number of markers or functional tests. Thus, MSC differentiation to ECs is not widely 
accepted and remains controversial. 
 
1.5.2. Differentiation of MSCs towards vSMCs 
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As mentioned above, vSMCs profoundly differ from SMCs of digestive, respiratory and 
urogenital tract by the presence of additional SMC-specific contractile component 
proteins, such as α-SMA, SM-MHC-1 and smoothelin-B. Several studies have 
demonstrated that MSCs can possess some inherent SMC-like characteristics. Human 
MSCs are similar to synthetic state vSMCs in their expression of several early contractile 
markers, α-SMA and calponin, as well as smoothelin-B, a novel marker for the mid 
differentiated contractile phenotype (Stephan et al., 2006). The transcription cofactor for 
serum response factor, myocardin, selectively binds to regions found in the promoters 
for several SMC genes, including α-SMA and SM-MHC-1, but not smoothelin-B (Du et al 
., 2003; Yoshida et al ., 2003). MSCs normally contain low levels of myocardin transcript, 
however when a myocardin adenovirus was transfected into MSCs, SM-MHC-1 was 
induced. Furthermore, serum response factor has also been shown to activate the small 
GTPase RhoA thereby promoting α-SMA gene expression (van Tuyn et al ., 2005). 
Recently PDGFR signalling has been implicated in determining vSMC fate of MSCs (Ball 
et al ., 2007b).  MSCs have a high ratio of PDGFRα:PDGFRβ, and PDGFRα signalling 
can activate RhoA through Rho-associated kinase dependent cofilin phosphorylation 
and myosin light chain kinase dependent pathways, resulting in enhanced α-SMA 
transcription and filament polymerisation. PDGF-BB mediated PDGFRβ signalling, 
however, was found to up-regulate RhoE, inhibiting RhoA-associated kinase and α-SMA 
filaments and inducing cofilin-mediated actin filament destabilisation (Ball et al ., 2007b). 
 
1.6. Regulation of the vascular differentiation of MSCs 
  
An important approach to elucidating the mechanisms involved in regulating MSC 
differentiation towards vascular cells is to selectively identify and examine in vitro 
specific environmental factors which may control MSC differentiation events. During 
neovascularisation in a wound, tumour or ischaemic injury, cellular exposure to local 
environmental factors en route or in situ or at these sites will be key elements in 
regulating the differentiation process. Such environmental factors will likely include 
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exposure to different types of cytokines and growth factors, vascular ECM molecules, 
cell-matrix and cell-cell interactions, cell density, mechanical strain, and oxygen tension. 
 
1.6.1. Growth factors 
 
1.6.1.1. VEGF and receptors  
 
VEGF is a homodimeric 34-42 kDa heparin-binding glycoprotein with potent angiogenic, 
mitogenic and vascular-permeability enhancing activities. The VEGF family consists of 
seven members, termed; VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and 
placental growth factor, which share a common structure of eight characteristically 
spaced cysteine residues in a VEGF homology domain. The main VEGF family member 
documented is VEGF-A, which induces angiogenesis and vasculogenesis in vivo and 
causes EC proliferation, sprouting, migration and tube formation (Li et al ., 2008a). 
VEGF-A has also been shown to stimulate vWF factor release from ECs and to be 
chemotactic for monocytes and osteoblasts in vitro (Cross et al ., 2003). In addition, 
VEGF-A induces angiogenesis in a variety of physiological and pathological conditions 
including embryogenesis, corpus luteum formation, tumour growth, wound healing, and 
compensatory angiogenesis in the heart (Ferrara et al., 2005). Furthermore, VEGF-A is 
known to promote EC survival by inducing the expression of the anti-apoptotic protein 
Bcl-2. VEGF-A mRNA expression is regulated by hypoxia, as it contains a hypoxic 
responsive element in its promoter (Matsumoto et al., 2001).  
 
VEGF-A mediates its responses primarily by activating the class III RTKs, VEGFR1 and 
VEGFR2 (expressed in ECs, as well as pericytes, placental trophoblasts, osteoblasts, 
monocytes/macrophages, renal mesangial cells and also in some HSCs) (Ferrara et al., 
2005). Two important alternatively spliced VEGF-A isoforms are VEGF-A165, which 
contains a heparin-binding domain, and VEGF-A121 which does not bind heparin. VEGF-
A165 binds to accessory neuropilin (NRP) co-receptors, NRP1 and NRP2, which are cell 
surface transmembrane glycoprotein receptors. Binding of VEGF-A165 to NRPs has been 
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shown to facilitate enhanced VEGFR mediated signalling (Claesson-Welsh et al, 2003) 
A novel VEGF-A signalling mechanism has been identified, whereby VEGF-A can 
directly stimulate PDGFR activation in BM-derived human adult MSCs that did not 
express VEGFRs (Ball et al ., 2007c).  
 
VEGFRs have seven extracellular immunoglobulin-like domains, a transmembrane 
region and a split intracellular kinase domain, which form receptor homodimers on ligand 
binding (Figure 1.7). Whilst VEGF-A binding to VEGFR1 induces only weak mitogenic 
signals in ECs, VEGF-A binding to VEGFR2 elicits strong signalling properties. As such, 
VEGFR2 is thought to be the primary receptor, which mediates VEGF-A induced 
signalling. However, VEGFR1 is associated with the recruitment and survival of BM-
derived progenitor cells. VEGFR1 expression has also been shown to be up- regulated 
during angiogenesis and by hypoxia, unlike that of VEGFR2 and VEGFR3 (Gerwins et al 
., 2000). The VEGF-A growth factor and its receptors act to facilitate neovascularisation, 
however the cellular response to these growth factors can vary according to growth 
factor availability, the duration of receptor exposure to the growth factor, and expression 
of different growth factor isoforms. Furthermore, growth factors can bind to and be 
sequestered by specific ECM molecules. Growth factor deposition within the ECM may 
create short range concentration gradients to facilitate chemotaxis. The composition of 
the ECM may therefore regulate the retention and presentation of bioactive ligands at 
the pericellular interface, thereby acting to modulate the intensity and/or duration of 
receptor signalling, resulting in distinct biological responses.  
 
1.6.1.2. PDGF and receptors  
 
The PDGF family consists of four ligands PDGFA-D, that form disulphide-linked 
homodimers (AA-DD). In addition, PDGF-A and PDGF-B can also form a heterodimer 
(AB). PDGF mediated biological actions occur via two structurally related but distinct 
RTKs, PDGFRα (170kDa) and PDGFRβ (190kDa), both comprising five immunoglobulin 
domains, a transmembrane region and a split intracellular kinase domain (Figure 1.8).  
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Figure 1.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Structure of the VEGF receptors 
VEGF receptors are shown spanning the plasma membrane. VEGFR1, VEGFR2, and VEGFR3 
are structurally homologous and consist of seven immunoglobulin homology domains in the 
extracellular region and a tyrosine kinase domain in the intracellular portion that is interrupted by a 
tyrosine kinase insert domain. A soluble form of VEGFR1 exists but is not shown. The extracellular 
domain of VEGFR3 is proteolytically cleaved in the fifth immunoglobulin-like domain and the 
fragments remain associated by disulfide bonds. Neuropilin 1 (NRP1) consists of a short 
intracellular domain and an extracellular domain containing two complement C1r/s homology 
domains, two domains with homology to coagulation factors V and VIII, and a single MAM domain. 
NRP2, also binds VEGF. The VEGF family members (represented as dimers) that interact with 
each receptor are indicated at the top of the figure and are represented in the diagram as dimers 
bound to the receptors.  
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On ligand binding, the receptors α and β can either homo- or hetero-dimerise into αα, αβ, 
and ββ combinations. Since the extracellular portion of these two receptors are only 31% 
identical, ligands have varying affinities for these different receptor combinations: PDGF-
AA binds only PDGFRαα, PDGF-CC and PDGF-AB bind either PDGFRαα or PDGFRαβ, 
PDGF-DD binds PDGFRαβ and PDGFRββ, while PDGF-BB binds all three receptor 
types. Binding of ligand causes receptor dimerisation and subsequent auto-
phosphorylation of tyrosine residues in the cytoplasmic domain of the receptor. This 
activated form of the receptor can then serve as docking sites for multiple protein 
complexes, leading to the initiation of signalling pathways including Ras-GTPase 
Activated Protein phosphatidylinositol 3-kinase, Src family kinases, and phospholipase-Cγ 
pathways (Claesson-Welsh et al, 1994; 1996; Westermark et al., 1990). PDGF-
B/PDGFRβ signalling is essential for regulating the migration and proliferation of mural 
(vSMC, pericyte) progenitor cells during vascular development (Hellstrom et al ., 1999). In 
addition, PDGF-B/PDGFRβ knockout studies revealed severe defects in vascular 
development, and subsequent death during the late embryonic stage (Leveen et al ., 
1994; Soriano et al, 1994). PDGF-A/PDGFRα signalling however is crucial for a wider 
variety of functions during both embryogenesis and organogenesis (Betsholtz et al, 
2004). PDGF-A/PDGFRα knockout mice are embryonic lethal, due to a range of 
mesenchymal tissue defects including vascular abnormalities (Betsholtz et al ., 2001). 
The PDGFR heterodimer (PDGFRαβ) may have a crucial role in mediating MSC 
differentiation events, since both in vitro and in vivo studies have demonstrated that 
PDGF-AB stimulation promoted the differentiation of adult BM-derived cells to 
cardiomyocytes (Xaymardan et al ., 2004). Furthermore, PDGF-CC, which can also 
stimulate PDGFRαβ, has been shown to be a potent angiogenic factor similar to VEGF-A 
(Cao et al ., 2002). It has been demonstrated that MSCs in vitro are defined by a high 
PDGFRα:β ratio, which could be a characteristic of relatively undifferentiated cells (Ball et 
al ., 2007a). Thus the cell surface PDGFR expression is likely to be an important 
determinant in mediating the fate of MSCs. Furthermore, recently it has been shown that 
NRP1 associates with phosphorylated PDGFRs, thereby regulating cell signalling, 
migration, proliferation and network assembly (Ball et al ., 2010a). 
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Figure 1.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Structure of the PDGF receptors. 
These receptors are transmembrane proteins that have an extracellular ligand-binding domain, a 
transmembrane domain, and a cytoplasmic tyrosine kinase domain. Extracellularly, each receptor 
contains 5 immunoglobulin-like domains, and intracellularly, there is a tyrosine kinase domain that 
contains a characteristic inserted sequence without homology to kinases. On ligand binding, 
PDGF receptors homodimerise or heterodimerise and phosphorylate each other on specific 
tyrosine residues, initiating signalling cascades. The binding interaction of mammalian PDGF 
ligands and PDGF receptors is shown, along with the receptor-binding specificity of the 5 PDGF 
and VEGF-A isoforms (rectangles). The ability of the five different dimeric isoforms of PDGF to 
bind and activate homodimeric and heterodimeric complexes of receptors are indicated with 
arrows. 
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1.6.2. Extracellular matrix 
 
The rigidity or elasticity of the matrix has been shown to play a key role in modulating 
MSC differentiation. Recently it has been shown that human MSCs grown on collagen I 
coated acrylamide gels (a soft extracellular environment) favours development of a 
neuronal phenotype, whereas moderate elasticity (compliance) promotes myogenic 
differentiation and a rigid extracellular environment results in osteogenic differentiation. 
Cells ‘sense’ matrix rigidity through their ability to transmit extracellular tension, 
mediated by focal adhesions and integrins which modulate intracellular tension within 
actin structures (Engler et al ., 2006). It is important to recognise that an in vitro two-
dimensional culture environment may modulate MSC differentiation differently, 
compared to a three-dimensional in vivo environment. As such, MSCs cultured within 
matrigel or fibrin gels may be useful in vitro model systems, more representive of three-
dimensional in vivo environments. Thus an important caveat to consider is that, since the 
majority of published MSC in vitro differentiation events have utilised two-dimensional 
tissue culture techniques, these studies are not fully representative of differentiation 
mechanisms occurring in vivo. 
 
1.6.3. Oxygen tension 
 
Low oxygen (hypoxic 1% O2) conditions within the BM provide an ideal niche for stem 
cells to proliferate and to maintain their stem cell phenotype (Ren et al ., 2006). Hypoxic 
conditions however, are also prevalent in the adult during vascular remodelling, such as 
angiogenesis in cancer (the formation of new blood vessels from a pre-existing 
vasculature), wound healing and ischaemic tissue disease. 
 
The molecular mechanisms of the cellular response to hypoxia are reasonably well 
understood. Under normoxia, the basic helix loop helix proteins designated hypoxia 
inducible factors (HIFs) HIF1α and HIF2α are hydroxylated at internal proline residues, 
and this hydroxylation creates a recognition site for binding of the Von-Hippel Lindau 
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protein. Following binding of Von-Hippel Lindau, HIFα subunits are rapidly degraded via 
the 26S proteosome, thereby preventing transactivation of HIF target genes under 
normoxia. During hypoxia however, prolyl hydroxylase enzymes which hydroxylate 
internal proline residues are inhibited since they utilise oxygen as a co-substrate. 
Unhydroxylated HIFα proteins escape recognition by Von-Hippel Lindau, and stabilised 
HIFα translocates to the nucleus where it binds its dimerisation partner to form an active 
transcription complex, thereby activating the transcription of close to 200 different genes. 
The resulting proteins are involved in a broad range of cellular processes, including cell 
proliferation and apoptosis (Insulin growth factor-2, TGF-α, TGF-β), gene expression  
and control of angiogenesis and vascular tone (VEGF, VEGFR2, Ang-2, Tie-2, and 
endothelin-1) (Hickey et al ., 2006). 
 
1.6.4. Mechanical strain  
 
The phenotype and morphology of MSCs are regulated not only by chemical factors, but 
also by mechanical forces such as fluid flow, shear stress and mechanical strain 
(Kobayashi et al ., 2004; Stohlberg et al ., 2009). The blood vessel wall is constantly 
subjected to cyclic mechanical strain in the circumferential direction due to the pulsatile 
nature of blood flow. Specific mechanical and chemical factors in the vascular 
microenvironment therefore may promote the differentiation of perivascular MSCs 
towards vascular cells (Ball et al ., 2010b; Buxboim et al ., 2010). Previous studies have 
shown that mechanical strain plays an important role in the remodelling of the vessel 
wall in vivo, and in the remodelling of tissue-engineered vascular grafts in vitro (Nerem 
et al ., 2001). Both equiaxial and uniaxial mechanical strain devices have been used to 
study cellular responses. One study investigated different modes of strain and showed 
that mechanical strain regulated gene expression in MSCs, with different modes of 
mechanical strain inducing different responses (Park et al ., 2004). Cyclic equiaxial strain 
downregulated α-SMA and smooth muscle protein 22-α in MSCs and decreased α-SMA 
filaments in stress fibers. In contrast, cyclic uniaxial strain transiently increased the 
expression of α-SMA and smooth muscle protein 22-α, which subsequently returned to 
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basal level after the cells aligned in the direction perpendicular to the strain direction 
(Park et al ., 2004). This study therefore shows that MSCs can sense the subtle 
difference between various types of mechanical loading in the microenvironment, and 
respond accordingly. Since the major mechanical stretch in the vessel wall is in the 
circumferential direction, uniaxial strain better simulates the in vivo condition, and thus 
may promote the differentiation of MSCs towards vascular cells.  
 
1.6.5. Cell-to-cell contact  
 
During vasculogenesis, contact and communication between differentiated ECs and 
uncommitted MSCs or between MSCs themselves may influence MSC differentiation. 
Although in healthy blood vessels, ECs are separated from other vascular cells by the 
internal elastic lamina, in injury and development ECs can be in direct contact with cells 
of mesenchymal origin. MSCs may “home” to specific repair sites in the vasculature 
where contact with local vascular cells may influence their phenotypic state.  
 
Direct co-cultures of human MSCs with ECs have previously been shown to lead to 
disruption of α-SMA filament organisation, suggesting decreased MSC contractility. 
Interestingly, co-culture of MSCs with fibroblasts leads to differentiation into 
myofibroblast-like cells (Ball et al ., 2004). Furthermore, direct cell-to-cell contact 
between rat MSCs and adult cardiomyocytes or SMCs is crucial in the differentiation of 
MSC into cardiomyocytes or SMCs (Xu et al ., 2004).  
 
These studies suggest that the local environment and resident cellular populations are 
major factors in determining MSC fate, with MSCs being specifically influenced by 
contact with differentiated cells or between MSCs themselves. A signalling pathway that 
may be crucial in mediating such cell-to-cell contact differentiation events is Notch 
signalling (Figure 1.9).  
 
1.6.5.1. Notch signalling 
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Notch signalling is characterised by transmembrane ligands and receptors, therefore 
signalling only occurs when cells are in close contact. Four mammalian Notch receptors 
(Notch 1–4) have been characterised in mammals. They bind to five ligands (Jagged 
(JAG) 1 and 2 and Delta-like (Dll) 1, 3 and 4) (Bray et al, 2006). The interaction between 
ligand and receptor leads to proteolytic cleavage and shedding of the extracellular 
portion of the Notch receptor. This process is followed by a second cleavage event by 
the enzyme gamma secretase resulting in membrane proteolysis that releases the 
intracellular part of the Notch molecule (NICD) from the cell membrane. The resulting 
intracellular Notch translocates to the nucleus, where it modulates transcription factor 
activity including hairy enhanced of split-1 (HES-1) and Hairy/enhancer-of-split related 
with YRPW motif 1 (HEY) by binding to the transcription factor recombination signal 
sequence-binding protein (also known as CBF-1/RJBk in mammals) (Yanjie et al ., 2007; 
Chiba et al, 2006; Bray et al, 2006) (Figure 1.9). Interestingly, many studies have 
reported that hypoxia can activate Notch-responsive promoters through interactions 
between the Notch intracellular domain and HIF-1 leading to increased expression of 
Notch downstream genes (Sainson et al ., 2006; Gustafsson et al ., 2005).  
 
Notch signalling has been demonstrated to play a critical role in both the differentiation 
and specification of the vasculature during development and homeostasis of vessels in 
the adult. Deletion of several Notch receptors and ligands by homologous recombination 
in mice results in embryonic lethality due to vascular and cardiac defects. In addition, 
several vascular abnormalities have been linked to Notch receptors and ligands (Alva et 
al  .,  2004; Bray et al, 2006; Opherk et al ., 2009) Notch signalling has been 
demonstrated to play a key role in enhancing MSC differentiation towards chondrocytes 
(Hardingham et al ., 2006) in defined differentiation medium. In addition, Notch signalling 
may, by modulating VEGF signalling, direct EC fate and coordinate the specification of 
arterial and venous ECs (Zhang et al ., 2008; Siekmann et al ., 2008). Furthermore, 
Notch activated experimentally over days in culture (Xu et al ., 2009), or during vascular 
development (Ohata et al ., 2009) can enhance endothelial differentiation from 
mesenchymal precursors. 
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Figure 1.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Model of the Notch signalling pathway.  
Four mammalian Notch receptors (Notch 1–4) have been characterised in mammals. They bind to 
five ligands (Jagged (JAG) 1 and 2 and Delta-like (Dll) 1, 3 and 4) (Bray et al, 2006). The 
interaction between ligand and receptor leads to proteolytic cleavage and shedding of the 
extracellular portion of the Notch receptor. This process is followed by a second cleavage event by 
the enzyme gamma secretase resulting in membrane proteolysis that releases the intracellular 
part of the Notch molecule (NICD) from the cell membrane. The resulting intracellular Notch 
translocates to the nucleus, where it modulates transcription factor activity including hairy 
enhanced of split-1 (HES-1) and Hairy/enhancer-of-split related with YRPW motif 1 (HEY) by 
binding to the transcription factor recombination signal sequence-binding protein (also known as 
CBF-1/RJBk in mammals). The Notch signalling inhibitor N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-
S-phenylglycine t-butyl ester (DAPT) which inhibits gamma secretase and the Notch activators 
recombinant Jagged-1 and EDTA are also depicted. 
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 1.7. Summary  
 
Currently very little is known about the differentiation of MSC along vascular cell 
lineages. While several studies provide evidence for the differentiation of MSCs towards 
vSMCs and differentiation to ECs, it is now increasingly accepted that MSCs also make 
a significant contribution to postnatal vasculogenesis in many in vivo situations. A major 
determinant in regulating the differentiation of MSCs to vascular cells is the in vivo micro 
environment, with growth factors, vascular ECM molecules, cell to cell contact, 
mechanical stress and oxygen tension likely to be the key mediators. By selectively 
examining these in vivo environmental elements in vitro, it should be possible to identify 
the key factors involved in modulating MSC differentiation towards vascular cells. 
Identifying influential environmental constituents which regulate the differentiation of 
MSCs to vascular cells and the mechanisms involved, will provide new opportunities for 
in vitro engineering of artificial vascularised tissues based on autologous MSCs. 
Furthermore, the in vitro definition of crucial regulatory components, will contribute to the 
therapeutic manipulation of MSCs within in vivo environments, potentially enabling the 
regulation of neovascularisation during ischaemia, wound healing and tumourigenesis. 
Thus to advance current therapeutic strategies towards controlling postnatal 
vasculogenesis, an understanding of how the micro-environmental niche can modulate 
MSC differentiation is essential.  
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1.8. AIMS 
 
The aim of this project is to investigate the differentiation of MSCs along the EC lineage, 
and to identify specific factors modulating this process and the mechanisms involved. 
 
Specific aims are: 
• To provide extensive evidence to show that MSCs can be induced to 
differentiate into a functional EC by examining:  
 
1. their morphology 
2. their expression of known EC markers, vWF, VEGFR1, VEGFR2, VE-
cadherin and PECAM-1 
3. EC functional tests including ac-LDL uptake, network formation on 
Matrigel and induction of VCAM-1 in response to TNFα 
4. the stability of the EC phenotype. 
 
• To investigate the roles of VEGF-A and cell density in inducing MSC 
differentiation to ECs. 
 
• To describe the mechanisms regulating MSC differentiation to ECs, specifically 
focussing on the involvement of the Notch signalling pathway. 
 
• To determine how ‘endothelialised MSCs’ respond in pro-angiogenic 
environments utilising three dimensional in vitro Matrigel culture and the chick 
chorioallantoic membrane (CAM) assay. 
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CHAPTER 2: MATERALS AND METHODS 
 
2.1. MATERIALS 
 
2.1.1. Cell lines 
 
All cell lines and growth medium, unless otherwise stated, were obtained from Lonza 
(Cambrex Bio Science, Wokingham, UK). Human MSCs were obtained from the normal 
human bone marrow of a 28 year old female (lot number 6F3974.) All experiments were 
repeated using MSCs obtained from bone marrow of a second individual (a 21-year-old 
male; lot number 6F3502). The MSCs had been confirmed to have the potential to 
differentiate into osteoblast, chondrocyte, and adipocyte lineages (McBeath et al ., 
2004), and they were positive for CD29, CD44, CD105, and CD166, but negative for 
hematopoietic cell markers CD14, CD34, and CD45. MSCs were routinely maintained in 
MSC basal medium containing batch selected 10% foetal bovine serum, 2% L-glutamine 
and 0.1% penicillin/streptomycin. MSCs were cultured under standard conditions i.e. in a 
humidified atmosphere of 20% O2, 5% CO2, and 37 oC at 70% confluence and used at 
passage 5. HUVECs from a 43-year-old and 29-year old female Caucasians (Cascade 
Biologics), were maintained on 5% gelatin in phosphate buffered saline (PBS) (Sigma) in 
endothelial cell basal medium containing 5% fetal bovine serum, 0.4% fibroblast growth 
factor, 0.1% VEGF, 0.1% Epidermal growth factor (EGF), 0.1% Insulin-like growth factor, 
0.1% gentamycin/amphotericin solution, 0.1% ascorbic acid and 0.04% hydrocortisone, 
and used at passage 6. HDFs from a 51-year-old male, obtained from the European 
Collection of Cell Cultures (CAMR, Porton Down, UK), were maintained in Dulbecco’s 
minimal essential medium (Gibco, Paisley, UK) containing 10% fetal bovine serum, 1% 
L-glutamine, 0.2% penicillin/ streptomycin and used at passage 6.  
 
 
2.1.2. Growth factors and inhibitors 
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VEGF-A165 (50 ng/ml) was obtained from R&D Systems (298-VS). To inhibit VEGFR 
signalling, VEGFR tyrosine kinase inhibitor III (Calbiochem, KRN633) was used at a 
concentration of 0.5 μM (designated VEGFR-I). The inhibitor is a cell-permeable, 
reversible, ATP-competitive inhibitor of VEGFR kinase activity (IC50 = 170 nM, 160 nM, 
and 125 nM for VEGFR1, VEGFR2, VEGFR3, respectively) and inhibits PDGFR-α and 
c-Kit only at higher concentrations (IC50 = 0.97 µM and 4.33 µM, respectively). VEGFR-I 
is inactive towards a panel of 17 other kinases (IC50 ≥ 10 µM). A VEGF neutralising 
monoclonal antibody (designated (VEGF-I) was purchased from R&D Systems (clone 
26503), and used at a concentration of 1 μg/ml. PDGFR tyrosine kinase inhibitor V 
(Calbiochem, 521234) was used at a concentration of 0.1 μM (designated PDGFR-I). 
This inhibitor is a cell-permeable quinolinyl-thiourea compound that acts a potent, ATP-
competitive, and reversible inhibitor of PDGFR (IC50 = 4 and 7.6 nM in ligand-induced 
cellular PDGFR phosphorylation and in in vitro kinase activity, respectively). Inhibits c-kit 
receptor only at higher concentrations (IC50 = 434 and 234 nM in receptor 
phosphorylation and kinase activity, respectively. Affinity purified goat anti human 
PDGFRα (AF-307-NA) and PDGFRβ (AF385) neutralising antibodies were purchased 
from R&D Systems and used at a concentration of 10 μg/ml. The gamma secretase 
inhibitor N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) 
(Sigma) was resuspended in DMSO and used at a concentration of 50 μM. DMSO alone 
was used as a control. Recombinant human TNF-α (10 ng/ml) was purchased from R&D 
Systems (210-TA-010). Fresh growth factors and inhibitors were re-applied to cells 
every two days throughout experiments. 
 
2.1.3. Primer sequences 
 
Oligonucleotide primers for PCR were designed using Primer3 software (Rozen & 
Skaletsky, 2000). Each primer pair were designed using the same parameters (70-100 
base pair product size and an optimum Tm of 60 oC, resulting in similar Tm values and 
product lengths, as shown: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (71-
bp), forward (5'-AAGGGCATCCTGGGCTAC-3') and reverse (5'-
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GTGGAGGAGTGGGTGTCG-3'); VEGFR1 (99-bp), forward (5'-
GCGACGTGTGGTCTTACG-3') and reverse (5'-GGCGACTGCAAAAGTCCT-3'); 
VEGFR2 (81-bp) forward (5'-CATCCAGTGGGCTGATGA-3') and reverse (5'-
TGCCACTTCCAAAAGCAA–3'); VEGFR3 (87-bp), forward (5'-
GATGCGGGACCGTATCTG-3') and reverse (5'-ATCCTCGGAGCCTTCCAC-3'); vWF 
(95-bp), forward (5'-GGTGTCCCTGCTTTCATC-3') and reverse (5'- 
GTTCCACTTCCGGTCCTG-3'); VEGF-A (98-bp), forward (5’-
CACCCATGGCAGAAGGAG-3’) and reverse (5’- CACCAGGGTCTCGATTGG–3’) Notch 
1 (75-bp), forward (5'-GAGGCATGCATCAGCAAC-3') and reverse (5'-
GATGGCCTTGCCATTGAC-3'); Notch 2 (84-bp), forward (5’-
CAGCCTCTGTGGGCAAGT-3’) and reverse (5’-TGACTGGGTGTTCGCTCA-3’), Notch 
3 (82-bp), forward (5’-GGCACCTGTACCGACCAC3’-) and reverse (5’-
GCAGGTCTTGTTCGCAGT-3’); Jagged-1 (90-bp), forward (5’-
TGTGGTTGGCTGGGAAAT-3’) and reverse (5’-GCAAGGGGACACACAACC-3’), DLL3 
(72-bp), forward (5’-CACGGTCCCTGTCTCCAC-3’) and reverse (5’-
ACAAGGCATCTGGTGGTA-3’); HES1 (91-bp), forward (5’-
CCAAAGACAGCATCTGAGCA-3’) and reverse (5’-TCAGCTGGCTCAGACTTTCA-3’); 
HES5 (85-bp), forward (5’-ACATCCTGGAGATGGCTGTC-3’) and reverse (5’-
TAGTCCTGGTGCAGGCTCTT-3’); VE-cadherin (74-bp), forward (5’-
GGAGCCGAGCATGTGTCT-3’) and reverse (5’-TCTGCAAGGTGTGCCTGA-3’).2. 2.  
 
2.1.4. Antibodies 
 
Primary antibodies used for immunoblot and immunofluorescence analysis were goat 
anti-human VEGFR1 (AF321); rabbit anti-human phospho-VEGF R1/Flt-1 (Y1213) 
(AF4170), Goat anti human HES-1 (AF3317), Goat anti human Jagged-1 (AF1277) 
(R&D Systems); mouse anti-human vWF (3H3126) (sc-73267); mouse anti-human 
Notch 1 (mN1A) (sc-32745) and rabbit anti-human Notch 2 (25-255) (sc-5545); rabbit 
anti-human Notch 3 (M-134) (sc-5593), mouse anti human VCAM-1 (P3C4) (sc-20070) 
rabbit anti-human PDGFRβ (P-20) (sc-339), rabbit anti human PDGFRα (C-20) (sc-338), 
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anti-phosphotyrosine (Tyr-P) (PY99; sc-7020) (all from Santa Cruz Biotechnology), 
rabbit anti-human VEGFR2 (55B11) (2479), rabbit anti-human Notch1 (C37C7), rabbit 
anti human and Notch2 (8A1), mouse anti-human PECAM-1 (89C2) (3528), rabbit anti-
human VE-cadherin (2158) (all from Cell Signalling Technology),  anti-GM130 
(35/GM130) antibody (BD Transduction Laboratories). All immunoblot HRP and FITC 
conjugated secondary antibodies and anti–IgG1 antibody, (X093101) were purchased 
from DAKO. Secondary antibodies used for Immunofluorescence were Alexa-Fluor 488 
conjugated or Alexa-Fluor 546/555 conjugated (Invitrogen). Primary antibodies used for 
flow cytometry were mouse anti–human VE-cadherin-PE (555511) and PECAM-1-PE 
(555446) (BD Pharmingen), CD73 (550256), CD29-PE (555443), CD44-PE (555479), 
CD51-PE (550037) CD14 (347460), CD45 (347490 BD Pharmingen), CD105-PE 
(FAB10971P R&D Systems), CD34 (CBL555 Chemicon).  
 
2.2. METHODS 
 
2.2.1. Cell Plating 
 
For standard plating density experiments, cells were seeded at 70,000 cells in 9.6 cm2 at 
initial plating (corresponding to 70% confluence). For high cell density experiments, 
MSCs were seeded at 100,000 cells in 9.6 cm2 at initial plating. For low density 
experiments, MSCs were seeded at 10,000 cells in 9.6 cm2 at initial plating.  
 
2.2.2. MSC differentiation assay 
 
The ability of MSCs to differentiate into adipogenic or osteogenic lineages was assessed 
using the MSC functional Identification kit (R&D systems).  
 
 For adipogenic differentiation, MSCs were seeded into 24 well plates at 100% 
confluence (2.1 × 104 cells/cm2). Adipogenic medium containing hydrocortisone, 
isobutylmethylxanthine, and indomethacin in 10% serum α-MEM was added to cells 
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every 3-4 days. After 14 days, adipocytes were fixed in 4% paraformaldehyde and 
staining performed for Bodipy 493/503 (1:1000 dilution) (Invitrogen) and immunostaining 
performed for FABP-4 (10μg/ml) (R&D Systems). 
 
For osteogenic differentiation, MSCs were seeded into 24 plates at 50-70% confluency 
(7.4 × 103 cells/well). Osteogenic medium containing dexamethasone, ascorbate-
phosphate, and β-glycerolphosphate in 10% serum α-MEM was added to cells every 3-4 
days. After 14 days, osteoblasts were fixed in 4% paraformaldehyde and Alizarin red 
staining performed (2g/100ml Alizarin red in ddH20) by staining cells for 1 hour at room 
temperature. Following Alizarin red staining cells images were captured using an 
Olympus (CK X41) phase contrast microscope.  
 
2.2.3. Polymerase chain reaction 
 
Total RNA was isolated from cultured cells using Trizol reagent. In brief, Trizol was 
added to cells and rocked for up to 1 hour. Flasks were vortexed for 1 minute and 
solution transfered to 15 ml falcon tubes. 1/5th volume chloroform was added to solution, 
the solution was shaken vigorously for 15 seconds, incubated for 3 minutes at room 
temperature and centrifuged at 12,000 × g for 15 minutes at 4 oC. Following 
centrifugation the aqueous phase was isolated and RNA precipitated by mixing with ½ 
volume propanol. Samples were incubated at room temperature for 10 minutes and 
centrifuged at 12,000 × g for 15 minutes at 4 oC.  Supernatants were removed 
completely and RNA pellet washed once with 1 volume 75% ethanol the centrifuged at 
7500 × g for 15 minutes. Residual ethanol was removed and RNA pellet air dried at 80 
oC for 5 minutes. RNA was dissolved in 50 μl DEPC treated water then quantitated by 
diluting 5 µl RNA in 50 μl elution buffer (Qiagen)and using a Genequant pro RNA/DNA 
calculator (Amersham Pharmacia, Cambridge, UK). For reverse transcription, 1 μg total 
RNA and 1 µl  diluted oligo dT primer (500µg/ml Promega) (4 µl oligo dT primer, 6 µl 
elution buffer, were incubated for 10 minutes at 65 oC, then reverse transcribed using 1 
µl 25U/μl AMV reverse transcriptase (Roche Diagnostics, Lewes, UK) in a mix of 4 μl 5× 
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RT buffer (Roche ), 2 μl 100 mM DTT (Promega ), 2 μl 10 mM dNTP (Promega), 0.5 μl 
40U/μl RNAse inhibitor (Roche) and ddH20 up to 9.5 μl and incubating for 10 minutes at 
30 oC, then 90 minutes at 42 oC.  
 
For reverse transcription polymerase chain reaction (RT-PCR), 50 μl reactions 
containing 5 μl cDNA, 1 μl dNTP, 1 μl primer mix (equal volumes of 100μM forward and 
reverse primer stocks), 5 μl 10× PCR buffer (Roche), 1 μl 3.5U/μl Enzyme (Roche) and 
ddH20 up to 37 μl were incubated for 3 minutes at 94 oC, immediately followed by 35 
cycles of 30 seconds at 94 oC, 1 minute at 60 oC, and 1 minute at 72 oC for 35 cycles, 
then a 7 minute incubation at 72 oC. Each set of RT-PCR experiments was performed 
using the same stock solutions, using the same GeneAmp PCR System 2700 
thermocycler (Applied Biosystems, California, USA). Following PCR, 1× DNA loading 
buffer (Bioline) was added to reaction products and products resolved using a 2.5% 
ultrapure agarose (Gibco, Paisley, UK) gel run at 100V for 2 hours in 1× TAE buffer (1 
litre: 50× TAE buffer: 242g Tris Base, 57.1ml glacial acetic acid, 100mls 0.5M EDTA pH 
8.0). 2.5 μl gene red (Biotium) was added to agarose to visualise products and a 25 
base pair DNA ladder (Promega) was used to determine product size.  
 
Quantitative PCR (QPCR) was performed using a Sybr green QPCR core kit No ROX 
reference dye (Eurogentec RT-SN10-05NR). Amplifications were performed as 25 μl 
reactions by making an initial QPCR Mastermix (1 ml master mix: 250 μl Buffer, 175 μl 
MgCl2, 100 μl dNTP, 12.5 μl Goldstar Taq polymerase, 75 μl Sybr green and 387 μl H20) 
and adding 10 μl of this mix to 2.5 μl primer mix and 11.5 μl H2O. 24 μl of this mix was 
then added to 1 μl cDNA and aliquoted into Low-Profile 96-Well Unskirted White PCR 
Plates (Biorad MLL-9651). Reaction mixtures were incubated for 50 oC for 2 minutes, 95 
oC for 10 minutes, followed by 39 cycles of 95 oC for 15 seconds and 60 oC for 1 minute. 
Melting curves were calculated from 70 oC to 94 oC, reading every 0.2 oC. QPCR was 
performed using the ABI PRISM 7000 thermocycler and Opticon Monitor 2 software. 
Data were normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
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Relative expression was calculated according to the 2-[Delta]CT formula (Potier et al., 
2007).   
 
2.2.4. Immunoblot analysis 
 
Cells were washed with phosphate buffered saline (PBS), incubated with lysis buffer (To 
make 200mls 10 × sodium vanadate (Na3V04): Na3Vo4 in 200mls 1 × PBS (10mM) was 
boiled until dissolved. The solution was adjusted to pH 10 until it turned yellow and re-
boiled until colourless. The solution was cooled on ice and re-adjusted to pH 10. The 
cycle was repeated until after cooling the pH remained at 10. The solution was stored at 
4oC. To make 300mls lysis buffer (pH 8: 0.727g Tris (20 mM), 0.28g ethylene diamine 
tetra-acetic acid (EDTA) (2.5 mM), 2.63g sodium chloride (150 mM), 3mls 
phenylmethanesulphonylfluoride (PMSF) (1 mM (0.1742g/10mls methanol)), a serine 
protease inhibitor, 30mls 10 × Na3V04 solution (1 mM), 3mls Tergitol-type nonyl 
phenoxylpolyethoxylethanol (NP) 40 (1%) 500μl aprotinin (trypsin inhibitor (Sigma) (10 
μg/ml from 5mg/ml stock) 500μl leupeptin (protease inhibitor (Sigma)) (10 μg/ml from 
5mg/ml stock) and 30mls glycerol (10%)) for 15 minutes on ice, vortexed for 1 minute, 
scraped gently from the tissue culture flask, then incubated for 30 minutes rotating at 
4oC. Supernatants were collected after centrifugation at 12,000 rpm, then total protein 
was quantitated using a BCA protein assay kit (Pierce, Perbio Science, Tattenhall, UK).  
 
Samples (100-200 μg) were electrophoresed using NuPAGE 3-8% Tris acetate or 4-12% 
Bis-Tris gel systems (Invitrogen, Groningen, The Netherlands) in 1× NUPAGE Tris-
acetate or MES SDS running buffer (Invitrogen) run at 150V or 200V (For Tris acetate or 
Bis Tris respectively) for 1.5 hours. 5 μl Precision plus dual colour protein standard 
(BioRad) was used as a size marker. Protein was transferred to a nitrocellulose 
membrane using a NuPAGE western transfer system (Invitrogen, Groningen, The 
Netherlands) in 1× NUPAGE Transfer buffer (Invitrogen) run at 35V for 1.5 hours. 
Membranes were blocked with 4% Marvel skimmed milk in 1× TBST (1 litre 10× TBST: 
12.114g Tris (0.01 M), 87.66g NaCl (0.15 M), 50mls (w/v) Tween 20 (0.5%)) pH 7.4) for 
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1 hour, then incubated overnight at 4oC with the primary antibody (1:500-1:1000 
dilution). Membranes were washed 3× in 1× TBST, incubated with HRP-conjugated 
secondary antibody (Dako, Ely, UK) (1:2000 dilution) for 2 hours, washed 3× with 1× 
TBST, then developed with Supersignal west dura enhanced chemiluminescence kit 
(Thermo scientific). Proteins were visualised using Kodak X-AR or Kodak-MR film and 
density of bands determined using Gene Tools software (Syngene) and normalisation to 
the corresponding loading control. 
 
2.2.5. Immunofluorescence microscopy 
 
After culturing cells on gelatin-coated 1.7 cm2 chamber slides (Becton Dickinson, Oxford, 
UK), cells were washed with PBS and fixed in 4% paraformaldehyde (To make 4% 
paraformaldehyde, 2 g paraformaldehyde was added to 25 ml 1× PBS and heated to 
50oC with constant stirring, 1M sodium hydroxide was added dropwise until solution 
cleared. 5 ml 10× PBS was added to the solution and the volume brought up to 50mls 
with ddH20 then the solution was allowed to cool to 37oC and pH adjusted to 7.4) for 20 
minutes at room temperature, then washed again with PBS. Paraformaldehyde was 
quenched in 0.1M glycine/PBS (Fisher Chemicals) for 20 minutes, washed 2× and cells 
permeabilised in 0.5% Triton-X-100 (Sigma) for 30 minutes. Non-specific binding was 
blocked with 2% fish gelatin in PBS (Sigma, Poole, UK) for 1 hour, then slides incubated 
overnight at 4oC with primary antibodies (1:50-100 dilution) contained in a 2% fish 
gelatin solution. After washing with PBS, diluted secondary antibodies (1:200) were 
added for 2 hours. F-actin was visualised using tetramethyl rhodamine isothiocyanate 
labeled Rhodamine Phalloidin (1:500 dilution) (Molecular Probes R-415), then slides 
washed and coverslips mounted using Prolong gold Antifade solution containing DAPI 
(Invitrogen).  
 
2.2.6. Immunoprecipitation analysis 
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Lysates were pre-cleared using 40 µl protein A–Sepharose (GE Healthcare) for 1 hour, 
protein A-Sepharose was removed by centrifugation at 2000 × g for 3 minutes and 
supernatants incubated with primary antibodies overnight at 4 oC (1:500 dilution). 
Immune complexes were isolated by incubation with 80 µl protein A–Sepharose for 2 
hours. Protein A-Sepharose beads were washed 3× with 500 μl ice cold lysis buffer, the 
supernatant removed and 25 µl loading buffer added for immuno-blot analysis. 
 
2.2.7. Proteome array analysis 
 
A human phosphorylated RTK array Kit (ARY001; R&D Systems) was used to 
simultaneously detect the relative tyrosine phosphorylation levels of 42 different RTKs. 
Each array contains duplicate validated control and capture antibodies for specific 
RTKs. In brief, array membranes were blocked, incubated with 500 μg MSC lysate 
overnight at 4oC, washed and incubated with anti-phosphotyrosine-HRP for 2 hours at 
room temperature, washed again, and developed with enhanced chemi luminescent 
western blotting detection reagent (GE healthcare), and RTK spots were visualised 
using Kodak MR or XAR film. 
 
2.2.8. Enzyme linked immunosorbent assays (ELISAs)  
 
ELISAs were performed using the Quantikine human VEGF, PDGF-AA, BB, AB 
immunoassays (R&D Systems) according to the manufacturer’s protocol.  
 
2.2.9. Flow cytometry 
 
MSCs, HUVECs, or HDFs were trypsinised, resuspended in 1ml media and allowed to 
recover for 1 hour. Cells were washed 2 × in 5 ml wash buffer, (0.5% BSA (Sigma)/PBS) 
and 1×105 cells incubated with either phycoerythrin (PE) or un-conjugated antibodies for 
1 hour (1:5 dilution).  After primary antibody incubation, cells were washed 3 × in 0.5% 
BSA/PBS wash buffer and unconjugated antibodies incubated with fluoroscein 
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isothiocyanate (FITC) secondary antibody (1:200 dilution) (Dako Cytomation) for 45 
minutes, washed twice in 0.5% bovine serum albumin in PBS and sent for analysis in 
Manchester University flow cytometry facility. 
 
2.2.10. siRNA transfections 
  
MSCs (5×105 cells), together with 3 μg siRNAs, were transfected by electroporation with 
a human Nucleofector kit (Amaxa) and cultured overnight in growth medium. Validated 
siRNAs, which were functionally tested to provide ≥70% target gene knockdown, were 
used for VEGF-A knockdown (QIAGEN). For Notch knockdowns, siRNAs for Notch1 (sc-
36095), Notch2 (sc-40135) and Notch3 (sc-37135) (Santa Cruz) were employed, with 
scrambled siRNA as a control (QIAGEN). 
 
2.2.11. VEGFR1 activation 
 
100 μM Pervanadate (30 mM sodium orthovanadate, 1× PBS, 0.18% (w/v) hydrogen 
peroxide in PBS) was added to MSCs or HUVECs for 5 minutes, washed 2× with 
calcium-free magnesium-free 1× PBS, and cell lysates extracted for VEGFR1 
phosphorylation analysis. 
 
2.2.12. Notch activation 
 
For EDTA experiments, cells were stimulated for 15 minutes with 5 mM EDTA, washed 
twice with MSC basal medium, left to recover overnight, and cell lysates extracted. 
Recombinant human Jagged-1/Fc chimera (R&D Systems, 1277-JG) was immobilised 
on culture plates by incubating plates with a solution of Jagged-1 (5 µg/ml) in PBS for 2 
hours at 37°C. MSCs were seeded onto plates and cultured for 24 hours. 
 
2.2.13. DiI-Ac-LDL uptake 
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Cells were incubated with 10 µg/ml 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine-labelled acetylated LDL (Dil-Ac-LDL) (Biomedical 
technologies Ltd (BT-906) for 3 hours at 37 °C to allow uptake, and immunofluorescence 
performed as above. 
 
2.2.14. Matrigel network formation assay 
 
200 μl growth factor reduced Matrigel (BD biosciences) was added to each well of a 24 
well plate on ice, then removed and plates incubated for 30 minutes at 37 oC. 25000 
cells in 0.5% fetal calf serum Dulbecco’s minimal essential medium were added to each 
well of the 24 well plate and plates visualised after 4 hours and 24 hours at 37oC for 
network formation. For Matrigel protein extraction, 2 ml growth factor reduced Matrigel 
(BD biosciences) was added to a 25cm2 flask on ice, Matrigel removed and plates 
incubated for 30 minutes at 37oC. After this time flasks were seeded with cells and 
protein extracted after 48 hours as previously described. 
 
2.2.15. Chorioallantoic membrane (CAM) assay 
 
Fertilized white chicken eggs (Henry Stewart company) were incubated for five days at 
37.5 oC and 43% humidity in a specialised egg incubator (R.Com King Suro 20 Digital 
Incubator). Under aseptic conditions in a laminar flow cabinet, cells were labelled with 10 
μg/ml DiI (Sigma 42364-100MG) for 30 minutes at 37 oC and the Matrigel assay 
prepared as above in 24 well plates on 13 mm diameter glass coverslips (Scientific 
Laboratory Supplies Ltd). Eggs were cleaned with 70% ethanol and a square window cut 
into the shell with dissecting scissors to reveal the underlying embryo and CAM blood 
vessels. The membrane covering the CAM surface was removed with forceps and 
coverslips placed gently on the CAM. The window was sealed with transparent tape and 
the egg returned to the incubator for 48 hours at 37.5 oC and 65% humidity, following 
which time coverslips were removed and prepared for immunofluorescence as 
previously described. Figure 2.1 shows a schematic of the coverslip method. 
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Figure 2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. The coverslip method for immunostaining cultured cells in the CAM assay 
(A) Stepwise procedure of the method. 1) Set up cells; 2) Carefully place coverslips in wells of 
tissue culture plates using curved tip forceps; 3) Apply 200μl matrix protein of interest to coverslips 
in dishes; 4) Apply cells to coverslips applying 1ml media to each well of tissue culture plate and 
allow cell to adhere to matrix by culturing at 37oC for 1 hour; 5) incubate eggs until desired stage 6) 
Carefully cut hole in egg and remove membrane covering the CAM surface 7) Remove media from 
prepared cells, and carefully dislodge coverslip with two bent end needles; 8) invert coverslip to 
allow direct contact of cells with chick CAM. 9) Place coverslips gently onto CAM; 10) Seal the 
window with transparent tape and return the egg to the incubator. Incubate eggs for desired length 
of time. 
(B) Either 20,000 DiI labelled control standard cultured MSCs (MSC-S), or endothelialised MSCs 
(MSC-H) were seeded on Matrigel, then placed into the chick CAM of a day 5 chick embryo for 48 
hours. Coverslips were then removed and processed for Immunofluorescence analysis. The 
underlying CAM blood vessels were imaged following coverslip removal. 
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2.2.16. Microscopy 
 
All light microscopy images were taken using an Olympus (CK X41) phase contrast 
microscope with attached digital camera using ×4, ×10 and ×20 objectives. CAM 
vascularisation was imaged using a Nikon stereo microscope. 
For fluorescence microscopy images were collected on an Olympus Widefield BX51 
upright microscope using a 20×/ UPlanFLN objective and captured using a Coolsnap HQ 
camera (Photometrics) through MetaVue Software (Molecular Devices). Specific band 
pass filter sets for DAPI, FITC, TRITC were used to prevent bleed through from one 
channel to the next. 
For confocal microscopy, images were collected using a Nikon C1 confocal on an 
upright 90i microscope with a 60×/ 1.40 Plan Apo objective and 3× confocal zoom. 
Images for DAPI, FITC and Texas red were excited with the 405nm, 488nm and 543nm 
laser lines respectively. Different sample images detecting the same antibodies were 
aquired under constant acquisition settings. Images were then processed using Nikon 
EZ-C1 Freeviewer v3.3 software.  
For Delta Vision microscopy, a Delta Vision RT (Applied Precision) restoration 
microscope 40×/ 0.85 UPlan Apo objective and Coolsnap HQ (Photometrics) camera 
was utilised. Raw images were deconvolved using the Softworx software; maximum 
intensity projections of these deconvolved images are shown. At least twenty 
representative images of each sample were taken. 
 
2.2.17. Transmission Electron Microscopy 
 
Samples were processed by University of Manchester electron microscopy facility, 
briefly samples were chemically fixed, dehydrated with solvent, embedded in special 
resins, sectioned with an ultramicrotome and stained using heavy metal salts. Imaging 
was performed using a Philips 400 Transmission Electron Microscope: 
 
2.2.18. Statistics 
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In all quantitation experiments, results are expressed as the mean ± the SD. Statistical 
differences between sets of data were determined by using a student t test on SigmaPlot 
8.0 software, with P < 0.05 considered significant. 
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CHAPTER 3: RESULTS 
 
3.1. High cell density induced endothelial characteristics in MSCs 
 
An increasing number of studies have now demonstrated that MSCs can differentiate to 
ECs (Al-Khaldi et al ., 2003; Alviano et al ., 2007; Bai et al., 2009; Chen et al ., 2009; 
Chung et al ., 2009; Lozito et al ., 2009a;b; Ohata et al., 2009;  Oswald et al ., 2004; 
Silva et al ., 2005;  Wu et al ., 2005; Xu et al ., 2009; Yue et al ., 2008; Zhang et al ., 
2008) and contribute to postnatal vasculogenesis (Aghi and Chiocca, 2005; Hung et al ., 
2005;  Tang et al ., 2006; Xin et al ., 2007; Roorda et al ., 2009). The environmental cues 
that MSCs sense when at sites of repair or regeneration, such as exposure to growth 
factors, ECM composition, cell-cell contact, shear stress or mechanical stretch are likely 
to be critical mediators in regulating their differentiation to an EC fate. 
 
A defining feature of ECs in growing blood vessels is their ability to switch from a 
migratory phenotype to a contact-inhibited phenotype within polarised monolayers which 
are stabilised by intercellular junctions (Dejana et al., 2004 Hordijk et al ., 1999). Both 
VE-cadherin and PECAM-1 are expressed constitutively at cellular junctions and induce 
rapid cellular responses to cell-cell contact (Newman et al ., 2003; Vestweber et al, 
2008; Vestweber et al ., 2009; Vincent et al ., 2004; Woodfin et al ., 2007). The adhesion 
molecules VCAM-1 and ICAM-1 are inducible by TNF-α in ECs (McHale et al ., 1999). 
Furthermore, the expression of specific cell surface RTKs can serve to identify ECs 
(Kliche et al ; 2001; Munoz-Chapuli et al ; 2004; Olsson et al ., 2006). The primary RTKs 
expressed by ECs are the VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1) and 
VEGFR3 (Flt-4) (Olsson et al ., 2006). Their expression is almost exclusively restricted 
to ECs, but they can be expressed by other cell types, for example, VEGFR1 can be 
expressed on monocytes (Schmeisser et al ., 2001; 2003) and both VEGFR1 and 
VEGFR2 can be expressed by some populations of vSMCs (Banerjee et al ., 2008; 
Greenberg et al ., 2008). In addition, ECs can also be identified by their expression of 
vWF, a large multimeric glycoprotein present in blood plasma and produced 
constitutively in endothelium, megakaryocytes and subendothelial connective tissue 
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(Sadler et al, 1998) and by functional assays such as uptake of ac-LDL and tubular 
network forming ability in semi-solid media (Voyta et al ., 1984; Baatout et al, 
1996;1997).  
 
As previously discussed, exogenous VEGF-A165 profoundly influences the endothelial 
differentiation of MSCs (Al-Khaldi et al ., 2003; Alviano et al ., 2007; Bai et al ., 2009; 
Chen et al ., 2009; Chung et al ., 2009;  Oswald et al ., 2004;  Wu et al ., 2005; Xu et al ., 
2009; Zhang et al ., 2008). However, the addition of exogenous VEGF-A in MSCs 
cultured at subconfluence for 5 hours was insufficient to induce endothelial marker 
expression (Ball et al ., 2007c), suggesting that VEGF-A alone is insufficient to induce 
endothelial marker expression in MSCs. 
 
Direct cell-cell interaction has also been shown to influence MSC differentiation events 
(Ball et al ., 2004; McBeath et al  2004). MSCs co-cultured with neonatal cardiomyocytes 
mediated MSC differentiation into cardiomyocytes (Xu et al ., 2004), whilst MSCs 
cocultured with ECs severely disrupted αSMA organisation and thus contractile function 
(Ball et al ., 2004; 2007a). In addition, cell density has been shown to modulate MSC 
morphology and induced differentiation of MSCs into adipogenic or osteogenic lineages 
(McBeath et al., 2004).  
  
Studies have shown that endothelial markers are strongly regulated by EC density, with 
PECAM-1 only being expressed when ECs form stable monolayers and not when the 
cells are sparsely distributed (RayChaudhury et al ., 2001; Lampugnani et al ., 1997). 
VEGFR2 activity has also been shown to be regulated by cell density, with high levels of 
VEGF dependent tyrosine phosphorylation detected in sparse cells, whilst confluent 
monolayers only exhibited very low levels of tyrosine phosphorylation (Rahimi et al ., 
1999). Furthermore, in subconfluent ECs, VE-cadherin phosphorylation was only 
enriched at areas of cell-cell contact (Lampugnani et al ., 1997).  
 
In this chapter, the effect of cell density on influencing MSC differentiation to an EC fate 
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was examined.  
 
3.2. MSC characterisation 
 
3.2.1. Morphological characterisation of MSCs 
 
MSCs are characterised morphologically by having a small cell body with long thin 
processes, often referred to as a spindle-shaped morphology (Baksh et al ., 2004). 
Figure 3.1 shows phase contrast images of human MSCs cultured for 24 hours at 10% 
confluence (Figure 3.1 (A); 3.1 (AI)), in standard conditions (70% confluency) (Figure 3.1 
(B); 3.1 (BI)), or at 100% confluence (Figure 3.1 (C); 3.1(CI)) showing small adherent 
cells displaying a spindle-shaped morphology. All experiments were performed on MSCs 
obtained from the normal human BM of a 28 year old female and repeated using MSCs 
obtained from BM of a a 21-year-old male (see Chapter 2: Materials and Methods 
section 2.1.1). 
 
3.2.2. Immunophenotypical characterisation of MSCs 
 
MSCs were characterised to ensure their immunophenotypic profile was consistent with 
the minimum criteria reported in the literature for human BM-derived MSCs in standard 
culture conditions (Dominici et al ., 2006; Huang et al 2009, Phinney and Prokop 2007a). 
Furthermore, it was necessary to verify that the MSCs were not contaminated by 
haematopoietic cells. Flow cytometry (Figure 3.2) revealed that the MSCs were positive 
for the characteristic MSC markers CD73 (ecto-5’-nucleotidase), CD29 (integrin β1 
chain), CD44 (hyaluronan receptor), CD51 (αV integrin) and CD105 (endoglin), whilst 
being negative for the haematopoietic cell marker CD34. In addition, these MSCs have 
been shown to be negative for the leukocytic markers CD14 and CD45 (McBeath et al ., 
2004). 
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Figure 3.1 
 
 
 
 
Figure 3.1. Morphological characterisation of MSCs 
Representative phase contrast images of MSCs cultured at 10% confluence (A,), 70% confluence 
(B) or 100% confluence (C) for 24 hours. Images were obtained using an Olympus (CK X41) 
microscope with attached digital camera (4× objective). Scale bars = 100μm. Figures AΙ-CΙ 
represent an enlarged region of A-C. Scale bars = 25μm. 10 representative images were taken for 
each analysis. 
 
B. MSC 70% confluent 
C. MSC 100% confluent 
A. MSC 10% confluent 
CI. MSC 100% confluent
BI. MSC 70% confluent
AI. MSC 10% confluent
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Immunophenotypical characterisation of MSCs 
 Flow cytometry of MSCs cultured under standard conditions (70% confluency) for 48 hours using 
phycoerythrin (PE) or FITC-conjugated antibodies. The MSC markers CD73 (ecto 5’ nucleotidase), 
CD29 (integrin β1 chain), CD44 (hyaluronan receptor), CD105 (endoglin) and CD51 (αV integrin) 
and the haemoatopoietic marker (CD34) are represented by coloured peaks (either green for FITC 
conjugated antibodies (FL1) or red for PE-conjugated antibodies (FL2). Black peaks represent the 
control IgG1.  Data are representative of two independent experiments for each analysis. 
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3.2.3. Differentiation capacity of MSCs 
 
MSCs have the capacity to differentiate into multiple cell types including osteoblasts, 
chondrocytes and adipocytes (Huang et al 2009, Phinney and Prokop 2007a; Pittenger 
et al., 1999). To confirm MSC multipotency, MSCs are induced to differentiate to 
osteoblasts, chondrocytes or adipocytes, following culture using defined differentiation 
media.  
 
MSCs were cultured in standard conditions using MSC basal medium for 14 days, or 
induced to differentiate to adipogenic or osteogenic lineages using defined differentiation 
media (Chapter 2: Materials and Methods, section 2.2.2) (Figure 3.3). Chondrogenic 
differentiation was not analysed due to the large number of cells needed for this assay. 
Adipogenic differentiation was detected by immunofluorescence microscopy using 
Bodipy 493/503, which stains lipid droplets, and FABP-4, which is characteristically 
present in adipocytes. Osteogenic differentiation was detected using Alizarin red staining 
which stains calcium rich deposits.  
 
Control non-induced MSCs cultured in MSC basal medium for 14 days (Figure 3.3 (A)) 
were negative for Bodipy 493/503 and FABP-4, suggesting no lipid containing vacuoles 
or FABP-4 were present. In contrast, confluent MSCs cultured in adipogenic media for 
14 days (Figure 3.3 (B)) exhibited a rounded morphology, and large lipid filled vacuoles 
were evident within the cells as detected by positive Bodipy 493/503 staining. In 
addition, positive FABP-4 immunoreactivity was apparent at the cell periphery. In 
contrast, MSCs induced to differentiate towards osteoblasts for 14 days adopted a more 
flattened morphology, and mineralised deposits could be detected with alizarin red 
staining (Figure 3.3 (D)). Alizarin red staining of MSCs cultured in MSC basal medium 
for 14 days which had a spindle shaped morphology, resulted in no detectable positive 
staining, suggesting mineralised deposits were not present (Figure 3.3 (C)). 
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Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Differentiation capacity of MSCs 
MSCs cultured in standard conditions for 24 hours (70% confluence) were induced to differentiate 
to adipogenic or osteogenic lineages by culture using defined differentiation media over 14 days. 
As non-induced MSC controls, (A, C) MSCs were cultured in standard conditions in MSC basal 
media over 14 days. (B, D) Induced MSCs. Adipocytes were detected by staining for Bodipy 
493/503 (green) and immunostaining for FABP-4 (red), using a Nikon C1 upright confocal 
microscope (60× objective). Nuclei are stained with DAPI (blue). Scale bars = 7μm. Osteoblasts 
were detected by alizarin red staining and phase contrast microscopy using an Olympus (CK X41) 
phase contrast microscope (20× objective). Calcium deposits are marked with white arrows. Scale 
Bars = 20μm. Each image is representative of ten random images captured for each treatment, 
with each analysis performed in triplicate.  
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Thus, MSCs in standard culture conditions maintained their potential to differentiate 
towards adipogenic and osteogenic lineages. 
 
3.3. MSCs cultured at high density had the potential to differentiate to ECs 
 
3.3.1. MSCs cultured at high cell density developed a cobblestone-like morphology   
 
Cell density can regulate the morphology and differentiation of MSCs (Ball et al ., 2004; 
McBeath et al ., 2004). For experiments examining the effects of cell density on 
endothelial marker expression, it is first necessary to define low cell density and high cell 
density in these studies. As mentioned in Chapter 2: Materials and Methods, section 
2.2.1 and above section 3.2.1, the term standard culture conditions, refers to MSCs 
plated and cultured up to 70% confluency. However, at 70% confluency, invariably a 
small proportion of MSCs will be in contact. Therefore at low cell density, MSCs were 
plated sparsely at 10% confluency to ensure minimal cell contact during culture. High 
cell density was defined as MSCs plated and cultured at 100% confluency, to ensure 
maximal cell contact from the moment of plating (see also Figure 3.1). After 48 hours in 
culture, MSCs at standard cell density (70% confluent at plating) (Figure 3.4 (A)), or at 
low cell density (10% confluent at plating) for 14 days (Figure 3.4 (B)), maintained a 
spindle-shaped morphology. In contrast, MSCs in close contact at high cell density 
(100% confluent at plating) for 14 days (Figure 3.4 (C)) developed a more rounded 
cobblestone-like morphology that was similar to HUVECs in standard culture conditions 
(Figure 3.4 (D)) and as reported in other EC lines (Hutley et al ., 2001). 
 
3.3.2. High cell density induced MSCs to express VEGFR1  
 
3.3.2.1. High cell density induced MSCs to express VEGFR1 transcripts 
 
MSCs cultured at high density for 14 days adopted a cobble-stone morphology similar to 
cultured ECs. To determine if MSCs cultured at high density were differentiating towards 
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Figure 3.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. MSCs cultured at high cell density developed a cobblestone-like morphology  
Representative phase contrast images of (A) MSCs in standard culture conditions (MSC-St) for 48 
hours, (B) MSCs cultured at low density (MSC-L) for 14 days or (C) MSCs cultured at high density 
(MSC-H) for 14 days. (D) HUVECs in standard culture conditions (HUV-St) were used as a 
positive cellular control. Images were obtained using an Olympus (CK X41) microscope with 
attached digital camera (4× objective). Inserts represent an enlarged region of each image. Each 
image is representative of two independent experiments with ten representative images taken for 
each analysis. Scale bars = 100μm. 
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an EC lineage, the expression of the endothelial markers VEGFR1, vWF, VE-cadherin 
and PECAM-1 were assessed. VEGFR1 is a RTK expressed on ECs (Kliche et al ., 
2001) as well as on some populations of vSMCs, HDFs, monocytes and macrophages 
(Banerjee et al ., 2008; Salmonsson et al ., 2003). VEGFR1 functions in vascular 
development as a “decoy receptor” to bind and sequester VEGF-A thereby regulating 
signalling through VEGFR2 (Shibuya et al, 2006a). Expression of VEGFR transcripts 
was determined using RT-PCR. HUVECs cultured in standard conditions, which were 
used as positive control cells, expressed VEGFR1 (Figure 3.5 (A); lane 1) and VEGFR2 
(Figure 3.5 (A); lane 2) but did not express VEGFR3 (Figure 3.5 (A); lane 3), as 
previously shown (Ball et al ., 2007c). MSCs cultured after plating at low cell density for 
14 days expressed no detectable VEGFR transcripts (Figure. 3.5 (A)), as reported (Ball 
et al ., 2007c), whilst MSCs cultured after plating at high cell density for 14 days 
expressed VEGFR1 (Figure 3.5 (A); lane 1) but no detectable VEGFR2 or VEGFR3 
transcripts (Figure 3.5 (A); lanes 2-3 respectively). Verification by quantitative PCR 
analysis of VEGFR1 transcripts expressed by MSCs cultured for 14 days revealed a low 
level of VEGFR1 transcripts in MSCs cultured at low cell density, but a significant 
increase (5.0±0.7 fold) in VEGFR1 transcripts in MSCs cultured at high cell density 
(Figure 3.5 (B)). 
 
3.3.2.2. High cell density induced MSCs to express VEGFR1 protein  
 
Immunoblotting analysis was used to detect VEGFR1 protein levels in MSCs that had 
been plated at low, standard or high cell density and cultured for 14 days. HUVECs in 
standard culture conditions were used as a positive control, which resulted in an 
immunopositive band at 180-kDa (Figure 3.6 (A); lane 1), corresponding to the expected 
size of VEGFR1. HDFs in standard culture conditions were used as negative control 
cells, which did not produce any detectable VEGFR1 immunoreactivity (Figure 3.6 (A); 
lane 2). In addition, minus primary (Figure 3.6 (A); lane 3), minus secondary (Figure 3.6 
(A); lane 4) or isotype specific IgG1 (Figure 3.6 (A); lane 5) controls displayed no binding. 
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. High cell density induced MSCs to express VEGFR1 transcripts  
 (A) VEGFR expression was examined by semi-quantitative RT-PCR analysis. HUVECs plated at 
standard cell density, and MSCs at low cell density (MSC-L) or at high cell density (MSC-H), were 
cultured for 14 days. Lane 1 is VEGFR1 (99-bp); lane 2 is VEGFR2 (81-bp); lane 3 is VEGFR3 
(87-bp). Two different primer pairs for VEGFRs 1-3 gave similar results, and GAPDH (71-bp) was 
a loading control.  
(B) Quantitative PCR analysis of VEGFR1 mRNA from MSCs cultured for 14 days after plating at 
low cell density (MSC-L) or at high cell density (MSC-H), each sample was run in triplicate. * 
represents p<0.05 compared to MSCs cultured after plating at low cell density. Data are 
representative of two independent experiments. 
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MSCs cultured under standard conditions (Figure 3.6 (A); lane 6) or at low density for 14 
days (Figure 3.6 (A); lane 7) produced no detectable VEGFR1 protein. In contrast, 
MSCs cultured at high density for 14 days expressed readily detectable VEGFR1 protein 
at 180-kDa (Figure 3.6 (A); lane 8).   
 
Having detected VEGFR1 transcript and protein expression in MSCs cultured at high 
density for 14 days, experiments were conducted to establish whether the induced 
VEGFR1 was capable of signalling (Figure 3.6 (B)). The phosphorylation status of 
VEGFR1 was analysed in unstimulated HUVECs and MSCs cultured at high density, or 
upon pervanadate stimulation, a potent inducer of tyrosine phosphorylation (Figure 3.6 
(B)) (Vecchi et al ., 1998). Immunoprecipitation then immunoblotting for VEGFR1 in 
unstimulated HUVECs and MSCs (Figure 3.6 (B); lanes 1 and 3) detected low levels of 
phosphorylated VEGFR1. In contrast, HUVECs and MSCs stimulated with pervanadate 
revealed prominent VEGFR1 tyrosine phosphorylation (Figure 3.6 (B); lanes 2 and 4 
respectively). Thus, VEGFR1 induced by MSCs cultured after plating at high cell density 
was capable of signalling. 
 
To determine whether the induced VEGFR1 was expressed on the MSC surface or had 
an intracellular distribution, single cell flow cytometry (Figure 3.6 (C)) was performed. 
MSCs cultured at low density for 14 days showed no apparent cell surface VEGFR1, 
whilst MSCs cultured at high density displayed only minimal levels of cell surface 
VEGFR1 expression, suggesting VEGFR1 expression may be predominantly 
intracellular. Following culture of MSCs at high density for 14 days it was difficult to obtain a 
homogenous single cell suspension, which may be reflected in the presence of a second peak on 
the histogram.  
 
3.3.2.3. Localisation of VEGFR1 in MSCs cultured at high density 
 
Immunofluorescence analysis was performed to establish whether the induced VEGFR1  
showed an intracellular distribution in MSCs. MSCs cultured at low or high density for 14 
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Figure 3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. High cell density induced MSCs to express VEGFR1 protein  
(A) Immunoblot analysis for VEGFR1 in 14 day total protein lysates. Lane 1, HUVECs (HUV) as a 
VEGFR positive-cell after plating at standard cell density; lane 2, HDFs as a VEGFR-negative cell 
after plating at standard cell density; lanes 3-5 are minus primary antibody (-1oAb), minus 
secondary antibody (-2oAb) and isotype specific (IgG1) negative controls, respectively; lane 6, 
MSCs at standard cell density (MSC-St); lane 7, MSCs at low cell density (MSC-L); lane 8, MSCs 
at high cell density (MSC-H). Membranes were reprobed with β-actin as loading controls. (B) 
Tyrosine phosphorylation analysis of VEGFR1 after immunoprecipitation in 14 day total protein 
lysates. HUVECs (HUV) were used as a VEGFR1 positive control and were stimulated with 100 
μM pervanadate (+P) (lanes 2 and 4) for 5 minutes at 37oC, or unstimulated (-P) (lanes 1 and 3). 
VEGFR1 was immunoprecipitated using an anti-VEGFR1 antibody, and phosphorylation detected 
by immunoblot using an anti-phosphoVEGFR1 antibody. Membranes were reprobed with anti-
VEGFR1 as loading controls. (C) Single colour flow cytometry analysis for VEGFR1 (green) using 
an unconjugated VEGFR1 primary antibody (AF321) and a FITC conjugated secondary antibody 
(FL1) in MSCs cultured at low density (MSC-L) or MSCs cultured at high density (MSC-H) for 14 
days. Black curves=IgG1. A representative of two independent experiments is shown for each 
analysis. 
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days were examined for total VEGFR1 and phosphorylated VEGFR1 (tyrosine residue 
Y1213) by immunofluorescence analysis (Figure 3.7), with HUVECs used as a VEGFR1 
positive cellular control. The isotype specific IgG1 was used as a negative control. 
HUVECs (Figure 3.7 (A)) were shown to express a large proportion of total VEGFR1 
resident within a compact juxtanuclear compartment that has been previously identified 
as the Golgi apparatus (Mittar et al ., 2009). In addition, variable amounts of total and 
phosphorylated (Y1213) VEGFR1 were found to be present within a diffuse punctate 
pattern, consistent with relatively small cytoplasmic vesicles documented previously 
(Mittar et al ., 2009) as well as present on the surface of the plasma membrane. Here, 
MSCs cultured at low density (Figure 3.7 (B)) exhibited only trace levels of 
immunostaining. However, in contrast, MSCs cultured at high density (Figure 3.7 (C)) 
displayed prominent VEGFR1 immunoreactivity (total and phosphorylated). However, it 
must be noted that the phosphorylated VEGFR1 immunostaining would be expected to 
overlap completely with the total VEGFR1 immunostaining. This result is unexplained 
and needs further validation. No binding of control IgG1 was detected (Figure 3.7 (D)).   
 
To determine whether the induced VEGFR1 in MSCs cultured at high density localised 
predominantly to the Golgi apparatus, immunofluorescence co-localisation analysis of 
total VEGFR1 and the Golgi marker GM130 (Figure 3.8 (A-D)) was determined. Co-
localisation analysis revealed total VEGFR1 was localised to the Golgi apparatus in 
MSCs cultured at high density. 
 
3.3.3. High density enhanced VEGF-A secretion in MSCs 
 
Since high MSC density induced prominent VEGFR1 phosphorylation (Y1213), ELISA 
assays were performed to establish whether autocrine secretion of the VEGFR1 ligand 
VEGF-A165 also increased in response to density (Figure 3.9). 
 
VEGF-A concentration significantly increased 3.5-fold (p=0.0009) in MSCs cultured at 
high density (Figure 3.9 (A)) compared to low density. In contrast, MSC density 
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Figure 3.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Localisation of VEGFR1 in MSCs cultured at high density 
Immunofluorescence analysis of VEGFR1 (green) and phosphorylated (Y1213) VEGFR1 
(pVEGFR1) (red) in (A) HUVECs cultured in standard conditions for 48 hours, (B) MSCs cultured 
at low density for 14 days  or (C) MSCs cultured at high density  for 14 days.  Nuclei are visualised 
with DAPI (blue). (D) The isotype specific (IgG1) negative control is shown for MSC-H. A 
representative of two independent experiments is shown for each analysis with ten representative 
images taken for each experiment using a Nikon C1 upright confocal microscope (60× objective). 
Scale bars = 7μm.  
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Figure 3.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. VEGFR1 was localised to the Golgi apparatus in MSCs cultured at high density. 
Co-localisation analysis of VEGFR1 and the Golgi marker GM130 in MSCs cultured at high 
density for 14 days is depicted in A-D. (A) MSCs immunostained for VEGFR1; (B) MSCs 
immunostained for GM130; (C) Merged image of VEGFR1 and GM130; (D) isotype specific IgG1 
negative control. A representative of two independent experiments is shown for each analysis with 
ten representative images taken for each experiment using a Olympus IX71 Deltavision 
microscope (40× objective). Scale bars = 10μm. 
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Figure 3.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. High density enhanced VEGF-A secretion in MSCs 
Enzyme linked immunosorbant assay (ELISA) showing (A) VEGF-A, (B) PDGF-AA,  (C) PDGF-
AB, or (D) PDGFBB isolated from media derived from MSCs cultured at low density or high density 
for 48 hours. * represents p<0.05 compared to growth factor secretion in MSCs cultured at low 
density. A representative of two independent experiments is shown for each analysis, with each 
analysis performed in duplicate. 
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produced no detectable change in the concetration of PDGF ligands (Figure 3.9 (B-D)). 
Thus, MSC exposure to VEGF-A was significantly increased at high cell density. It must 
be noted that the production of VEGF-A on a per cell basis may be unchanged as the 
data is not normalised to the total number of cells within the population. This increased 
VEGF-A exposure may account for the high levels of phosphorylated VEGFR1 seen in 
MSCs cultured at high density. 
 
3.3.4. High density enhanced vWF expression in MSCs 
 
3.3.4.1. High density enhanced vWF transcript expression in MSCs 
 
vWF is a multimeric glycoprotein produced constitutively in endothelium within rod 
shaped organelles called Weibel-Palade bodies (Sadler et al, 1998) which has been 
shown to be a characteristic marker for ECs. However, vWF is also expressed in 
megakaryocytes within α-granules of platelets (Schick et al ., 1997). Therefore to further 
define the role of MSCs density in directing an EC fate, vWF expression was also 
examined (Figure 3.10). 
 
RT-PCR was used to determine vWF transcript expression, by MSCs initially seeded at 
low or high cell density then cultured for 14 days (Figure 3.10 (A)). HUVECs, used as a 
positive control, demonstrated prominent vWF transcript expression (Figure 3.10 (A); 
lane 1). While MSCs cultured at low cell density displayed a low levels of vWF transcript 
(Figure 3.10 (A); lane 2), in comparison, MSCs cultured at high cell density exhibited 
enhanced vWF transcript expression (Figure 3.10 (A); lane 3).  Quantitative PCR 
analysis revealed that MSCs cultured at high cell density produced a significant increase 
in vWF transcript expression (2.9±0.4 fold), compared with MSCs cultured at low cell 
density (Figure 3.10 (B)).  
 
3.3.4.2. High density enhanced vWF protein expression in MSCs 
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Figure 3.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. High density enhanced vWF expression in MSCs 
vWF expression was examined by (A) RT-PCR analysis or (B) Quantitative PCR analysis. 
HUVECs (HUV) plated at standard density, or MSCs plated at low cell density (MSC-L) or high cell 
density (MSC-H) were cultured for 14 days and RNA extracted. (A) Lane 1, vWF transcript (95-bp) 
in HUVECs; lane 2, vWF transcript in MSC-L; lane 3, vWF transcripts in MSC-H. Two different 
primer pairs for vWF produced similar results, GAPDH (71-bp) was used as a loading control. (B) 
Quantitative PCR analysis of vWF transcript expression in MSC-L or MSC-H. Each sample was 
run in triplicate. * represents p<0.05 compared to MSC-L. (C) Immunoblot analysis of vWF protein 
after 14 days in culture. Lane 1, HUVECs as a positive control cell; lane 2, MSC-H; lane 3, MSC-L; 
lanes 4-6, minus primary antibody (-1oAb), minus secondary antibody (-2oAb) and isotype specific 
(IgG1) negative controls, respectively. vWF typically displays a ladder of bands representing the 
different sized vWF multimers, with the mature vWF subunit corresponding to the 225-kDa band 
(Zimmerman et al., 1986). Membranes were reprobed with β-actin as loading controls.  
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Immunoblotting analysis was used to detect vWF protein levels, following 14 days 
culture of MSCs after plating at low or high cell density. HUVECs, used as a positive 
control, displayed a characteristic ladder of bands of vWF multimers, with the mature 
vWF subunit represented by the 225-kDa band (Figure 3.10 (C); lane 1) (Zimmerman et 
al ., 1986). In this respect, while the mature vWF subunit was prominently expressed in 
MSCs cultured at high density (Figure 3.10 (C); lane 2), it was barely detectable in 
MSCs cultured at low density (Figure 3.10 (C); lane 3). Antibody controls were all 
immunonegative (Figure 3.10 (C); lanes 4-6). 
 
3.3.4.3. Distribution of vWF in MSCs cultured at high density 
 
Cell density dependent expression of vWF protein by MSCs was confirmed by 
immunofluorescence analysis after culture for 14 days (Figure 3.11). Using HUVECs as 
vWF-positive control cells, all HUVECs per field of view exhibited characteristic punctate 
vWF immunoreactivity, together with a perinuclear ring of vWF immunoreactivity (Figure 
3.11 (A) see arrows). MSCs cultured after plating at low cell density exhibited only 
minimal levels of vWF immunoreactivity (Figure 3.11 (B)), in contrast however, MSCs 
cultured at high cell density showed widespread punctate vWF immunoreactivity, 
together with a prominent perinuclear ring of vWF immunoreactivity similar to the 
HUVEC control (Figure 3.11 (C)). An isotype-specific IgG1 antibody, used as a negative 
control (Figure 3.11 (D)), displayed only minimal binding. 
 
3.3.4.4. Transmission electron microscopy of MSCs cultured at high density 
 
Having shown vWF transcript and protein expression in MSCs cultured at high density 
after 14 days, transmission electron microscopy was performed to determine if vWF 
storage organelles, known as Weibel-Palade bodies could be detected (Figure 3.12). 
Weibel-Palade bodies are described as having a single membrane in HUVECs, with a 
dense interior and rod-shaped, rounded or oval profile (Ewenstein et al ., 1987). 
Transmission electron microscopy analysis of MSCs cultured at low density showed no  
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Figure 3.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Distribution of vWF in MSCs cultured at high density 
Immunofluorescence analysis of vWF in (A) HUVECs, (B) MSCs cultured at low density (MSC-L) 
or (C) MSCs cultured at high density (MSC-H) for 14 days. (D) Isotype specific IgG1 negative 
control. A representative of two independent experiments is shown with ten representative images 
taken for each experiment using an Olympus IX71 Deltavision microscope (40× objective). Arrows 
delineate perinuclear vWF staining. Scale bars = 10μm. 
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Figure 3.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Transmission electron microscopy of MSCs cultured at high density 
Representative micrographs of (A, B) MSCs cultured at low density (MSC-L) or (C, D) MSCs 
cultured at high density (MSC-H) for 14 days. Arrows depict possible Weibel-Palade like 
structures. Scale Bars = 500nm. D represents an enlargement of C. 
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evidence of Weibel-Palade body-like structures (Figure 3.12 (A, B)).  In contrast, 
transmission electron microscopy of MSCs cultured at high density for 14 days, identified 
possible Weibel-Palade body-like structures (Figure 3.12 (C,D)).  
 
3.3.5. High MSC density induced VE-cadherin expression 
 
3.3.5.1. High density induced VE-cadherin expression in MSCs  
 
VE-cadherin is an endothelial specific adhesion molecule involved in regulating vascular 
permeability and leukocyte trafficking. In addition, VE-cadherin has been shown to 
regulate cell proliferation, apoptosis and modulates VEGF receptor functions (Gavard et 
al ., 2008; Hodijk et al ., 1999; Lampugnani et al., 2006; Vestweber et al, 2008). RT-PCR 
and immunoblotting were used to determine the levels of VE-cadherin expressed by 
MSCs cultured at low or high cell density for 14 days (Figure 3.13 (A)). RT-PCR 
demonstrated HUVECs, used as a positive control, expressed a high level of VE-
cadherin transcript. In comparison, MSCs cultured at high cell density expressed a lower 
level of VE-cadherin transcript, but no expression was detected in MSCs cultured at low 
cell density (Figure 3.13 (A)). Similarly, immunoblot analysis of HUVECs demonstrated 
prominent VE-cadherin protein at 130-kDa, while MSCs at high cell density expressed a 
lower level of VE-cadherin, but no VE-cadherin protein was observed in MSCs cultured 
at low cell density (Figure 3.13 (B)) 
 
3.3.5.2. Distribution of VE-cadherin in MSCs cultured at high density 
 
To determine if the induced VE-cadherin expression in MSCs cultured at high density 
demonstrated a cell surface or intracellular distribution, single cell flow cytometry was 
employed to detect cell surface VE-cadherin expression (Figure 3.13 (C)). While MSCs 
cultured at low density showed no apparent cell surface VE-cadherin expression 
(mean=3.89), MSCs cultured at high density displayed a minimal level of cell surface 
VE-cadherin (mean=14.5). 
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Figure 3.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. High density induced VE-cadherin expression in MSCs 
 
VE-cadherin expression in MSCs cultured at low (MSC-L) or high density (MSC-H) up to 14 days 
was determined by (A) semi-quantitative RT-PCR and (B) immunoblot analysis. HUVECs (HUV) in 
standard culture conditions for 48 hours were used as a positive control.  Lane 1, HUVECs; lane 2, 
MSC-H cultured at for 7 days; lane 3, MSC-H cultured for 14 days; lane 4, MSC-H cultured for 14 
days. GAPDH or β-actin, were used as loading controls. (C) Single colour flow cytometry analysis 
of VE-cadherin cell surface expression in MSC-L (blue curves) or MSC-H (red curves) cultured for 
7 days. Isotype specific IgG1 was used as a negative control. PE=phycoerythrin conjugated 
antibodies (FL2). A representative of two independent experiments is shown for each analysis. 
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Cell density dependent expression of VE-cadherin protein by MSCs cultured for 14 days 
was confirmed by immunofluorescence analysis (Figure 3.14). Using HUVECs as VE-
cadherin-positive control cells, all HUVECs per field of view exhibited VE-cadherin 
localisation at the cell membrane as well as displaying punctate intracellular 
immunoreactivity (Figure 3.14 (A)). VE-cadherin could not be detected in MSCs in 
standard culture conditions (Figure 3.14 (B)), but MSCs cultured at high cell density 
exhibited punctate intracellular VE-cadherin immunoreactivity at a lower level but similar 
to HUVEC controls (Figure 3.14 (C)). An isotype-specific IgG1 antibody, used as a 
negative control (Figure 3.14 (D)), displayed only minimal binding. 
 
3.3.6. High density enhanced PECAM-1 expression in MSCs 
 
3.3.6.1. High density enhanced PECAM-1 protein expression in MSCs 
 
PECAM-1 is an adhesion molecule belonging to the immunoglobulin superfamily. It is a 
transmembrane glycoprotein and is constitutively expressed on the surface of all ECs, 
monocytes, neutrophils and platelets (Newman et al . 2003; Raychaudhury et al ., 2001; 
Rival et al., 1996; Woodfin et al., 2007). Immunoblotting for PECAM-1 in lysates derived 
from HUVECs as a positive cellular control, demonstrated an immunopositive band of 
130-kDa, which was the expected size of PECAM-1 (Figure 3.15 (A); lane 1). 
Immunoprecipitation then immunoblotting for PECAM-1 in lysates derived from MSCs 
cultured at high density for 14 days, revealed PECAM-1 immunoreactivity at 130-kDa 
(Figure 3.15 (A); lane 2). In contrast, MSCs cultured at low density for 14 days displayed 
only minimal levels of PECAM-1 immunoreactivity (Figure 3.15 (A); lane 3). As 
previously discussed and reported, PECAM-1 predominantly exists as a membrane 
receptor in cultured ECs (Newman et al ., 2003; Woodfin et al ., 2007). Single colour flow 
cytometry was therefore performed to determine the expression of PECAM-1 on the 
surface of MSCs following culture at low or high density for 14 days. However, flow 
cytometry analysis was unable to detect PECAM-1 on the surface of MSCs after 14 days 
culture at low or high density (Figure 3.15 (B)).  
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Figure 3.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Distribution of VE-cadherin in MSCs cultured at high density 
 
Immunofluorescence analysis of VE-cadherin in (A) HUVECs in standard conditions for 48 hours, 
(B) MSCs in standard culture conditions for 48 hours, or (C) MSCs cultured at high density (MSC-
H) for 28 days. (D) Isotype specific IgG1 negative control for MSC-H. VE-cadherin = green, nuclei 
were stained with DAPI = blue. A representative of two independent experiments is shown with ten 
representative images taken for each experiment using a Nikon C1 upright confocal microscope 
(60× objective). Scale bars = 7μm. 
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Figure 3.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. High density enhanced PECAM-1expression in MSCs 
 
(A) PECAM-1 expression in MSCs cultured at low (MSC-L) or high density (MSC-H) for 14 days 
was determined by immunoprecipitation and immunoblot analysis. Total cell lysates were 
extracted from MSC-L or MSC-H, then PECAM-1 immunoprecipitated followed by PECAM-1 
immunoblot analysis. Lysate (40μg) extracted from HUVECs (HUV) in standard culture conditions 
for 48 hours was used as a positive control.  Lane 1, HUVECs cultured in standard conditions for 
48 hours; lane 2, MSC-H cultured for 14 days; lane 3, MSC-L cultured for 14 days. Equal volumes 
of lysate were immunoblotted for β-actin to determine equal loadings. (B) Cell surface PECAM-1 
expression was determined by single colour flow cytometry. Isotype specific IgG1 was used as a 
negative control. MSC-L (blue curves) MSC-H (red curves) cultured for 7 days. PE = phycoerythrin 
conjugated antibodies (FL2).  A representative of two independent experiments is shown for each 
analysis. 
 
 
 
PECAM-1
β-actin
HUV-St    MSC-H   MSC-L
130-kDa
42-kDa
MW                  1               2            3
PECAM-1-PEIgG-PE
MSC-L
MSC-H
MSC-L Mean = 3.71
MSC-H Mean = 7.04
MSC-L Mean = 3.62
MSC-H Mean = 6.94
A
B
FL2 FL2 
  
 - 96 - 
3.3.6.2. Distribution of PECAM-1 in MSCs cultured at high density  
 
To further investigate the density-dependent expression of PECAM-1 in MSCs, 
immunofluorescence analysis was performed (Figure 3.16). HUVECs, as previously 
reported, expressed PECAM-1 predominantly as a broad ribbon of sub-plasma-lemmal 
staining at cell-cell contact sites (Figure 3.16 (A)) (Woodfin et al ., 2007). In addition, fine 
intracellular PECAM-1 immunofluorescence was also detected. In comparison, MSCs 
cultured in standard conditions for 48 hours exhibited a low level of intracellular PECAM-
1 immunoreactivity (Figure 3.16 (B)). In contrast however, MSCs cultured at high density 
for 28 days displayed prominent intracellular punctuate PECAM-1 immunoreactivity 
(Figure 3.16 (C)). 
 
3.3.7. Functional properties of MSCs cultured at high density 
 
3.3.7.1. MSCs cultured at high density uptake ac-LDL  
 
Having established that MSCs cultured at high density adopt an endothelial-like cell 
morphology and express endothelial markers after 14 days of culture, MSCs cultured at 
high density for 28 days were subjected to endothelial functional tests.  
 
DiI-Ac-LDL is commonly used to label and isolate ECs from a mixed cell population 
(Voyta et al ., 1984). ECs or macrophages labelled with DiI-Ac-LDL take up the 
lipoprotein within 4 hours then the lipoprotein is subsequently degraded by lysosomal 
enzymes (Voyta et al ., 1984; Schmeisser et al  2001; 2003). The fluorescent probe (DiI) 
accumulates within intracellular membranes enabling fluorescent detection. However, 
other cell types such as HDFs, pericytes, vSMCs and epithelial cells, do not take up DiI-
Ac-LDL and are not labelled. 
 
The ability of MSCs to uptake DiI-ac-LDL was therefore established. Using HUVECs as 
a positive cellular control, MSCs in standard culture conditions for 48 hours or MSCs  
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Figure 3.16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Distribution of PECAM-1 in MSCs cultured at high density 
  
Immunofluorescence analysis of PECAM-1 expression in (A) HUVECs in standard culture 
conditions for 48 hours, (B) MSCs in standard culture conditions for 48 hours, or (C) MSCs 
cultured at high density (MSC-H) for 28 days. (D) Isotype specific IgG1 negative control for MSC-
H. PECAM-1=green, nuclei were stained with DAPI=blue. A representative of two independent 
experiments is shown with ten representative images were taken for each experiment using a 
Nikon C1 upright confocal microscope (60× objective). Scale bars = 7μm. 
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cultured at high density for 28 days were cultured for four hours with 10μg/ml DiI-ac-LDL, 
then uptake determined by fluorescence microscopy. HUVECs in standard culture 
conditions for 48 hours displayed virtually 100% uptake of Dil-ac-LDL (Figure 3.17 (A)). 
In comparison, MSCs cultured in standard conditions for 48 hours did not take up DiI-ac-
LDL (Figure 3.17 (B)). However, in contrast, MSCs cultured at high density for 28 days 
exhibited DiI-ac-LDL uptake in approximately 53% of cells analysed (Figure 3.17 (C) and 
Figure 3.17 (D)).  
 
 3.3.7.2. MSCs pre-cultured at high density displayed enhanced networks 
 
Matrigel, an extract of the basement membrane from the Englebreth-Holm-Swarm 
tumour, is liquid at 4oC and forms a gel at 37oC (Baatout et al ., 1996; 1997). When 
plated on Matrigel, ECs rapidly form capillary-like structures within 24 hours in vitro 
(Figure 3.18 (A)).  The functional behaviour of MSCs which had been cultured at high 
density was further tested by seeding these cells on Matrigel (Figure 3.18). MSCs pre-
cultured in standard conditions for 48 hours then seeded onto Matrigel, formed thin 
elongated branched networks within 24 hours (Figure 3.18 (B)). In contrast, MSCs pre-
cultured at high density for 28 days, then seeded onto Matrigel formed a significantly 
enhanced number of branch points within 24 hours (Figure 3.18 (C) and Figure 3.18 
(D)). Further analysis of endothelialised MSCs in Matrigel culture is shown in Chapter 5. 
 
3.3.7.3. High density MSCs induced VCAM-1 following TNFα exposure 
 
The adhesion molecule VCAM-1 is inducible by TNF-α in ECs (Figure 3.19 (A and B)), 
(McHale et al ., 1999). To determine whether VCAM-1 could be induced in MSCs 
cultured at high density for 28 days exposed to 10ng/ml TNF-α, immunofluorescence 
microscopy was performed. MSCs cultured in standard conditions detectected no 
VCAM-1 immunoreactivity in the presence or absence of 10ng/ml TNF-α (Figure 3.19 
(C, D)). MSCs cultured at high density detected no VCAM-1 immunoreactivity in 
unstimulated cells (Figure 3.19 (E)), but in contrast, VCAM-1 immunoreactivity was 
  
 - 99 - 
Figure 3.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. MSCs cultured at high density uptake ac-LDL 
Immunofluorescence analysis showing DiI-Ac-LDL uptake in (A) HUVECs, (B) MSCs in standard 
culture conditions (MSC-St) for 48 hours and (C) MSCs cultured at high density (MSC-H) for 28 
days. DAPI=blue, DiI-Ac-LDL uptake=Red. Images were taken on a Olympus upright widefield 
fluorescence microscope (BX51) using a 20× objective. Scale bars = 20μm. A representative of 
two independent experiments is shown. Insets show a second representative image. (D) The total 
number of cells exhibiting DiI-ac-LDL uptake were calculated as a percentage and plotted as a bar 
graph. * = p<0.05 compared to MSC-St. 
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Figure 3.18 
 
 
Figure 3.18. MSCs pre-cultured at high density displayed enhanced networks 
(A) HUVECs cultured in standard conditions for 48 hours (HUV-St), (B) MSCs cultured in standard 
conditions for 48 hours (MSC-St) or (C) MSCs cultured at high density for 28 days (MSC-H), were 
seeded onto growth factor reduced Matrigel in 0.5% serum DMEM for 48 hours. Images were 
obtained using an Olympus (CK X41) microscope with attached digital camera (10× objective). 
Scale bars = 40 μm. (D) Average number of branch points was determined and plotted as a bar 
graph. * = p<0.05 compared to MSC-St.  
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induced in response to 10ng/ml TNF-α stimulation (Figure 3.19 (F)). Thus, VCAM-1 
could be induced in MSCs cultured at high density in response to exogenous TNF-α 
stimulation. 
 
3.3.7.4. High cell density did not stimulate EC markers in HDFs 
 
To determine whether high cell density induced other cell types to express EC markers, 
the effects of cell density on HDFs was examined by immunofluorescence analysis. 
While HDFs cultured for 14 days were immunopositive for VEGFR1, which 
predominantly localised to the Golgi apparatus as judged by GM130 colocalisation 
analysis, (Figure 3.20 (A, B), Figure 3.8) no detectable difference in 
immunofluorescence was observed at either low or high HDF cell density. Furthermore, 
HDFs were immunonegative for vWF (Figure 3.20 (C, D)) and VE-cadherin (Figure 3.20 
(E, F)) at either low or high cell density. Thus, HDF cell density does not regulate the 
expression of the EC markers VEGFR1, vWF or VE-cadherin. 
  
3.4. High density MSCs maintained a moderately stable phenotype 
 
3.4.1. Re-plating at low density largely maintained EC marker expression 
 
To assess the stability of the MSC density-dependent EC like phenotype, MSCs that 
had been pre-cultured at high density for 28 days were seeded back at low density for 7 
days (Figure 3.21). While MSCs cultured at high density for 28 days maintained a 
cobble-stone morphology (Figure 3.21 (A)), when these cells were then re-seeded at low 
density for 7 days, they adopted a flattened morphology very different to their original  
morphology (Figure 3.21 (B), Figure 3.1).  Immunoblot analysis for VEGFR1 and vWF in 
the cells seeded at low density demonstrated that they still largely maintained a high 
level of vWF and VEGFR1 expression, similar to MSCs cultured at high density (Figure 
3.21 (C, D)). 
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Figure 3.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19. High density MSC culture induced VCAM-1 following TNFα exposure 
Immunofluorescence analysis of VCAM-1 in (A, B) HUVECs in standard culture conditions for 48 
hours, (C,D) MSCs in standard culture conditions (MSC-St) for 48 hours (E,F) MSCs at high 
density  (MSC-H) for 28 days. (A, C, E) unstimulated cells; (B, D, F) cells stimulated with 10ng/ml 
TNFα for 24 hours. VCAM-1 = green, nuclei were stained with DAPI = blue. A representative of 
two independent experiments is shown and ten representative images were taken for each 
experiment using a Nikon C1 upright confocal microscope (60× objective). Scale bars = 7μm. 
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Figure 3.20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20. High cell density did not stimulate EC markers in HDFs 
Immunofluorescence analysis of EC markers VEGFR1, vWF and VE-cadherin in HDFs cultured at 
low density (HDF-low) (A, C, E, G) or high density (HDF-High) for 14 days (B, D, F, H). (G,H) 
Isotype specific IgG1 negative controls. EC markers = green, nuclei were stained with DAPI = blue. 
A representative of two independent experiments are shown, with ten representative images were 
taken for each experiment using a Nikon C1 upright confocal microscope (60× objective). Scale 
bars = 7μm. 
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3.4.2. MSC characterisation markers were decreased in MSCs at high density 
 
As previously discussed, MSCs are typically characterised by their expression of the 
surface antigens CD29, CD44, CD51, CD105 and CD73 as well as their induced 
differentiation potential into osteoblasts, chondrocytes and adipocytes (Huang et al 
2009, Phinney and Prokop 2007a; Pittenger et al . ,1999). To establish whether 
differentiation of MSCs to ECs resulted in a concomitant decrease or loss of 
characteristic MSC surface antigens, their expression was determined by single colour 
flow cytometry following MSC culture at high density for 7 days (Figure 3.22). MSCs 
cultured at high density showed a decrease in surface antigens CD29 (mean = 124.98), 
CD105 (mean = 144.88) and CD44 (mean = 242.39) compared to MSCs cultured at low 
density (means =230.02, 224.56 and 389.41 respectively). Since leukocytes have 
previously been shown to express vWF and VEGFR1 and to form networks in Matrigel 
(Schmeisser et al ., 2001), expression of the leukocyte marker CD45 was also 
determined following MSC culture at low or high density. Flow cytometry confirmed that 
MSCs cultured at high or low density for 7 days did not express cell surface CD45, 
demonstrating the MSCs were not differentiating towards a leukocyte lineage.  
 
3.4.3. MSC density did not up-regulate other cell lineage differentiation markers 
 
To establish whether MSC density regulated the expression of other lineage markers, 
the effects of cell density on adipogenic, chondrogenic or osteogenic markers were also 
examined (Figure 3.23). Quantitative PCR was used to determine MSC transcript 
expression for adipogenic markers; PPAR γ and AP2, osteogenic markers; osteopontin 
and ALKP as well as chondrogenic markers; Col2A1 and Col9A2 (see Chapter 1: 
introduction section 1.2.3) . Analysis of adipogenic differentiation marker AP2 (Figure 
3.23 (A)) and PPAR-Gamma (Figure 3.23 (B)) or chondrogenic marker Col2A1 
(Figure3.23 (E)) and Col9A2 (Figure 3.23 (F)) expression at low or high MSC density, 
demonstrated that their expression did not significantly change. In contrast, the  
  
 - 105 - 
Figure 3.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. High density MSCs maintained a moderately stable phenotype 
To determine the stability of MSC density dependent EC-like phenotype, MSCs cultured at high 
density for 28 days were seeded back at low density for 7 days.  (A) MSCs cultured at high density 
for 28 days or (B) the same MSCs seeded at low density for 7 days. Representative phase 
contrast images using a 20× objective lens. Scale bars = 50µm. Immunoblot analysis of (C) 
VEGFR1 or (D) vWF expression, in MSCs cultured at high density for 28 days (high) or the same 
MSCs seeded at low density for 7 days (low). Membranes were reprobed with β-Actin as loading 
controls. 
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Figure 3.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. High density MSCs decreased MSC characterisation markers 
 
Flow cytometry analysis of characteristic MSC surface antigens CD29 (integrin β1 chain), CD105 
(endoglin), CD44 (hyaluronan receptor) and the leukocytic marker CD45 using PE (FL2) 
conjugated or FITC labeled (FL1) antibodies, in MSCs cultured at low (MSC-L = blue curves) or 
high density (MSC-H = red curves) for 7 days. IgG1 was used as a negative control. 
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 osteogenic marker osteopontin significantly (p=0.0077) increased in MSCs at high 
density (Figure 3.23 (C)), However, since the melting curve shows two peaks for 
osteopontin, the increase may be over-estimated. In comparison, the osteogenic marker 
AlkP (Figure 3.23 (D)) significantly (p=0.0200) decreased in MSCs at high density.  
 
3.4.4. High density MSCs could not be induced to differentiate to adipocytes 
 
To establish further whether MSCs cultured at high density for 28 days were displaying 
lineage commitment, their potential to be induced towards adipogenic and osteogenic 
lineages was evaluated. These experiments were performed at the same time as those 
in Figure 3.3. In contrast to the un-induced control cells (Figure 3.24 (A), also shown in 
Figure 3.3), MSCs cultured in standard conditions exposed to adipogenic media for 14 
days exhibited a rounded morphology and detected prominent Bodipy 493/503 staining 
and FABP-4 positive immunoreactivity was detected, (characteristic for lipid droplets) 
(Figure 3.24 (B) also shown in Figure 3.3). However, similar to the un-induced control 
(Figure 3.24 (C)), MSCs cultured at high density for 28 days then exposed to adipogenic 
media for 14 days demonstrated no discernible Bodipy 493/503 positive vesicles or 
FABP-4 immunoreactivity (Figure 3.24 (D)), suggesting that these MSCs could not be 
differentiated towards adipocytes. 
 
3.4.5. High density MSCs could not be induced to differentiate to osteoblasts 
 
Similarly, in contrast to the un-induced control cells (Figure 3.25 (A), also shown in 
Figure 3.3), MSCs cultured in standard conditions exposed to osteogenic media for 14 
days exhibited a flattened morphology and produced alizarin red positive staining 
indicative for calcium deposits (Figure 3.25 (B), also shown in Figure 3.3). However, 
similar to the un-induced control (Figure 3.25 (C)), MSCs cultured at high density for 28 
days, then exposed to osteogenic differentiation media for 14 days displayed no 
discernible alizarin red positive staining (Figure 3.25 (D)), indicating that these MSCs  
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Figure 3.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. MSC density did not up-regulate other cell lineage differentiation markers 
Quantitative PCR analysis of adipocyte differentiation markers (A) AP2, (B) PPARγ osteoblast 
markers (C) Osteopontin, (D) AlkP and chondrocyte markers (E) Col2A1, (F) Col9A2 using RNA 
taken from MSCs cultured at low density (MSC-L) or high density (MSC-H) for 3 days. The double 
delta Ct method was used to transform Ct values into relative quantities with standard deviations. 
Minus RT (–RT) and minus cDNA (-cDNA) reactions were also performed for each reaction to 
verify there was no genomic DNA or reagent contamination. * represents p<0.005 compared with 
MSC-L. For each analysis, a representative of two independent experiments is shown with each 
sample run in triplicate. Melting curves are shown on right. 
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Figure 3.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24. High density MSCs could not be induced to differentiate to adipocytes 
 
MSCs cultured in standard conditions for 24 hours or cultured a high density for 28 days were 
induced to differentiate to adipocytes by exposure to adipogenic differentiation media over 14 
days. Adipocytes were detected by staining for Bodipy 493/503 (green) and immunostaining for 
FABP-4 (red) using a Nikon C1 upright confocal microscope (60× objective). Nuclei are stained 
with DAPI (blue). (A) MSCs in standard culture conditions in basal media for 14 days; (B) MSCs in 
standard culture conditions exposed to adipogenic differentiation media for 14 days; (C) MSCs at 
high density in basal media for 14 days; (D) MSCs at high density exposed to adipogenic 
differentiation media for 14 days. Figures A and B are also shown in Figure 3.3. Ten 
representative images were taken for each treatment with each analysis performed in triplicate. 
Scale bars = 7μm 
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Figure 3.25 
 
 
 
 
Figure 3.25. High density MSCs could not be induced to differentiate to osteoblasts 
MSCs cultured in standard conditions for 24 hours or at high density for 28 days were induced to 
differentiate to osteoblasts by exposure to osteogenic differentiation media over 14 days. 
Osteoblasts were detected by alizarin red staining using an Olympus (CK X41) phase contrast 
microscope (20× objective) and images captured. (A) MSCs in standard culture conditions in basal 
media for 14 days; (B) MSCs in standard culture conditions exposed to osteogenic differentiation 
media for 14 days; (C) MSCs at high density in MSC basal media for 14 days; (D) MSCs at high 
density exposed to osteogenic differentiation media for 14 days. Figures A and B are also shown 
in Figure 3.3. Ten representative images were taken for each treatment with each analysis 
performed in triplicate. Black arrows depict calcium deposits. Scale Bars = 20μm. 
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were unable to differentiate to osteoblasts. These experiments were performed at the 
same time as those in Figure 3.3. 
 
3.5. Discussion 
 
The potential for adult bone marrow-derived MSCs to differentiate into ECs is a critical 
determinant which may direct many postnatal vascularisation events (Aghi and Chiocca, 
2005; Hung et al ., 2005; Tang et al ., 2006; Xin et al ., 2007). In this study, human BM-
derived MSCs, plated and cultured at high cell density developed a cobblestone-like 
morphology that was similar to ECs in culture. Moreover, MSCs cultured at high cell 
density began to express EC markers and a proportion of these cells acquired the ability 
to perform endothelial functional tests. These cellular changes appeared to be 
differentiation events specific to MSCs, since HDFs cultured at high density did not 
express EC markers.  
 
It has been proposed that, during embryogenesis haematopoietic cells and ECs are both 
derived from a common mesoderm precursor (Bailey et al ., 2003; Eilken et al., 2009; 
Lancrin et al ., 2009; Lacaud et al ., 2009; Vogeli et al ., 2006) (see also Chapter 1: 
introduction section 1.4.1 and Figure 1.5). Thus, the identification of unique markers that 
define ECs has generated much controversy, and a universally accepted functional 
assay or specific endothelial marker for ECs is lacking. The close embryonic relationship 
between the haematopoietic and vascular systems has consequently resulted in 
overlapping marker expression, common to both leukocytic lineages and 
vSMCs/pericytes (Bailey et al ., 2006; Schlingemann et al ., 1991; Reddy et al ., 2008; 
Schmeisser et al ., 2003; Zovein et al ., 2006). VE-cadherin, thought to be exclusively 
expressed on ECs, has now been detected on fetal HSCs (Kim et al ., 2005b). More 
recently, evidence has been shown that the cell type consistent with current definitions of 
a blood derived EPC phenotype may arise from an uptake of platelet microparticles by 
mononuclear cells resulting in a gross misinterpretation of their cellular progeny (Prokopi 
et al ., 2009). In addition, vSMCs and macrophages have been shown to express 
VEGFR1 and VEGFR2, generally defined as EC specific markers (Banerjee et al ., 
  
 - 112 - 
2008; Salmonsson et al ., 2003), whilst monocytes have been documented to express 
endothelial markers and form networks in Matrigel in the presence of angiogenic stimuli 
(Bailey et al ., 2006., Schmeisser et al ., 2001; 2003). Interestingly, HUVECs exposed to 
equilaxial stretch in vitro can express MHC-1, most probably reflecting the adaptability of 
vascular cells during normal physiological and aberrant pathological events (Cevallos et 
al ., 2006). Thus verification of ECs requires the expression of a complement of EC 
markers, EC functional assays and lack of non-EC cell lineage markers. In this study, 
the absence of leukocytic markers by MSCs cultured at high density, together with the 
appearance of a subset of EC markers and the ability to perform EC functional tests in a 
small proportion of MSCs, may indicate that a subpopulation of MSCs cultured at high 
density were differentiating to an EC fate. To help give a more definitive identification, 
further indicators of a fully functional EC could be tested including prostacylin and nitric 
oxide release, E-cadherin expression as well as determining whether leukocytes could 
transmigrate across a monolayer of these ‘endothelialised cells’.  
 
It should be noted that HUVECs, a relatively specialised embryonic EC population 
derived from the umbilical vein, were used throughout this study as a EC standard, 
primarily due to their availability and ease of culture in vitro. However, fully differentiated 
ECs derived from MSCs may be more similar to adult mature ECs such as HCAECs, 
microvascular ECs or even tumour endothelium. These different ECs all display distinct 
differences from HUVECs in terms of their morphology, abundance of endothelial 
markers and functional endothelial behaviour (Aird et al, 2003; Garlanda et al ., 1997). 
Such differences are largely pre-determined by EC position within the vascular tree and 
blood flow velocity which all play important roles during EC differentiation. ECs 
incorporated into larger blood vessels interact with a specialised basement membrane 
derived from surrounding contractile vSMCs or pericytes, which also regulate EC 
differentiation events. Thus, ECs derived from MSCs during postnatal vasculogenesis, 
may prove to be more similar to HCAECs than HUVECs. 
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Following MSC culture at high density, the same cells then re-seeded at low density only 
lost a small proportion of their expression of vWF and VEGFR1, which may suggest that 
these cells could be sub-cultured. However, the expression of these markers was only 
monitored in reseeded cells for 7 days and ideally these cells would need to be 
monitored for longer time periods. MSCs cultured at high density showed a decrease in 
the stem cell markers CD29, CD44 and CD105 together with a complete loss of their 
potential to differentiate towards osteogenic or adipogenic lineages. It is important to 
consider that only a small decrease in MSC associated markers was observed in MSCs 
cultured at high density which may reflect that perhaps only a subpopulation is changing 
and/or the change elicited is only partially towards a fully committed EC or that these 
markers are also expressed on ECs. The osteogenic marker osteopontin was up-
regulated during high density culture. Interestingly, it has recently been shown that 
osteopontin can also function as an intrinsic marker of hypoxia (Zhou et al ., 2009). This 
study demonstrated that high cell density-mediated pericellular hypoxia was an 
important factor in inducing expression of osteopontin in human prostate tumour cells 
and may explain the significant up-regulation of osteopontin in MSCs cultured at high 
density. 
 
The MSC density induced cobble-stone morphology was lost when these cells were re-
seeded at low density when a more flattened cell morphology was adopted. The change 
in cellular morphology may not indicate a dramatic loss of EC differentiation, but may 
well reflect the immaturity of the EC phenotype. While fully differentiated ECs maintained 
their cobblestone morphology, immature ECs may well have a less defined morphology, 
displaying a range of phenotypes, with the majority displaying rounded cobblestone 
morphologies but also exhibiting spindle shaped and flattened morphologies (Aird et al, 
2003; Garlanda et al ., 1997). These differences in morphology may reflect different 
stages of maturity, with rounded reflecting fully differentiated ECs, while spindle and 
flattened morphologies may be indicative of an immature phenotype. Alternatively, these 
MSCs cultured for up to 28 days at high density could have entered replicative senescence; this 
could be determined by testing for beta galactosidase activity, a biomarker of senescence. In 
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addition, a number of studies have shown how migratory ECs typically display a 
fibroblast-like phenotype whilst confluent ECs adopt a cobble-stone morphology within 
polarised monolayers (Dejana et al, 2004). Thus re-seeding MSC-derived ECs at low 
density directly onto tissue culture plastic may not be the ideal situation for maintaining a 
cobble-stone morphology, and for example, re-seeding the differentiated cells onto 
Matrigel may be more appropriate. 
 
Interestingly, the main EC signalling receptor VEGFR2 was not expressed by MSCs 
cultured at high density. It has previously been established that VEGFR1 and VEGFR2 
play different roles during physiological and pathological angiogenesis (Kliche et al ., 
2001; Huusko et al ., 2009; Matsumoto et al ., 2006; Olsson et al ., 2006; Takahashi et al 
., 2001; 2005). VEGFR1 plays a negative role during embryonic vasculogenesis where it 
acts as a “decoy receptor” for VEGF-A, preventing growth factor binding to VEGFR2. In 
contrast, VEGFR1 has been shown to play a positive role in adulthood during postnatal 
vascular remodelling, activating EC proliferation and promoting tumour growth, 
metastasis and inflammation (Shibuya et al, 2006a, b; Takahashi et al ., 2005). In 
contrast, VEGFR2 is considered the major inducer of vascular remodelling. VEGFR2 
gene knock-out mice die at E8.0-8.5 due to a lack of vasculogenesis and VEGFR2 was 
shown to have a major role in tumor angiogenesis and diabetic retinopathy using animal 
models (Shalaby et al ., 1995; 1997, Shibuya et al, 2006c). VEGFR2 is also known to 
interact with VE-cadherin and integrins, to regulate many steps of angiogenesis (Shay-
Salit et al., 2002; Stupack et al.,, 2004). While the MSC-derived endothelial-like cells 
generated in this study, exhibited a wide range of characteristics indicative for ECs, the 
lack of VEGFR2 further supports the concept of an immature EC phenotype, with a more 
mature phenotype represented by VEGFR2 expression (see Chapter 5).  
 
Immunofluorescence analysis of the EC markers VEGFR1, VE-cadherin and PECAM-1 
showed a predominantly intracellular distribution. Total cellular VEGFR1 predominantly 
localised within the Golgi apparatus as previously demonstrated (Mittar et al., 2009). 
These authors postulated that compartmentalisation of VEGFR1 may regulate VEGF-A 
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mediated responses, by preventing VEGFR1 from sequestering circulating VEGF-A. 
High levels of internalised phosphorylated VEGFR1 were detected within the cytoplasm 
of MSCs at high density, suggesting that VEGFR1 was signalling, presumably through 
the up-regulated autocrine VEGF-A, and cycling to intracellular storage compartments. 
In this study, both VE-cadherin and PECAM-1 exhibited a punctate intracellular 
distribution. The biosynthesis, processing and turnover of the adhesion molecules VE-
cadherin and PECAM-1, has previously been shown to have distinct cellular localisations 
(Goldberger et al ., 1994; Mamdouh et al ., 2003; Rival et al ., 1996; Xiao ., 2003). VE-
cadherin is constitutively internalised from cell borders and internalised VE-cadherin has 
been shown to localise to cytoplasmic vesicles (Xiao et al ., 2003). VE-cadherin 
internalisation has been shown to be tightly controlled by VEGF-A abundance. In ECs, 
VEGF-A binding to VEGFR2 led to VE-cadherin phosphorylation, promoting VE-cadherin 
internalisation (Mukherjee et al ., 2006; Gavard et al ., 2006; Wallez et al ., 2006; 2007). 
Therefore in this study, the levels of VEGF-A secreted by MSCs at high density may 
activate VEGFR1 signalling to promote VEGFR1, VE-cadherin and PECAM-1 
internalisation.  
 
As previously discussed, non-clonal MSCs are heterogenous with regard to their 
differentiation potential (Ho et al ., 2008; Huang et al ., 2009; Phinney et al, 2007b). This 
heterogeneity may give rise to MSC populations that have higher EC potential and may 
explain the low proportion (~50%) of MSCs amenable to taking up ac-LDL and the lower 
expression levels of vWF, PECAM-1 and VE-cadherin compared with HUVECs. 
Immunofluorescence analysis suggested that most MSCs were expressing EC markers, 
but at varying levels. It has recently been reported that single-cell-derived clonal 
populations could be isolated from human umbilical cord derived perivascular cells, 
known as HUCPVCs (Sarugaser et al ., 2009). Definitive parent and daughter clones 
were isolated from mixed suspensions and then assayed for their ability to differentiate 
into one or more of five mesenchymal lineages. These single cell-derived clones 
maintained extensive self-renewal capacity in vitro and clonally produced daughter 
populations of cells with different differentiation potentials. In addition, the VE-cadherin 
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promoter fused to green fluorescent protein was used to identify endothelialised ESCs 
and to screen for factors that promoted vascular commitment (James et al ., 2010). 
Using such techniques or by performing fluorescence activated cell sorting for DiI-ac-
LDL uptake, it may be possible to isolate endothelialised MSCs from the total cellular 
population generating a more homogeneous source of EC-differentiated MSCs.  
 
This chapter has suggested that high density culture may induce a proportion of MSCs 
to differentiate towards an EC lineage. The next chapter focuses on dissecting the 
mechanisms involved in regulating these differentiation events. 
 
3.6. Summary 
 
• MSCs cultured at high density adopted a cobble-stone like morphology 
• VEGFR1 and VE-cadherin were induced in MSCs cultured at high density 
• PECAM-1, vWF and VEGF-A were significantly enhanced in MSCs cultured at high 
density  
• VEGFR1 was predominantly localised to the Golgi apparatus  
• VWF showed punctate perinuclear localisation  
• VE-cadherin and PECAM-1 showed punctate intracellular immunoreactivity 
• MSCs cultured at high density exhibited ac-LDL uptake in a proportion of cells 
• MSCs cultured at high density showed enhanced Matrigel network formation 
• VCAM-1 could be induced by exogenous TNF-α in MSCs cultured at high density 
• High density culture did not stimulate EC markers in HDFs 
• The EC lineage was largely retained in low density culture at 7 days 
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CHAPTER 4: RESULTS 
 
4.1. Mechanisms regulating the differentiation of MSC to ECs 
 
It is becoming increasingly recognised that MSCs make an important contribution to 
promoting postnatal vascularisation during ischaemic myocardial tissue regeneration, 
wound healing and tumour vasculogenesis (Aghi et al., 2005; Al-Khaldi et al., 2003; 
Huang et al ., 2008; Reddy et al ., 2008; Roorda et al ., 2009; Silva et al ., 2005; Tang et 
al ., 2006; Wu et al ., 2005). To enable the therapeutic manipulation of MSCs during 
postnatal vasculogenesis, it is therefore crucial to determine the mechanisms which 
direct MSC differentiation towards an EC fate.  
 
In Chapter 3 Results, high density culture induced MSCs to exhibit a range of EC 
characteristics, suggesting MSC differentiation towards ECs. To determine which 
molecular mechanisms may regulate this density-dependent differentiation to ECs, it 
was therefore necessary to consider the micro-environmental factors likely to influence 
cells in high density culture.  
 
The level of secreted VEGF-A was significantly increased by MSCs that were cultured at 
high density (Chapter 3: Results, section 3.3.3). Previous studies have reported that 
MSCs can differentiate to ECs following exposure to exogenous VEGF for up to 14 days 
(Al-Khaldi et al ., 2003; Alviano et al ., 2007; Bai et al ., 2009; Chen et al., 2009; Chung 
et al ., 2009;  Oswald et al., 2004;  Wu et al ., 2005; Xu et al ., 2009; Zhang et al ., 2008). 
Furthermore, the addition of 50ng/ml VEGF-A to culture medium have been shown to 
up-regulate venous markers, whereas the addition of higher VEGF concentrations 
(100ng/ml) induced arterial marker genes (Zhang et al., 2008).  
 
Since MSCs cultured at high density have a high degree of cell-cell contact, cell contact 
mechanisms, including Notch signalling, are expected to play an important role in 
regulating MSC density-dependent differentiation events. Notch signalling is critical in 
vascular development, regulating arterio-venous specification, vessel branching and 
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endothelial tip cell formation (Lawson et al ., 2001; Gridley et al, 2007; Boulton et al ., 
2008a,b), and can direct MSCs to differentiate along chondrogenic, cardiomyocyte and 
osteogenic lineages (Hardingham et al ., 2006; Li et al., 2006; Oldershaw et al ., 2008; 
Scaffidi et al ., 2008). Its importance in blood vessel formation is highlighted by vascular 
abnormalities caused by mutations in the Notch receptors and ligands (Alva et al ., 2004; 
Bray et al, 2006; Opherk et al ; 2009). Furthermore, Notch signalling induced by cellular 
interactions has previously been implicated in MSC-endothelial differentiation (Zhang et 
al ., 2008; Siekmann et al ., 2008. Ohata et al., 2010). Notch signalling activated by cell-
cell contact may, in part by modulating VEGF signalling, direct EC fate and coordinate 
the specification of arterial and venous ECs (Zhang et al ., 2008; Siekmann et al ., 
2008). Notch activated experimentally over days in culture (Xu et al  2009), or during 
vascular development has been shown to enhance the differentiation of mesenchymal 
precursors to ECs (Ohata et al ., 2010).  
 
In this section, the effects of VEGF-A and Notch signalling in regulating density-
dependent differentiation of MSCs to an EC fate were investigated.  
 
4.2. MSC density-dependent differentiation to ECs occurred in two phases 
 
To identify mechanisms which regulate MSC differentiation towards ECs during high 
density culture, it was essential first to establish the timeframes which define initial MSC 
to EC commitment and subsequent differentiation events (Figure 4.1).  
 
MSCs were cultured at low density for 14 days, or at high density from 24 hours up to 14 
days (see Chapter 2:Materials and Methods, section 2.2.1 for definition of low and high 
density). Both PECAM-1 (Figure 4.1 (A)) and vWF (Figure 4.1 (B)) showed up-regulated 
expression after 24 hours at high density culture. While PECAM-1 expression remained 
constant up to 14 days, vWF expression significantly increased throughout the 14 day 
culture period. The expression of VEGFR1 (Figure 4.1 (C)) was induced after 24 hours 
culture at high density, which significantly increased during the 14 day culture period. 
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. MSC density dependent differentiation to ECs occurred in two phases 
 
Immunoblot analysis of (A) PECAM-1, (B) vWF, (C) VEGFR1 and (D) VE-cadherin in MSCs 
cultured at low density (MSC-L) for 14 days or at high density (MSC-H) up to 14 days, depicting 
initial MSC  to EC commitment events and later differentiation events to consolidate the EC fate. 
For vWF, VEGFR1 and VE-cadherin, membranes were stripped and re-probed with β-actin to 
ensure equal loadings. For PECAM-1, equal volumes of lysate were immunoblotted for β-actin to 
determine equal loadings. Pixel density was normalised to β-actin and plotted as a bar graph. * 
represents p<0.05. Representatives of two independent experiments are shown for each analysis. 
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In contrast, the expression of VE-cadherin (Figure 4.1 (D) was only induced after 7 days 
of culture at high density, after which the expression remained constant up to 14 days. 
Thus, density-dependent differentiation of MSCs to ECs occurred in two phases, 
comprising an initial induction phase and a subsequent enhancement phase. Initial MSC 
commitment towards an EC fate, characterised by increased expression of PECAM-1 
and vWF and induction of VEGFR1 expression, occurred during the first 24 hours of 
culture at high density, whilst later commitment characterised by VE-cadherin expression 
occurred after 7 days of culture at high density. 
 
4.3. Involvement of VEGF-A in initiating MSC commitment to ECs 
 
4.3.1. Exposure to VEGF-A did not induce MSCs to express EC markers 
 
The angiogenic growth factor VEGF-A has been implicated in directing MSC 
differentiation towards ECs (Al-Khaldi et al ., 2003; Alviano et al ., 2007; Bai et al ., 2009; 
Chen et al ., 2009; Chung et al ., 2009;  Oswald et al., 2004;  Wu et al ., 2005; Xu et al., 
2009; Zhang et al ., 2008) (see chapter 1: Introduction). However, these studies only 
analysed endothelial marker expression after 7-14 days in culture, by which time matrix 
deposition, autocrine growth factor secretion and cell density effects may also be critical 
mediators of this EC fate decision.  
 
To establish whether MSCs could be induced to express EC markers by short term 
exposure to exogenous VEGF-A, MSCs in standard culture conditions (see Chapter 2: 
Materials and Methods, section 2.2.1 for definition) were exposed to 50ng/ml VEGF-A 
for 24 hours (Figure 4.2). Immunoblot analysis demonstrated that PECAM-1 (Figure 4.2 
(A)), VEGFR1 (Figure 4.2 (B)) or VE-cadherin (Figure 4.2 (C)) were not expressed by 
MSCs in standard culture conditions  in the presence of 50ng/ml VEGF-A suggesting 
that exposure to exogenous VEGF-A alone was not sufficient to induce MSCs to express 
endothelial markers. 
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Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Exposure to VEGF-A did not induce MSCs to express EC markers 
To determine whether exposure to exogenous VEGF-A alone could induce MSCs to express the 
EC markers (A) PECAM-1, (B) VEGFR1 or (C) VE-cadherin, MSCs cultured in standard conditions 
were stimulated with 50ng/ml VEGF-A for 24 hours (MSC+) or unstimulated (MSC-). HUVECs in 
standard culture conditions were used as a positive control. β-actin was used as loading controls. 
Representatives of two independent experiments are shown for each analysis. 
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4.3.2. VEGF-A neutralisation did not alter EC marker expression  
 
As previously shown and discussed (Results chapter 3, section 3.3.3), MSCs cultured at 
high density displayed significantly enhanced VEGF-A secretion after 14 days. MSCs at 
high density also secreted increased VEGF-A after 24 hours (2466±48 pg/ml), compared 
with MSCs cultured at low density (910±51 pg/ml) (Figure 4.3 (A)). To determine 
whether up-regulated autocrine VEGF-A stimulated MSC towards EC commitment, 
MSCs were cultured at high density in the presence of a VEGF-A neutralising antibody 
(designated VEGF-I) for 24 hours (Figure 4.3 (B, C)).  VEGF-I was subsequently 
confirmed to block VEGFR phosphorylation (see Antibody controls Figure 4.20). 
However, VEGF neutralisation over 24 hours had no detectable effect on either vWF 
(Figure 4.3 (B); lane 2) or VEGFR1 (Figure 4.3 (C); lane 2) compared to untreated 
controls (Figure 4.3 (B, C); lanes 1).  
 
4.3.3. VEGF-A siRNA knockdown did not alter EC marker expression  
 
To examine whether autocrine VEGF-A stimulation of MSCs at high cell density, 
contributed to inducing VEGFR1 or up-regulating vWF expression, VEGF-A siRNA 
knockdown was performed (Figure 4.4). Following VEGF-A siRNA knockdown for 24 
hours, VEGF-A transcript level was markedly decreased (Figure 4.4 (A) and VEGF-A 
secretion significantly reduced by 79% (Figure 4.4 (B)), compared to MSCs transfected 
with scrambled siRNA. However, immunoblot analysis of MSCs transfected with VEGF-
A siRNAs revealed no change in VEGFR1 or vWF protein levels after 24 hours (Figure 
4.4 (C), 4.4 (D); lanes 2), compared to MSCs transfected with scrambled siRNAs (Figure 
4.4 (C), 4.4 (D); lanes 1). Thus, exposure of MSCs to either high exogenous or low 
endogenous levels of VEGF-A for 24 hours did not contribute to inducing VEGFR1 or 
enhancing vWF expression during the first 24 hours of culture at high cell density. 
Therefore, exposure to VEGF-A was not sufficient to initiate density dependent 
differentiation of MSCs to an EC fate.  
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Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. VEGF-A neutralisation did not alter EC marker expression  
(A) ELISA assay of VEGF-A from the medium of MSCs cultured at low (MSC-L) or high density 
(MSC-H) for 24 hours. * represents p<0.05 compared to MSC-L. A representative of two 
independent experiments is shown for each analysis with each analysis performed in duplicate. 
(B-C) To verify whether the VEGF-A secreted by MSCs altered at high cell density for 24 hours, 
induced  MSCs to express VEGFR1 or up-regulate vWF, MSCs were treated with 1μg/ml VEGF 
neutralising antibody (VEGF-I) during the 24 hour culture period. Immunoblot analysis of (B) vWF 
or (C) VEGFR1 protein levels in untreated (cont) (lanes 1) or VEGF-I treated MSCs (lanes 2) is 
shown. β-actin was used as loading controls. Pixel density was normalised to β-actin and plotted 
as a bar graph. A representative of two independent experiments is shown. 
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Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. VEGF-A siRNA knockdown did not alter EC marker expression  
To examine whether autocrine stimulation of MSCs at high cell density, contributed to inducing 
VEGFR1 or increasing vWF expression, VEGF-A siRNA knockdown was performed for 24 hours.  
(A) Semi-quantitative RT-PCR analysis using RNA isolated from MSCs cultured after plating at 
high cell density (MSC-H) for 24 hours after transfection with 3 μg scrambled siRNA as a control 
(S) or VEGF-A siRNAs (V). Lanes 1-2, GAPDH; lanes 3-4, VEGF-A transcripts.  
(B) VEGF-A secreted by MSCs cultured at high density following transfection with 3 μg scrambled 
(Scr) control or VEGF-A  siRNAs for 24 hours. * represents p<0.05 compared to Scr.  
Following siRNA knockdown of VEGF-A, immunoblot analysis was performed to detect (C) 
VEGFR1 and (D) vWF protein levels. Lanes 1, scrambled (Scr) control transfected MSCs; lanes 2, 
VEGF-A siRNA transfected MSCs. Membranes were re-probed with β-actin as loading controls. A 
representative of two independent experiments is shown. Pixel density was normalised to β-actin 
and plotted as a bar graph.  
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4.4. Involvement of Notch signalling in initiating MSC commitment to ECs. 
 
4.4.1. MSCs expressed Notch Receptors 1, 2 and 3 
 
Having established that MSC exposure to VEGF-A did not initiate differentiation to an 
EC fate during the first 24 hour culture period at high cell density, other potential 
initiating mechanisms were examined. The possibility that Notch signalling was involved 
in directing the differentiation of high density MSCs towards an EC fate was therefore 
examined. MSCs were initially characterised for their expression of Notch receptors 
(Figure 4.5). Notch signalling, which requires receptor-ligand interactions between 
adjacent cells, is mediated by four transmembrane receptors (Notch 1-4) and five 
transmembrane ligands, Jagged 1 and 2 and Delta-like 1, 3 and 4 (Bray et al, 2006) (see 
Chapter 1: Introduction, section 1.6.5.1). Immunofluorescence analysis was performed 
to detect the Notch receptors 1-4 in MSCs cultured at low or high density for 24 hours. 
Immunofluorescence analysis identified cell surface localisation of Notch receptor 1, in 
both low and high density cultured MSCs (Figure 4.5 (A, B) respectively). Compared to 
low density cultures (Figure 4.5 (C)), interestingly, immunofluorescence analysis 
detected widespread prominent nuclear Notch receptor 2 expression in MSCs cultured 
at high density (Figure 4.5 (D)). In contrast, Notch receptor 3 predominantly localised to 
the Golgi apparatus in both low (Figure 4.5 (E)) and high density MSC cultures (Figure 
4.5 (F)), while nuclear expression was also detected at high density.  
 
4.4.2. High density MSC culture increased Notch signalling components 
 
Having confirmed the expression of Notch receptors 1-3 in MSCs, RT-PCR analysis was 
performed to detect Notch signalling transcripts in MSCs during the first 24 hours at high 
density culture and up to 7 days (Figure 4.6). Compared to MSCs cultured at low density 
for 4 hours (Figure 4.6 (A)), culture at high density for 4 hours (Figure 4.6 (B); lane 1) 
increased the expression of all the Notch signalling transcripts examined; Notch receptor 
1, 2, 3, Jagged-1, Delta-like 3 and the downstream Notch transcription factor HES-1. 
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Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. MSCs expressed Notch receptors 1, 2 and 3 
(A-F) Immunofluorescence analysis of Notch receptors 1-3 in MSCs cultured at low (MSC-L) or 
high density (MSC-H) for 24 hours. Notch receptors = green, DAPI = blue. Primary antibodies 
used were Notch1 (C37C7) (recognises full length and transmembrane/intracellular region); 
Notch2 (8A1) (recognises full length and transmembrane/intracellular region); Notch3 (sc-5593) 
(recognises epitope corresponding to amino acids 2107-2240 mapping near the C-terminus of 
Notch 3) Ten representative images were taken using a Nikon C1 upright microscope (60× 
objective). Data are representative of two independent experiments. (G, H) IgG1 is shown as a 
negative control. Scale bars = 7μm 
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After 10 hours, MSCs cultured at high density maintained their expression of Notch 
receptor 2, JAG-1, DLL3 and HES-1 transcripts (Figure 4.6 (B); lane 2), while the Notch 
receptor 1 transcript decreased, but the Notch receptor 3 transcript increased. At 24 
hours, (Figure 4.6 (B); lane 3), the Notch receptor 3 transcript expression increased 
further, while the other Notch signalling transcripts decreased. At 7 days (Figure 4.6 (B); 
lane 4) the expression of Notch receptors 2 and 3 transcript levels were maintained, but 
the other Notch signalling transcripts decreased. Thus, RT-PCR analysis revealed that 
the highest levels of Notch 1 transcript expression occurred after 4 hours at high MSC 
density. The highest levels of Notch 2, JAG-1 and HES-1 occurred up to 10 hours. In 
contrast, the highest levels of DLL3 transcript occurred at 10 hours, while Notch 3 
transcript expression increased up to 24 hours and was maintained after 7 days at high 
MSC density.  
 
4.4.3. Notch signalling components fluctuated at high density 
 
To further examine the levels of Notch signalling transcripts during the first 24 hours of 
MSC culture at high density, quantitative PCR was employed (Figure 4.7). While 
quantitative PCR demonstrated marked fluctuations in the levels of Notch signalling 
components during the 24 hour period examined, in general, the expression pattern 
coincided with those determined by RT-PCR analysis (Figure 4.6). 
 
4.4.4. Notch signalling inhibition decreased EC markers and VEGF-A secretion 
 
To investigate whether Notch signalling was involved in inducing MSC expression of 
VEGFR1, vWF and VEGF-A at high cell density, MSCs were treated with the Notch 
signalling inhibitor DAPT. DAPT is a chemical inhibitor of the enzyme gamma-secretase 
that cleaves Notch and allows the transcription of target genes, including HES, HEY and 
HES related repressor protein family members (Boulton et al ., 2008a) . Following MSC 
treatment with DAPT for 24 hours, down-regulation of the Notch transcription factor 
HES1 by DAPT was confirmed by RT-PCR analysis (see control 
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Figure 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  High density MSC culture increased Notch signalling components 
The expression of Notch signalling transcripts; Notch receptors 1-3 (75-bp, 84-bp and 82-bp 
respectively), the Notch ligands Jagged-1 (JAG-1) (90-bp) and Delta-like 3 (Dll3) (72-bp) and the 
downstream Notch transcription factor (Hairy-Enhancer of Split-1 (HES-1) (91-bp) were examined 
by RT-PCR analysis (35 cycles), following culture of MSCs at (A) low density (MSC-L) for 4 hours, 
or (B) high density (MSC-H) for 4 (lane 1), 10 (lane 2), 24 hours (lane 3) and 7 days (lane 4). 
GAPDH expression of each time point was examined as a loading control. Two different primer 
pairs for each of the Notch transcripts gave similar results. Data are representative of two 
independent experiments.  
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Figure 4.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Notch signalling components fluctuated at high density 
Quantitative PCR analysis of Notch signalling components, using RNA isolated from MSCs 
cultured at high density for 1-24 hours, with 2-(ddCt) values plotted against time. Following 
quantitative PCR reactions, samples were run on a 2.5% agarose gel to verify that the correct 
product had been amplified. GAPDH was used to determine 2-(ddCt) values. Data are representative 
of two independent experiments, with each sample run in triplicate 
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 Figure 4.22). Immunoblot analysis of lysates derived from MSCs cultured at high density 
after DAPT treatment for 24 hours revealed a significant 66.9% decrease in VEGFR1 
protein level, compared to DMSO-treated control MSCs (Figure 4.8 (A) lanes 1 and 2 
respectively). Similarly, DAPT treatment resulted in a significant 60% decrease in vWF 
protein level compared to DMSO-treated control MSCs (Figure 4.8 (B) lanes 1 and 2 
respectively). Furthermore, ELISA analysis of medium derived from MSCs cultured at 
high density for 24 hours also revealed that DAPT treatment inhibited endogenous 
VEGF-A expression (Figure 4.8 (C)). Thus, Notch signalling within the first 24 hours of 
culturing MSCs at high cell density, up-regulated the expression of VEGFR1, vWF and 
VEGF-A.  
 
4.4.5. Notch receptor siRNA knockdown inhibited EC marker expression  
 
To further confirm that Notch receptors induced MSC density-dependent expression of 
VEGFR1 and vWF, siRNA oligonucleotides (three target specific siRNAs in each case) 
were utilised to knockdown expression of Notch receptors 1, 2 and 3, respectively 
(Figure 4.9). The efficacy of each siRNA knockdown compared to scrambled siRNAs, 
was confirmed by immunoblot analysis (see control Figure 4.22). The specificity of each 
siRNA Notch receptor knockdown was confirmed by re-probing the blots for a non-target 
Notch receptor, which revealed unchanged protein levels in each case (see Figure 4.22).  
 
Immunoblot analysis was used to determine which Notch receptors contributed to 
inducing MSCs to express VEGFR1 when cultured at high cell density for 24 hours 
(Figure 4.9). MSCs transfected with siRNA oligonucleotides for Notch receptor 1, Notch 
receptor 2 or Notch receptor 3 all demonstrated a significant decrease in VEGFR1 
protein expression (p<0.05) (Figure 4.9 (A); lanes 2, 4, 6 respectively) compared to 
MSCs transfected with scrambled siRNAs (Figure 4.9 (A); lanes 1, 3, 5). Thus, Notch 
receptors 1, 2 and 3 all contributed to inducing MSCs to express VEGFR1.  
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Figure 4.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Notch signalling inhibition decreased EC markers and VEGF-A secretion 
To determine whether Notch signalling regulated MSC density dependent expression of VEGFR1 
and vWF, protein levels were determined following inhibition of Notch signalling by DAPT 
treatment (50 μM). DMSO was used as a diluent control.  (A) immunoblot analysis of VEGFR1 
protein or (B)  vWF protein, derived from MSCs cultured for 24 hours at high cell density (MSCH) 
in the presence of DAPT (lanes 1) or DMSO (lanes 2). Pixel density was normalised to β-actin and 
plotted as a bar graph. * represents p<0.05 compared to MSCs cultured after plating at high cell 
density in the presence of DMSO only. (C) ELISA assay of VEGF-A from medium derived from 
MSCs at low cell density (L) or at high cell density (H) in the presence of DMSO with or without 
DAPT. * represents p<0.05. Membranes were reprobed with β-actin as loading controls. Data are 
representative of two independent experiments with each ELISA sample run in duplicate. 
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Figure 4.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Notch receptor siRNA knockdown inhibited EC marker expression 
 
To determine whether Notch signalling mediated MSC density dependent expression of VEGFR1 
and vWF, siRNA knockdown of Notch receptors 1-3 was performed. Immunoblot analysis of (A) 
VEGFR1 and (B) vWF from MSCs cultured for 24 hours at high cell density, following transfection 
with scrambled (scr) controls (lanes 1, 3 and 5) or siRNAs for Notch receptors 1, 2 and 3 (lanes 2, 
4 and 6). Membranes were reprobed with β-actin as loading controls. Pixel density was normalised 
to β-actin and plotted as a bar graph. * represents p<0.05 compared to scrambled control 
transfected MSCs. Data are representative of two independent experiments.  
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Similarly, following Notch 1 or 2 receptor siRNA knockdowns in MSCs cultured at high 
cell density for 24 hours (Figure 4.9 (B); lanes 2, 4), immunoblot analysis revealed that 
both knockdowns significantly decreased vWF protein expression (p<0.05), compared to 
MSCs transfected with scrambled siRNAs (Figure 4.9 (B), lanes 1 and 3). In contrast, 
however Notch 3 siRNA knockdown had no detectable effect on vWF protein expression 
(Figure 4.9 (B), lane 6), compared to scrambled siRNA control (Figure 4.9 (B), lane 5). 
Thus, Notch receptors 1, 2 and 3 are involved in inducing MSCs at high density to 
express VEGFR1, while Notch receptors 1 and 2 are involved in directing MSCs at high 
density to up-regulate vWF expression. 
 
4.4.6. Notch activation stimulated MSCs at low density to express EC markers 
 
Since inhibition of Notch signalling in MSCs cultured at high density for 24 hours 
significantly regulated the expression of VEGFR1 and vWF, experiments were 
conducted to establish whether activation of Notch signalling in MSCs cultured at low 
density would induce the expression of VEGFR1 and vWF (Figure 4.10). Notch 
signalling can be activated by treating cells with cation chelators, which cause the rapid 
shedding of the Notch extracellular domain, increasing Notch receptor 1 intranuclear 
staining and transcription of CBF1, a nuclear mediator of Notch signalling (Aster et al., 
1999; Rand et al ., 1997, 2000). MSCs that had been cultured at high cell density in the 
presence of 5 mM EDTA displayed an increase in HES1 activation, demonstrating the 
effectiveness of EDTA treatment (see control Figure 4.22).  Immunoblot analysis of 
MSCs cultured at low cell density for 24 hours in the presence of EDTA, demonstrated 
both VEGFR1 (Figure 4.10 (A); lane 2) and vWF expression (Figure 4.10 (B); lane 2). In 
comparison neither VEGFR1 nor the 225-kDa fragment of vWF could be detected after 
24 hours in the absence of EDTA (Figure 4.10 (A, B); lanes 1). Thus, activation of Notch 
signalling in MSCs cultured at low density by EDTA exposure was sufficient to induce 
the expression of EC markers that would otherwise only be expressed by MSCs at high 
density. 
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Figure 4.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Notch activation stimulated MSCs at low density to express EC markers 
To determine whether experimental activation of Notch could induce MSCs at low cell density for 
24 hours to express vWF and VEGFR1 protein, MSCs were treated with Notch activators. (A-C). 
Immunoblot analysis of (A) vWF  or (B) VEGFR1 from MSCs cultured after plating at low cell 
density (L) (lanes 1 and 2) or high cell density (H) (lanes 3 and 4) in the absence (-) (lanes 1 and 
3) or presence (+) (lanes 2 and 4) of 5 mM EDTA. (C) To further verify that MSCs cultured at low 
cell density could be induced to express vWF by Notch activation, Notch was activated using 
immobilised Jagged-1. Immunoblot analysis of vWF protein expression in MSCs cultured at low 
cell density (lanes 1 and 2) or high cell density (lanes 3 and 4) for 24 hours in the absence (-) 
(lanes 1 and 3) or presence  (+) (lanes 2 and 4) of immobilised Jagged-1. Membranes were 
reprobed with β-actin as loading controls. Data are representative of two independent 
experiments. 
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To further demonstrate that MSCs cultured at low density for 24 hours could be induced 
to up-regulate their expression of vWF by Notch activation, MSCs at low density were 
exposed to the Notch ligand Jagged-1 (Figure 4.10 (C). Recombinant Jagged-1 was 
immobilised onto plates, the MSCs seeded at high or low cell density and cultured for 24 
hours. Immunoblot analysis demonstrated that Jagged-1 enhanced the abundance of 
the high molecular weight (400 kDa) fragment of vWF in MSCs cultured in low density 
(Figure 4.10 (C); lane 2), compared to unstimulated MSCs, which only expressed low 
levels of this fragment (Figure 4.10 (C); lane 1). Thus, Jagged-1 activation of Notch 
signalling was sufficient to stimulate vWF expression in MSCs cultured at low cell 
density. 
 
4.5. Involvement of VEGF-A in consolidating the EC fate. 
 
4.5.1. Sustained exposure to VEGF-A enhanced VEGFR1 expression  
 
Previous studies have analysed endothelial marker expression after 7-14 days in culture 
(see chapter introduction section 4.1). The effects of MSC expression of endothelial 
markers following sustained exposure to VEGF-A for 14 days was therefore examined. 
 
MSCs cultured at high cell density were exposed to exogenous 50 ng/ml VEGF-A for 14 
days (Figure 4.11). RT-PCR analysis demonstrated that exposure to VEGF-A markedly 
increased VEGFR1 transcript expression after 14 days (Figure 4.11 (A); lane 3 and 6), 
but no detectable change in the level of vWF expression was detected (Figure 4.11 (A); 
lane 9 and 10). Subsequent immunoblot analysis confirmed that VEGF-A exposure for 
14 days significantly increased the level of VEGFR1 protein expressed by MSCs 
cultured at high density (Figure 4.11 (B); lane 2) compared to unstimulated MSCs 
cultured at high density (Figure 4.11 (B); lane 1). In contrast, exposure to VEGF-A for 14 
days produced no detectable change in the level of vWF expressed by MSCs cultured at 
high density (Figure 4.11 (C); lane 2) compared to unstimulated MSCs cultured at high 
density (Figure 4.11 (C); lane 1). 
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Figure 4.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Sustained exposure to VEGF-A enhanced VEGFR1 expression  
(A) MSCs cultured at high density were stimulated with 50ng/ml VEGF-A every other day for 14 
days, then VEGFR1-3 (99-bp, 81-bp, 87-bp respectively) and vWF transcripts (95-bp) examined 
by semi-quantitative RT-PCR analysis. GAPDH (71-bp) was used to confirm equal RNA 
concentrations. Lanes 1-2, GAPDH in unstimulated (control) or VEGF-A treated MSCs 
respectively; lanes 3-5, VEGFR1-3 transcripts respectively in unstimulated MSCs; lanes 6-8, 
VEGFR1-3 transcripts respectively in VEGF-A treated MSCs; lanes 9-10, vWF transcripts in 
unstimulated or VEGF-A treated MSCs respectively. Two different primer pairs for VEGFR1-3 and 
vWF transcripts gave similar results. Red boxes = unstimulated cells; blue boxes = VEGF-A 
stimulated cells. Data are representative of two independent experiments. (B, C) Immunoblot 
analysis of (B) VEGFR1 or (C) vWF protein levels in MSCs cultured at high density for 14 days. 
Lanes 1, unstimulated MSCs, lanes 2, MSCs exposed to 50ng/ml VEGF-A. β-Actin was used as a 
loading control. Pixel density was normalised to β-actin and plotted as a bar graph. * represents 
p<0.05 compared to unstimulated MSCs cultured at high cell density. Data are representative of 
two independent experiments. 
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 4.5.2. Sustained VEGF stimulation up-regulated EC markers 
 
To determine whether endogenous levels of VEGF-A played a role in regulating the 
level of EC markers expressed by MSCs cultured at high density, MSCs were cultured in 
the presence of the VEGF-A neutralising antibody (VEGF-I) or a VEGFR signalling 
inhibitor (VEGFR-I) for 14 days (Figure 4.12). After 14 days in the presence of VEGF-I 
(Figure 4.12 (A); lane 2) or VEGFR-I (Figure 4.12 (A); lane 3), immunoblot analysis of 
MSCs cultured at high density revealed a significant decrease in VEGFR1 protein 
expression (the effectiveness of these inhibitors is shown in Figure 4.20), compared to 
untreated MSCs (Figure 4.12 (A); lane 1). In contrast, MSCs cultured at high density 
exposed to VEGF-I or VEGFR-I demonstrated no significant effect on vWF expression 
(Figure 4.12 (B) lanes 2 and 3 respectively), compared to the untreated cells (Figure 
4.12 (B); lane 1). However, immunoblot analysis of VE-cadherin expressed by MSCs 
cultured at high density and exposed to VEGFR-I for 14 days (Figure 4.12 (C); lane 2) 
demonstrated a significant decrease in VE-cadherin expression, compared to the 
untreated cells (Fig 4.12 (C); lane 1). Thus, over a period of 14 days, autocrine VEGF-A 
stimulation of MSCs at high cell density specifically enhanced the expression of 
VEGFR1. In addition, inhibition of VEGFR1 signalling significantly reduced the induction 
of VE-cadherin expression by MSCs cultured at high cell density. 
 
4.5.3. Notch and VEGF-A stimulated MSC differentiation to ECs over 14 days 
 
Having established that sustained VEGF-A exposure significantly enhanced VEGFR1 
expression over 14 days and that Notch signalling regulated both VEGFR1 and vWF 
expression after 24 hours, experiments were conducted to determine the effects of 
inhibiting both signalling pathways over 14 days. 
 
When MSCs were cultured at high density in the presence of DAPT and VEGF-I for 14 
days, immunoblot analysis demonstrated a significant decreased in VEGFR1 expression  
(Figure 4.13, lane 1), compared to MSCs treated with DAPT (Figure 4.13, lane 2) or 
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Figure 4.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12.  Sustained VEGF stimulation up-regulated EC markers 
Immunoblot analysis of (A) VEGFR1, (B) vWF and (C) VE-cadherin expression by MSCs cultured 
at high density for 14 days, in  the presence of 1 μg/ml VEGF neutralising antibody (VEGF-I) or 0.5 
μM VEGFR tyrosine kinase inhibitor (VEGFR-I). Untreated MSCs were used as a control (cont). 
Membranes were re-probed with β-actin as loading controls. Pixel density was normalised to β-
actin and plotted as a bar graph. * represent p<0.05 compared to untreated (cont) MSCs. A 
representative of two independent experiments is shown for each analysis. 
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 VEGF-I alone (Figure 4.13, lane 3).Furthermore, when both inhibitors were removed 
and MSCs allowed to recover for 48 hours (Figure 4.13, lane 5) the level of VEGFR1 
expressed by MSCs cultured a high density was restored to pre-inhibition levels (Figure 
4.13, lane 4). 
 
4.5.4. VEGF-A up-regulated PECAM-1 expression 
 
As previously described, MSCs cultured at high density significantly upregulated 
PECAM-1 expression within 24 hours (see Results chapter 3, section 3.3.6). 
Experiments were therefore conducted to determine whether autocrine VEGF-A 
signalling regulated PECAM-1 expression by MSCs cultured at high density for 24 hours 
(Figure 4.14). When MSCs were cultured at high density for 24 hours in the presence of 
the VEGFR signalling inhibitor (VEGFR-I), immunoblot analysis revealed no change in 
PECAM-1 expression (Figure 4.14 (A); lane 2), compared to untreated MSCs. (Figure 
4.14 (A); lane 1) However, when MSCs were cultured at high density for 24 hours in the 
presence of the VEGF neutralising antibody (VEGF-I), immunofluorescence analysis 
demonstrated a marked reduction in PECAM-1 immunopositivity (Figure 4.14 (D)) 
compared to control MSCs (Figure 4.14 (B)) or MSCs cultured in the presence of 
VEGFR-I (Figure 4.14 (C)). Thus, autocrine VEGF-A stimulated MSCs at high density to 
enhance PECAM-1 expression, but this stimulation was not mediated by VEGFR1. 
 
4.5.5. MSCs at high density up-regulated PDGFR expression and signalling 
 
Studies in this lab have previously shown that, in MSCs cultured in standard conditions 
which did not express VEGFRs, VEGF-A can signal through the PDGFRs (Ball et al ., 
2007c). Immunoblot analysis of PDGFRα or PDGFRβ in MSCs cultured at either high or 
low density, in the presence of DAPT or DMSO, demonstrated that their expression 
(Figure 4.15 (A)) and phosphorylation status (Figure 4.15 (B)) increased at high density.  
 
In these conditions, the level of PDGFRα expression was significantly up-regulated by 
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Figure 4.13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Notch and VEGF-A stimulated MSC differentiation to ECs over 14 days 
To determine the effects of inhibiting both Notch and VEGF signalling pathways over 14 days, 
MSCs were cultured at high density for 14 days in the presence of both 50 μM DAPT and 1μg/ml 
VEGF neutralising antibody (VEGF-I). Lane 1, DAPT and VEGF-I; lane 2, DAPT alone; lane 3, 
VEGF-I alone; lane 4, without DAPT or VEGF-A. In addition, following culture of MSCs at high 
density for 14 days in the presence of inhibitors MSCs were washed twice then cultured for 48 
hours in the presence of fresh inhibitors. Lane 5, MSCs cultured for 14 days with DAPT and 
VEGF-I then cultured for 48 hours with media alone; lane 6, MSCs cultured for 14 days with DAPT 
alone replaced with VEGF-I alone; lane 7, MSCs cultured for 14 days with VEGF-I alone replaced 
with DAPT alone; lane 8, MSCs cultured for 14 days in the absence of DAPT and VEGF-I replaced 
with DAPT and VEGF-I. Membranes were reprobed with β-actin as loading controls. Pixel density 
was normalised to β-actin and plotted as a bar graph. * represents p<0.05. Data are representative 
of two independent experiments.  
DAPT                 +       +       - - - - +        +
VEGF-I                +        - +      - - +       - +
control Recovery
*
*
*
*
*
*
P
ix
el
 d
en
si
ty
180-kDa
42-kDa
DAPT        +        +        - - - - +          +
VEGF-I      +        - +        - - +         - +
control Recovery
MW                      1        2        3    4             5         6        7         8
VEGFR-1
β-actin
*
*
*
P
ix
el
 d
en
si
ty
  
 - 142 - 
Figure 4.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. VEGF-A up-regulated PECAM-1expression 
(A) Immunoprecipitation then immunoblot analysis of PECAM-1 expression in MSCs cultured at 
high density for 24 hours in the presence of 0.5μM VEGFR-I or untreated (Cont). Equal volumes of 
lysates were probed for β-actin and used as a loading control. (B-E) Immunofluorescence analysis 
of PECAM-1 in MSCs cultured at high density for 24 hours in the presence of 0.5μM VEGFR-I or 
1μg/ml VEGF-I or untreated (cont). Twenty representative images of each analysis were taken 
using a Nikon upright C1 microscope (60× objective). DAPI = blue, PECAM-1 = green. Data 
represent two independent experiments. Arrows depict PECAM-1 immunopositivity. Scale bars = 
7μm 
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Notch signalling inhibition, whilst the expression of PDGFRβ did not alter following DAPT 
treatment (Figure 4.15 (A)). Notch inhibition did not appear to decrease the level of 
PDGFR phosphorylation (Figure 4.15 (B)).  
 
4.5.6. VEGF-A-PDGFR signalling up-regulated PECAM-1 expression  
 
To determine whether VEGF-A mediated PDGFR signalling regulated PECAM-1 
expression in MSCs cultured for 24 hours at high density, MSCs were cultured in the 
presence of a PDGFR receptor inhibitor (designated PDGFR-I) or VEGF-I for 24 hours 
(Figure 4.16). Control experiments were performed to demonstrate that PDGFR-I 
inhibited PDGFRβ phosphorylation in MSCs (Figure 4.21). Immunoblot analysis of MSCs 
cultured at high density in the presence of either PDGFR-I or VEGF-I, showed a 
decrease in PECAM-1 expression compared to control untreated MSCs (Figure 4.16 
(A)). To determine whether VEGF-A mediated PDGFR signalling regulated PECAM-1 
expression, immunofluorescence analysis of PECAM-1 expression was performed. 
MSCs cultured at high density for 24 hours in the presence of PDGFR-I (Figure 4.16 
(C)), demonstrated loss of PECAM-1 immunostaining compared to untreated MSCs 
(Figure 4.16 (B)). The isotype IgG1 control did not bind (Figure 4.16 (D)). 
 
4.5.7. PDGFRα mediated PECAM-1 expression 
 
To verify whether VEGF-A signalling through the PDGFRs regulated PECAM-1 
expression, MSCs were cultured at high density in the presence of 10μg/ml PDGFR-α or 
PDGFRβ neutralisation antibodies (Figure 4.17). Control experiments were performed to 
demonstrate that the neutralisation antibodies blocked their target PDGFR 
phosphorylation in MSCs (Figure 4.21). Compared to untreated control MSCs (Figure 
4.17 (A)), treatment with PDGFRα neutralisation antibody (Figure 4.17 (B)) resulted in 
loss of PECAM-1 immunoreactivity. In contrast however, PDGFRβ neutralisation had no 
effect on PECAM-1 immunoreactivity (Figure 4.17 (C)). Thus, PDGFRα mediated 
PECAM-1 expression during the first 24 hours of culturing MSCs at high density.
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Figure 4.15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. MSC at high density up-regulated PDGFR expression and signalling 
(A) Immunoblot analysis of PDGFRα and β expression in MSCs cultured at high (MSC-H) or low 
(MSC-L) density in the presence of 50μM DAPT or DMSO. β-actin was used as a loading control. 
Pixel density was normalised to β-actin and plotted as a bar graph. * represents p<0.05.  
(B) Receptor tyrosine kinase phosphorylation array (RTK) analysis using lysates derived from 
MSC-L or MSC-H cultured for 24 hours in the presence of DMSO or DAPT (MSC-H + DAPT). Data 
are representative of two independent experiments. 
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Figure 4.16 
 
Figure 4.16. VEGF-A- PDGFR signalling up-regulated PECAM-1 expression 
(A) Immunoprecipitation and Immunoblot analysis of PECAM-1 expression in MSCs cultured at 
high density for 24 hours in the presence of 1 µg/ml VEGF-I or 0.1 µM PDGFR-inhibitor (PDGFR-I) 
or untreated (Cont). Equal volumes of protein lysate was blotted for β-actin and used as loading 
controls for each analysis.  
(B-D) Immunofluorescence analysis of PECAM-1 in MSCs cultured at high density for 24 hours in 
the presence of 0.1 µM PDGFR-I or untreated (cont). Twenty representative images of each 
analysis were taken using a Nikon upright C1 microscope 60× objective. DAPI = blue, PECAM-1 = 
green. Data are representative of two independent experiments. Arrows depict PECAM-1 
immunopositivity. Scale bars = 7 µm 
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4.5.8. VEGF-A did not regulate Notch signalling  
 
The close relationship between the Notch signalling pathway and the VEGF signalling 
pathway has been shown in a number of studies (Kearney et al ., 2002; Cameliet et al., 
2009; Phng et al ., 2009; Boulton et al ., 2008b). As shown previously (Figure 4.8), Notch 
signalling inhibition with DAPT significantly inhibited VEGF-A autocrine secretion. In 
addition, previous studies have demonstrated that VEGF can regulate the expression of 
Notch signalling components (Kearney et al ., 2002; Cameliet et al ., 2009; Phng et al ., 
2009; Boulton et al ., 2008b) (Chapter 4: Results; section 4.1).  
 
To determine whether autocrine VEGF-A can regulate Notch signalling components in 
MSCs cultured at high density, MSCs were treated with VEGF-I for 48 hours and the 
expression of HES-1, Notch receptor 2, Notch receptor 3 and Jagged-1 determined by 
immunoblot analysis (Figure 4.18). However, treatment with VEGF-I (Figure 4.18; lane 
2), had no significant difference in the expression of the Notch components, compared to 
MSCs cultured in the absence of VEGF-I (Figure 4.18; lane 1), Thus, autocrine VEGF-A 
stimulation was not a major mechanism regulating Notch signalling in MSCs cultured at 
high density.  
 
4.6. Other possible mechanisms involved in density-dependent differentiation  
 
This study has demonstrated how Notch signalling is a major determinant in initiating 
MSC commitment to ECs, whilst VEGF-A is essential to consolidate the EC fate. 
However other signalling mechanisms are also likely to play a role in regulating density- 
dependent MSC differentiation. RTK analysis which determines phosphorylation status of 
forty-two different RTKs, identified several RTKs which were significantly activated in cell 
lysates derived from MSCs cultured at high density (Figure 4.19). These RTKs which 
included hepatocyte growth factor receptor (HGFR), epidermal growth factor receptor 
(EGFR/ErbB-1/HER1)), EphA7, Insulin receptor, IGF receptor and Axl may also play a 
critical role in regulating cell density dependent differentiation towards ECs. 
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Figure 4.17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. PDGFRα mediated PECAM-1 expression. 
MSCs were incubated with (B) 10μg/ml anti PDGFRα or (C) anti-PDGFRβ neutralisation 
antibodies for 24 hours at 37oC. (A) Untreated MSCs were used as a control (Cont). IgG1 is shown 
as a control. Cells were immunostained for PECAM-1 = green, nuclei stained with DAPI = blue. 
Twenty representative images of each analysis were taken using a Nikon upright C1 microscope 
(60× objective). Scale bars = 7μm.  
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Figure 4.18 
 
 
 
 
Figure 4.18. VEGF-A did not regulate Notch signalling 
To determine whether VEGF-A regulates Notch signalling, immunoblot analysis was performed for 
the Notch components (A) HES-1, (B) Notch receptor 2 and (C) Notch receptor 3 and (D) the 
Notch ligand Jagged 1 (JAG-1) in MSCs cultured at high density for 24 hours in the presence of 1 
μg/ml VEGF-I or 50 µM DAPT. Untreated MSCs at high density for 24 hours were used as controls 
(Cont). Membranes were reprobed with β-actin as loading controls. Data are representative of two 
independent experiments. 
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Figure 4.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19. Involvement of other signalling mechanisms in density dependent differentiation 
RTK phosphorylation array using lysates taken from MSCs cultured at low density (MSC-L) or high 
density (MSC-H) for 24 hours showing phosphorylation status of 42 different RTKs. Receptors 
showing a significant increase in phosphorylation during MSC culture at high density are 
highlighted, these include epidermal growth factor receptor (EGFR/ErbB-1/HER1)), hepatocyte 
growth factor receptor (HFGR) and insulin growth factor receptor (IGF-R). Data are representative 
of two independent experiments. 
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Figure 4.20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. VEGFR signalling controls  
(A) HUVECs were treated with 0.5 μM VEGF receptor tyrosine kinase inhibitor (KRN633) or were 
left untreated (Cont). VEGFR1 was isolated by immunoprecipitation using an anti-VEGFR1 
antibody, and tyrosine phosphorylation was detected by immunoblot analysis using an anti-
phosphoVEGFR1 antibody. Membranes were re-probed with an antibody to total VEGFR1 as a 
loading control. (B) HUVECs were treated with 1 μg/ml anti-VEGF neutralising antibody (+VEGF-
I), or were left untreated (Cont), for 15 minutes in 0.5% serum DMEM, then cells stimulated with 
50 ng/ml VEGF-A. VEGFR2 was isolated by immunoprecipitation using an anti-VEGFR2 antibody, 
and tyrosine phosphorylation detected by immunoblot analysis using an anti phosphotyrosine 
antibody. Membranes were re-probed with an antibody to total VEGFR2 for loading controls.  
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Figure 4.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21. PDGFR signalling controls 
MSCs cultured at high density were treated with 10µg/ml PDGFRα or PDGFRβ neutralisation 
antibodies or 0.1μM PDGFR-I for 48 hours, or were left untreated (cont). (A) PDGFRβ or (B) 
PDGFRα were isolated by immunoprecipitation using anti-PDGFRβ antibody or anti-PDGFRα 
antibodies, then tyrosine phosphorylation detected by immunoblot analysis using an anti 
phosphotyrosine antibody. Membranes were re-probed with β-actin for loading controls.  
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Figure 4.22 
 
Figure 4.22. Notch signalling controls. 
 
(A) As a control for DAPT treatment, HES1 transcript levels were determined by RT-PCR, 
following 50 μM DAPT treatment in MSCs cultured at low (L) or high density (H) for 24 hours. 
GAPDH was used as loading controls. 
(B) As a control for EDTA treatment, HES1 transcript levels were determined by RT-PCR, 
following 5 mM EDTA treatment in MSCs cultured at high density (H) for 24 hours. GAPDH was 
used as loading controls. 
(C) siRNA knockdown of Notch receptors. Immunoblot analysis of Notch1 (N1), Notch2 (N2) and 
Notch3 (N3) protein expression in MSCs which were cultured for 24 hours at high cell density, 
following transfection with 3 μg scrambled (scr) siRNA as controls (lanes 1, 3 and 5) or target 
siRNAs for Notch receptors 1, 2 or 3 (lanes 2, 4 and 6 respectively). Membranes were re-probed 
with an alternative Notch receptor as loading controls and to validate the specificity of each Notch 
receptor siRNA.  
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4.7. Discussion  
 
Identifying the initial regulating mechanisms which direct MSC differentiation towards 
ECs, is fundamental to utilising MSCs in future therapeutic applications. In this study, the 
Notch signalling pathway was shown to be a primary mechanism in controlling the initial 
stages of directing MSCs to differentiate towards an EC fate. 
 
Previous studies have reported that MSCs exposed to VEGF-A over 14 days, 
differentiate towards ECs (Chapter 4: Results; section 4.1). Consequently, exposure to 
VEGF-A was presumed to be the primary stimulus driving differentiation, even though in 
some cases the MSCs were shown to express no VEGFRs. (Oswald et al ., 2004; Chen 
et al ., 2009). In these studies, the MSCs were cultured at low cell density in the 
presence of VEGF-A, which resulted in EC markers only being detected after 7 days. As 
MSCs cultured for 7 days would be at high density by this time, VEGF exposure alone is 
therefore not the only mechanism involved in directing MSCs to differentiate towards 
ECs.  
 
In this study, MSCs cultured at low density in the presence of VEGF-A for 24 hours did 
not express EC markers, whilst culture of MSCs at high density for 24 hours was 
sufficient to induce the expression of EC markers. Furthermore, analysis of MSCs 
cultured at high density for 24 hours following VEGF-A siRNA knockdown or 
neutralisation, revealed that VEGF-A did not control the initiation of VEGFR1 expression 
or up-regulation of vWF expression. Thus, VEGF-A was not sufficient to initiate the 
differentiation of MSCs to ECs. However, since VEGF-A has been shown to stimulate 
proliferation, VEGF-A may well play an important role in accelerating density-dependent 
differentiation. 
 
Notch signalling was found to induce MSC cultured at high density to express VEGFR1. 
Previous studies have suggested that Notch signalling can alter expression levels of all 
three VEGF receptors (Suchting et al , 2007; Harrington et al , 2008).  Two recent 
reports suggest that VEGFR1 expression may be increased by Notch signalling. 
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(Suchting et al , 2007; Harrington et al , 2008). The Notch target gene Hey1 has been 
shown to downregulate VEGFR2 (Holderfield et al ., 2006; Taylor et al , 2002) 
suggesting that Notch can provide negative feedback to reduce the activity of the 
VEGF/VEGFR system. In addition, studies in several systems, established that VEGF 
regulates the expression of Notch signalling components (Thurston et al ., 2008; Patel et 
al ., 2005; Hainaud et al ., 2006; Ridgway et al ., 2006). Here, Notch-dependent VEGF-A 
secretion was found to induce VE-cadherin expression through VEGFR1 signalling and 
stimulated PECAM-1 expression through PDGFR-α signalling. Thus, whilst VEGF-A is 
not sufficient to induce MSC differentiation to ECs, VEGF-A is essential to consolidate 
the EC fate. VEGF-A has previously been demonstrated to induce VE-cadherin 
expression, which is considered to be a late EC differentiation marker, in rat placental 
trophoblasts (Nikolova-Krstevski et al ., 2008; Chang et al ., 2005), however it is 
unreported whether VEGF acting through VEGFR1 mediated the induction in this 
system. Thus, a complex relationship exists between the signalling mediated by Notch, 
VEGFR1, PDGFRα and VEGF-A which control EC specification (Jakobsson et al ., 
2009; Kearney et al ., 2002; Carmeliet et al ., 2009; Phng et al ., 2009; Boulton et al ., 
2008b).  
 
As previously mentioned, the results indicated that VEGF-A signalling through PDGFRα 
in MSCs cultured at high density stimulated PECAM-1 expression. In MSCs which 
expressed no VEGFRs, VEGF-A has been shown to signal through both PDGFRs (Ball 
et al ., 2007c). In MSCs at high density which express low levels of surface VEGFR1, 
VEGF-A may thus signal through both VEGFR and PDGFR systems. PDGFR signalling 
plays a predominant role in regulating the vSMC phenotype and function (Owens 1995) 
and regulating the SMC characteristics of MSCs (Ball et al., 2007a; 2010b; Kinner  et al., 
2002). Furthermore, studies have shown that PDGFRα signalling mediated by a RhoA 
and Rho-associated kinase dependent mechanism, enhanced αSMA filament 
polymerisation (Ball et al ., 2007b). In addition, mechanical stress shown to increase 
PDGFRα signalling in SMCs, induced MSCs to express enhanced SMC markers, 
suggesting a differentiation to a SMC phenotype (Hu et al ., 1998). Interestingly Notch 
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signalling has been shown to regulate PDGFR signalling in vSMCs, with activation of 
either Notch 1 or Notch 3 up-regulating PDGFRβ, but down-regulating PDGFRα 
expression (Jin ., 2008) In this study, whilst the expression of PDGFRα was down-
regulated in response to Notch activation, signalling of both PDGFRs on MSCs 
increased with high density culture and were not affected by DAPT treatment. It is 
probable that whilst PDGFRα signalling mediates SMC differentiation in MSCs which 
lack VEGFRs, PDGFRα signalling acting in concert with VEGFR1 signalling, may 
contribute to determining an EC fate, by decreasing the SMC signalling pathways. Thus, 
these two crucial signalling systems are intricately linked in MSC fate determination. 
 
The localisation of Notch receptors in MSCs cultured at high density during the first 24 
hours showed that Notch receptor 2 was predominantly localised to the nucleus, 
reflecting active Notch signalling. In comparison, Notch receptor 1 was largely localised 
to the cell periphery while Notch receptor 3 was mainly localised to the Golgi apparatus 
with only a small proportion detected in the nucleus indicating a low level of active Notch 
signalling. This result may be explored further by confirming the distribution by western 
blot of cellular fractions (nuclear, cytoplasms and membrane bound). Previous studies 
have shown that Notch receptor proteins display a selective cellular and tissue 
distribution. In the vasculature, ECs express all four Notch receptors but Notch receptor 
4 displays an almost exclusively endothelial expression pattern, whereas Notch 
receptors 1-3 are expressed more ubiquitously (Uyttendaela et al ., 1996; Quillard et al ., 
2009). While Notch receptor is predominantly expressed by vascular ECs, prominent in 
both arteries and veins, the expression of Notch receptor 2 has also been reported in 
pulmonary endothelium (Villa et al ., 2001). Notch receptor 3 is primarily expressed in 
adult arterial vSMCs (Mumm et al ., 2000).The localisation of Notch receptors correlates 
with siRNA knockdown of the individual receptors showing Notch receptors 1 and 2 to be 
key in regulating both VEGFR1 and vWF expression, whilst Notch receptor 3 did not 
have any detectable effect on vWF protein expression. All three Notch receptors 
regulated VEGFR1 expression which may suggest that each Notch receptor has an 
essential non-redundant function in regulating MSC commitment towards ECs. The 
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ability of more than one Notch receptor to regulate the same event has previously been 
documented in vascular smooth muscle cells where both Notch 1 and 3 regulate cell 
growth, apoptosis and migration (Sweeney et al., 2004). However, the thresholds of 
detection may be misleading in this case as the Notch receptor expression is low in the 
scrambled control, thus each knockdown may only have a partial effect on VEGFR1 
levels. 
 
Recently, Notch signalling has been shown to be important in regulating chondrogenesis 
in human BM stromal cells during 3D cell aggregate culture (Oldershaw et al ., 2008). 
Expression analysis of Notch signalling components demonstrated a sharp increase in 
Jagged-1 and HEY-1 expression during the initial stages of aggregate culture, followed 
by a decline in expression with time.  Attenuation of Notch signalling was critical for the 
MSCs to complete chondrogenesis, since continuous elevated expression of Jagged-1, 
by adenoviral transduction, completely blocked chondrogenesis. There are interesting 
parallels between culturing BM-derived stromal cells in 3D aggregates and density 
dependent differentiation of MSCs to ECs, however, there are also distinct differences. 
One such difference is the use of defined chemicals to induce chondrogenesis in 
aggregate culture and subsequent suspension culture of aggregates. Moreover, the 
surface area in contact and the degree of hypoxia elicited in aggregate culture all reflect 
important differences from density-dependent differentiation of MSCs to ECs.  
 
This study demonstrated that Notch signalling in MSCs cultured at high density was 
most critical during the first 24 hours, when VEGFR1 was induced and vWF and 
PECAM-1 expression were significantly enhanced. This up-regulation in EC markers 
correlated with high expression levels of Notch receptors and Jagged-1 and HES-1 
transcripts. These Notch signalling components decreased with time, similar to their 
expression pattern in 3D aggregate cultures during chondrogenesis. However, VE-
cadherin expression was only induced after 7 days of high density culture. Furthermore, 
when MSCs cultured at high density were sub-cultured at low density, the expression of 
both vWF and VEGFR1 was retained (see Results chapter 3, section 3.4.1) suggesting 
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that sustained Notch signalling was not necessary for maintaining differentiation and 
consolidating the EC phenotype. Interestingly, Notch signalling inhibition by DAPT in 
MSCs cultured at high density for 14 days resulted in a significant decrease in both 
VEGFR1 and VE-cadherin expression, but this may well be an indirect effect resulting 
from the decrease in Notch regulated VEGF-A secretion and autocrine stimulation. This 
was further reflected when DAPT inhibition was removed, resulting in restoration of 
VEGFR1 expression. It would be interesting to determine whether sustained Notch 
activation could prevent differentiation of MSCs to ECs, similar to that determined in 3D 
aggregate cultures of BM-derived stromal cells during differentiation to chondrocytes. 
 
Due to their pluripotency, numerous studies have shown that ESCs can readily be 
induced to differentiate to ECs (Levenberg et al ., 2002; McCloskey et al ., 2006; 
Nikolova-Krstevski et al ., 2008; Yamamoto et al., 2005; Zeng et al ., 2006). Mechanisms 
which have been identified to control ESC differentiation to ECs, may also be involved in 
regulating MSC differentiation to ECs. In this respect, laminar flow was shown to 
enhance ESC proliferation and differentiation towards ECs by stabilising and activating 
histone deacetylase 3  (Zeng et al ., 2006). Interestingly, a similar signalling pathway was 
also detected during VEGF–induced ESC differentiation to ECs (Zeng et al ., 2006). 
histone deacetylase 3 is also involved in epigenetic modification of the chromatin to 
regulate gene transcription, which is essential for modulation of EC marker gene 
expression and has been shown to modulate EC marker gene expression (Zeng et al ., 
2006; Yamamoto et al ., 2005), however whether histone deacetylase 3 is activated in 
MSCs following VEGF-A stimulation remains to be determined. 
MSCs cultured at high density activated a number of different RTKs. Notably, high 
density MSC culture significantly increased the phosphorylation status of both PDGFRα 
and PDGFRβ, EGFR, EphA7, Axl and the insulin receptor. VEGF-A165 stimulation of 
MSCs has previously been shown to induce a similar complement of RTKs including 
tyrosine PDGFRs, EGFR, EphA7, and Axl, (Ball et al ., 2007c) and these receptors are 
therefore likely to have key roles in density dependent differentiation of MSCs to ECs. 
Density dependent differentiation phosphorylation of EGF receptor may also be a 
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secondary consequence of VEGF or Notch stimulation and may play an important role 
during MSC differentiation since EGF receptor signalling has recently been documented 
to reversibly prevent multilineage differentiation in BM-derived MSCs, indicating that the 
EGF receptor may control lineage commitment (Bobis et al ., 2006; Krampera et al., 
2005). The insulin receptor has been reported to play an important function during 
chondrogenesis aggregate culture, with insulin-like growth factor-1 modulating MSC 
chondrogenesis by stimulating proliferation, regulating cell apoptosis and inducing 
expression of chondrocyte markers (Longobardi et al., 2006). Since there are clear 
parallels between MSCs cultured in 3D aggregate culture to induce chondrogenesis and 
MSCs cultured at high density to induce differentiation to ECs, it would be interesting to 
determine whether the insulin receptors play a key role in this study. 
Here, Notch signalling activated in MSCs cultured at high cell density was a critical step 
in initiating differentiation to ECs. These mechanistic insights further our understanding 
of how MSCs differentiation is regulated and provide the basis for therapeutic 
manipulation during postnatal vasculogenesis events and in tissue engineering 
applications. The next chapter therefore focuses on the response of MSCs cultured at 
high density to pro-angiogenic environments. 
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4.8. Summary. 
• MSCs cultured at high density for 24 hours expressed VEGFR1, vWF and 
PECAM 
• MSCs expressed Notch receptors 1, 2 and 3  
• Notch signalling up-regulated VEGFR1, vWF and VEGF-A expression within 24 
hours. 
• VEGF-A stimulation did not modulate VEGFR1 or vWF expression within 24 
hours. 
• Notch receptors 1, 2 and 3 regulated VEGFR1 and vWF expression 
• Activation of Notch signalling alone was sufficient to induce EC markers in 
MSCs at low density. 
• Notch dependent VEGF-A signalling mediated by PDGFRα, regulated PECAM-1 
expression. 
• Notch dependent VEGF-A signalling regulated the expression of VEGFR1 over 
14 days. 
• Notch dependent VEGF-A signalling mediated by VEGFR1 induced VE-cadherin 
expression. 
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CHAPTER 5: RESULTS 
 
5.1. Behaviour of Endothelialised MSCs in angiogenic environments. 
 
To understand the mechanisms regulating the differentiation of stem cells, it is critical to 
consider the surrounding environment. Most of our knowledge of MSC biology is derived 
from in vitro culture studies that are often highly contrived to favour MSC culture 
expansion or differentiation events. It has been suggested that ECs derived from in vitro 
differentiated stem cells may lack complete functional maturation (McCloskey et al ., 
2006). In comparison to normal mature adult ECs, ESC derived ECs expressed lower 
levels of PECAM-1 and VE-cadherin and significantly lower levels of ac-LDL uptake and 
vWF expression. In addition, although ESC derived ECs expressed VE-cadherin, it did 
not localise to the cell-cell junctions, similar to the findings in this study (see Chapter 3 
Results, section 3.3.52).  
 
Thus, any conclusions drawn from in vitro studies regarding MSC differentiation capacity 
or therapeutic potential for cell transplantation therapy must therefore be validated by in 
vivo studies; which requires model systems for MSC transplantation that are permissive 
for both engraftment and differentiation. 
 
As previously discussed, the MSC microenvironment has a critical role in modulating 
MSC behaviour and function. Within a specific MSC niche, a dynamic complement of 
microenvironmental factors such as mechanical cues, soluble factors and cell-matrix and 
cell-cell interactions will contribute to regulating MSC differentiation, and will also 
modulate MSC signalling to the surrounding environment (Butler et al ., 2010; Edelberg 
et al., 2008; Kuhn et al ., 2009; Moore et al ., 2006; Scadden et al, 2006). In this respect, 
the vascular niche of small calibre arteries and veins not only permits the delivery of 
essential nutrients and oxygen, but also functions to provide angiogenic factors, or direct 
EC-MSC interactions which may instructively regulate MSC differentiation, initiate MSC 
mobilisation and facilitate tissue regeneration (Abedin et al ., 2004; Huang et al ., 2008; 
Jakobsson et al ., 2007; Sales et al ., 2005; Riha et al ., 2005). Furthermore, MSCs can 
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secrete paracrine factors such as VEGF-A, which can act to regulate EC growth and 
sprouting (Sorrell et al., 2009). 
 
Previous studies have shown that MSCs can be differentiated into ECs in vitro (see 
Introduction). This study has shown that MSC-to-EC in vitro differentiation is strongly 
regulated by cell density and initiated and consolidated by Notch and VEGF-A, 
respectively (see Chapter 3:Results; Chapter 4:Results). In addition, MSCs cultured at 
high density in three dimensional Matrigel culture, a basement membrane extract 
derived from the Engelbreth-Holm-Swarm mouse tumour on which MSCs spontaneously 
form networks, were shown to exhibit significantly enhanced networks and branch points 
(see Chapter 3: Results; Chapter 4: Results). While a range of two-dimensional and 
three-dimensional environments have been investigated for the manipulation of MSC 
differentiation pathways in vitro, three-dimensional environments have been shown to 
profoundly influence EC growth and differentiation (Baatout et al, 1997; Kleinman et al ., 
2005; O'Cearbhaill et al., 2010).  
 
In this chapter, MSCs that had been pre-cultured at high density for 28 days 
(endothelialised MSCs) were cultured within three-dimensional Matrigel and the effects 
on MSC differentiation and maturation to ECs determined. In addition, the response of 
endothelialised MSCs within the chick chorioallantoic membrane (CAM), a highly 
vascularised membrane produced by fusion of the allantois and the chorion, a commonly 
used angiogenesis assay (Ribatti et al ., 2006; Storgard et al ., 2005) was evaluated. 
Furthermore, endothelialised MSCs were monitored for integration into the functional 
host vasculature, as well as determining potential effects on blood vessel growth.  
 
5.2. Effects of in vitro Matrigel culture on MSC differentiation to ECs. 
 
 
5.2.1. Endothelialised MSCs enhanced VE-cadherin in Matrigel 
 
 
This study has previously shown that MSCs cultured at high density form enhanced 
networks in Matrigel (Chapter 3: Results section 3.3.7.2). Since three dimensional 
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culture has been reported to promote EC differentiation (Baatout et al ., 1996), MSCs 
that had been pre-cultured at high density for 28 days (endothelialised MSCs) were 
cultured in three dimensions using Matrigel, and the effects on differentiation towards 
ECs evaluated by determining VE-cadherin expression.  
 
Immunofluorescence analysis revealed endothelialised MSCs in Matrigel exhibited 
enhanced VE-cadherin expression compared with MSCs pre-cultured in standard 
conditions (Figure 5.1 (A)). Furthermore, immunoblot analysis of endothelialised MSCs 
cultured in Matrigel demonstrated a significant increase in VE-cadherin expression 
(Figure 5.1 (B)) compared to the same endothelialised MSCs cultured on tissue culture 
plastic.  
 
5.2.2. Endothelialised MSCs potentially expressed VEGFR2 in Matrigel 
 
VE-cadherin is known to form a complex with β-catenin, phosphoinositide-3-OH kinase 
and VEGFR2 in response to VEGF-A induced survival signals (Carmeliet et al ., 1999). 
In addition, VE-cadherin has been shown to regulate VEGFR2 internalisation and 
signaling from intracellular compartments (Lampugnani et al., 2006). Conversely, VEGF-
A stimulated VEGFR2 signalling has been shown to regulate VE-cadherin internalisation 
(Gavard et al., 2006; Wallez et al., 2007; Lampugnani et al ., 2006). Thus the signalling 
pathways mediated by VE-cadherin and VEGFR2 are intricately linked in ECs. Since 
three dimensional Matrigel culture of endothelialised MSCs increased their expression of 
VE-cadherin, the effects of Matrigel culture on VEGFR2 expression was also examined. 
 
Immunofluorescence analysis demonstrated that endothelialised MSCs in Matrigel 
displayed potential positive VEGFR2 immunoreactivity, whereas MSCs pre-cultured in 
standard conditions exhibited no detectable VEGFR2 immunoreactivity (Figure 5.2 (A)). 
To confirm that Matrigel induced endothelialised MSCs to express VEGFR2, immunoblot 
analysis was performed. Using HUVECs cultured on tissue culture plastic as a positive 
control, a double band was detected at 220-kDa which correlated to the anticipated size 
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Endotheliallised MSCs enhanced VE-cadherin in Matrigel 
To determine whether an in vitro three-dimensional culture environment influenced MSC 
differentiation to ECs, either 20,000 HUVECs as a control, standard cultured MSCs (MSC-S) or 
endothelialised MSCs (MSC-H) were seeded onto growth factor reduced Matrigel (MAT), or on 
tissue culture plastic (TCP), in 0.5% serum DMEM for 48 hours. (A) Immunofluorescence analysis 
of VE-cadherin expression in Matrigel. Widefield images using 20× objective. Scale bars= 200μm. 
DAPI (blue), VE-cadherin (green) (B) Immunoblot analysis of VE-cadherin protein levels in lane 1, 
HUVECs; lane 2, MSC-H cultured on TCP; lane 3, MSC-H cultured on Matrigel. * represents 
p<0.05 compared to endothelialised MSCs cultured on TCP. 
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of VEGFR2 (Figure 5.2 (B); lane 1). In comparison, this double band was not detected in 
endothelialised MSCs cultured on tissue culture plastic (Figure 5.2 (B); lane 2), 
demonstrating that Matrigel induced endothelialised MSCs to potentially express 
VEGFR2.  
 
5.2.3. Endothelialised MSCs decreased PECAM-1 in Matrigel 
 
To further examine the effects of Matrigel on influencing endothelial MSC differentiation, 
the expression of PECAM-1 was also evaluated. Immunofluorescence analysis of 
endothelialised MSCs in Matrigel displayed increased PECAM-1 immunoreactivity, 
compared to MSCs pre-cultured in standard conditions (Figure 5.3 (A)). Interestingly, 
immunoblot analysis of endothelialised MSCs cultured in Matrigel demonstrated a 
significant decrease in PECAM-1 expression (Figure 5.3 (B)), compared to when the 
same endothelialised MSCs were cultured on tissue culture plastic. RTK phosphorylation 
array analysis of endothelialised MSCs cultured of tissue culture plastic or Matrigel, 
demonstrated a significant decrease in PDGFRα and PDGFRβ phosphorylation levels 
as well as the epidermal growth factor receptor (EGFR/ErbB-1/HER1) and EphA7 
(Figure 5.3 (C)). In this respect, previous studies have demonstrated that PECAM-1 can 
be downregulated during angiogenesis (Romero et al., 1997; Berger et al ., 1993; 
Delisser et al ., 1997). 
 
Having established that an in vitro three-dimensional Matrigel environment promoted 
endothelialised MSCs to form increased network assemblies, enhanced VE-cadherin 
expression and induced VEGFR2 expression, the effects of an in ovo environment was 
next evaluated.   
 
5.3. Effect of in ovo Matrigel culture on MSC differentiation to ECs  
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Figure 5.2 
 
 
 
 
Figure 5.2. Endothelialised MSCs potentially expressed VEGFR2 in Matrigel 
MSCs pre-cultured in standard conditions (MSC-S) or endothelialised MSCs (MSC-H) were 
seeded onto growth factor reduced Matrigel for 48 hours. (A) Immunofluorescence analysis of 
VEGFR2 expression taken using an Olympus BX51 widefield microscope 20× objective. Scale 
bars represent 200 μm. (B) Immunoprecipitation then immunoblot analysis of VEGFR2 protein 
levels in MSC-H cultured in HUVECs (HUV) as controls (lane 1); MSC-H cultured on tissue culture 
plastic (TCP) (lane 2); MSC-H cultured on Matrigel (MAT) (lane 3). * represents p<0.05 compared 
to endothelialised MSCs cultured on TCP. For VEGFR2, equal volumes of protein lysate was 
blotted for β-actin and used as loading controls for each analysis. A representative of two 
independent experiments is shown in each case. 
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Figure 5.3 
 
 
Figure 5.3. Endothelialised MSCs decreased PECAM-1 expression in Matrigel 
MSCs pre-cultured in standard conditions (MSC-S) or endothelialised MSCs (MSC-H) were 
seeded onto growth factor reduced Matrigel for 48 hours. (A) Immunofluorescence analysis of 
PECAM-1. Widefield images using 20× objective. Scale bars represent 200μm. (B) 
Immunoprecipitation then Immunoblot analysis of PECAM-1 protein levels in HUVECs as controls 
(lane 1); endothelialised MSCs (MSC-H) cultured on tissue culture plastic, TCP (lane 2); 
endothelialised MSCs cultured on Matrigel, MAT (lane 3). * represents p<0.05 compared to 
endothelialised MSCs cultured on TCP. For PECAM-1, equal volumes of protein lysate was 
blotted for β-actin and used as loading controls for each analysis (C) RTK phosphorylation array 
analysis using lysates derived from endothelialised MSCs cultured on TCP or on Matrigel. 
Coloured boxes indicate RTK receptor displaying a difference between conditions. 
EGFR=epidermal growth factor receptor. A representative of two independent experiments is 
shown in each case. 
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5.3.1. Endothelialised MSCs formed enhanced networks within the CAM 
  
Immunofluorescence analysis of coverslips that had been removed from the chick CAM 
revealed that endothelialised MSCs formed enhanced networks on Matrigel, compared 
to MSCs pre-cultured in standard conditions (Figures 5.4, 5.5). In these analyses, MSC 
were labelled with DiI to distinguish implanted MSCs from endogenous chick cells. 
These enhanced networks displayed a marked increase in immunoreactivity for the EC 
markers vWF (Figure 5.4), VE-cadherin (Figure 5.5), PECAM-1 (Figure 5.7) and 
VEGFR2 (Figure 5.8) which were all widely distributed throughout the networks. In 
addition VE-cadherin became localised at the cell surface (Figure 5.6).  
 
5.3.2. Endothelialised MSCs promoted CAM vascularisation 
 
 
It is widely acknowledged that MSCs release a number of angiogenic ligands and 
cytokines (Chen et al ., 2008; Beckermann et al ., 2008; Burchfield et al ., 2008). 
Increasing evidence suggests that an important mechanism of action by which MSCs 
provide tissue protection and repair, is the release of paracrine factors which have the 
potential to stimulate neovascularisation and blood vessel growth (Beckermann et al ., 
2008; Chen et al ., 2008; Greenberg et al ., 2008). Furthermore, in this study (Chapter 3: 
Results, section 3.3.3), it was established that high density culture stimulated the 
secretion of the angiogenic growth factor VEGF-A in MSCs.  
 
To determine whether endothelialised MSCs induced a pro-angiogenic effect of the chick 
CAM vasculature, the size and length of the underlying CAM blood vessels were 
examined (Figure 5.9). CAMs which had not been exposed to implanted cells or 
exposed to implanted HUVECs or MSCs pre-cultured in standard conditions exhibited no 
significant difference in length or size of vessels or number of junctions, as quantified by 
angioquant software. In contrast however, endothelialised MSCs implanted onto the 
chick CAM for 48 hours, promoted extensive blood vessel growth in the underlying CAM, 
significantly enhanced the total number of junctions and diameters and lengths of  
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Figure 5.4 
 
 
 
 
 
 
Figure 5.4. Endothelialised MSCs formed enhanced networks within the CAM 
To determine whether an in vivo three-dimensional environment influenced MSC differentiation towards 
ECs, either 20,000 DiI labelled control standard MSCs (MSC-S) (left panels) or endothelialised MSCs 
(MSC-H) (right panels) were seeded onto growth factor reduced Matrigel-treated coverslips in 0.5% 
serum DMEM. Cells were left to adhere for one hour, then placed upon the chick CAM of a day five 
chick embryo for 48 hours. Immunofluorescence analysis of vWF using Olympus BX51 widefield 
microscope and 20× objective. vWF = green; DiI = red. Scale bars represent 200µm. A representative of 
two independent experiments are shown in each case. 
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Figure 5.5 
 
 
 
 
 
 
Figure 5.5. VE-cadherin expression in endothelialised MSC networks within the CAM. 
Either 20,000 DiI labelled control standard cultured MSCs (MSC-S) (left panels), or endothelialised 
MSCs (MSC-H) (right panels) were seeded on Matrigel, then placed into the chick CAM for 48 
hours. Immunofluorescence analysis of VE-cadherin expression. Images were obtained using an 
Olympus BX51 widefield microscope and 20× objective. Scale bars represent 200µm. VE-cadherin 
= green; DiI = red. A representative of two independent experiments is shown in each case. 
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Figure 5.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. VE-cadherin localised to the cell surface in endothelialised MSCs within the CAM  
Either 20,000 DiI labelled control standard cultured MSCs (MSC-S) (left panels), or endothelialised 
MSCs (MSC-H) (right panels) were seeded on Matrigel, then placed into the chick CAM for 48 
hours. Immunofluorescence analysis of VE-cadherin expression. Images were obtained using a 
Nikon C1 upright confocal microscope with 60× objective. Scale bars represent 7µm. VE-
cadherin= green; DiI=red. A representative of two independent experiments is shown in each 
case. 
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Figure 5.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. PECAM-expression in endothelialised MSCs within the chick CAM  
 
Either 20,000 DiI labelled control standard cultured MSCs (MSC-S) (left panels), or endothelialised 
MSCs (MSC-H) (right panels) were seeded on Matrigel, then placed into the chick CAM for 48 
hours. Immunofluorescence analysis of PECAM-1 expression. Images were obtained using a 
Nikon C1 upright confocal microscope with 60× objective. Scale bars represent 7µm. PECAM-1= 
green; DiI=red. A representative of two independent experiments is shown in each case. 
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Figure 5.8 
 
 
 
 
 
 
 
 
 
Figure 5.8. VEGFR2 expression in endothelialised MSCs within the chick CAM 
Either 20,000 DiI labelled control standard cultured MSCs (MSC-S) (left panels), or endothelialised 
MSCs (MSC-H) (right panels) were seeded on Matrigel, then placed into the chick CAM for 48 
hours. Immunofluorescence analysis of VEGFR2. Images were obtained using a Nikon C1 upright 
confocal microscope with 60× objective. Scale bars represent 7µm. VEGFR2= green; DiI=red. A 
representative of two independent experiments is shown in each case. 
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Figure 5.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9. Endothelialised MSCs promoted CAM vascularisation 
Either 20,000 HUVECs, MSCs pre-cultured in standard conditions (MSC-S) or endothelialised 
MSCs (MSC-H) were seeded onto Matrigel coated coverslips, then placed onto a chick CAM for 
48 hours. Following removal of the coverslips, the degree of vascularisation was quantified with 
Angioquant software measuring total number of junctions, total size of complexes and total lengths 
of complexes. * represent p<0.05 compared to MSC-S. Ten representative images were taken for 
each treatment, using a Nikon stereo microscope with each analysis performed in triplicate.  Scale 
bars represent 6 mm. A representative of two independent experiments is shown in each case. 
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vessels, compared to the same number of implanted HUVECs or MSCs pre-cultured in 
standard conditions (Figure 5.9).   
 
5.3.3. MSCs integrated into preformed endothelial networks 
 
Having established that endothelialised MSCs significantly enhanced the underlying 
CAM vascularisation, it was necessary to determine whether increased blood vessel 
growth resulted from MSC paracrine effects and/or from direct integration of MSCs into 
the pre-existing vasculature. Experiments were initially conducted in vitro to determine 
whether endothelialised MSCs could integrate into preformed HUVEC networks on 
matrigel. HUVECs were labelled with DiI, to distinguish HUVECs from unlabelled MSCs, 
then seeded onto Matrigel for 24 hours. Once HUVEC networks were established, 
unlabelled MSCs in standard culture conditions or endothelialised MSCs were seeded 
onto the preformed EC networks. Both MSCs pre-cultured in standard conditions or 
endothelialised MSCs were found to integrate into preformed HUVEC networks (Figure 
5.10), suggesting that direct integration may occur to enhance vascularisation in the 
chick CAM. 
 
To further validate this hypothesis, preliminary studies were carried out in vivo to 
determine whether endothelialised MSCs could integrate into the chick vasculature 
(Figure 5.11). Interestingly, MSCs pre-cultured in standard conditions could not be 
detected within the CAM vasculature. In contrast however, endothelialised MSCs were 
detected within the CAM blood vessels, suggesting that endothelialised MSCs may 
integrate directly into the pre-existing CAM vasculature resulting in enhanced vessel 
growth.  
 
5.4. Discussion 
 
BM–derived MSC have demonstrated considerable potential for regenerative medicine 
strategies (Adams et al ., 2007; Bobis et al ., 2006; Dai et al ., 2009; Granero- 
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Figure 5.10 
 
 
 
Figure 5.10. MSCs integrated into preformed endothelial networks 
HUVECs were labelled with 10μg/ml DiI and seeded onto growth factor reduced matrigel for 24 
hours to enable network formation to occur. Unlabelled MSCs (arrows) were then seeded onto 
preformed HUVEC networks and cultured for 24 hours, then immunofluorescence analysis was 
performed. Images were obtained using a Nikon C1 upright confocal microscope with 60× 
objective. Scale bars represent 7µm. αSMA/vWF/VEGFR1 = green; DiI = red. A representative of 
two independent experiments is shown in each case. 
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Figure 5.11 
 
 
 
 
 
Figure 5.11. Endothelialised MSCs were detected on the CAM surface 
 
Either 20,000 DiI labelled MSCs pre-cultured in standard conditions (MSC-S) or endothelialised 
MSCs (MSC-H) were seeded onto Matrigel coated coverslips, then placed onto a chick CAM for 48 
hours. Following removal of the coverslips the number of DiI labelled MSCs localising on the 
surface of the chick CAM was evaluated (arrows) and quantified as a bar graph. DiI=red (arrows). 
Scale bars represent 6 mm. A representative of two independent experiments is shown, in each 
case 10 representative images were taken for each analysis using the RFP channel or the GFP 
channel to eliminate autofluorescence. *=p<0.05 compared to MSC-S. 
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Molto et al., 2008; Hanson et al ., 2009; Miura et al ., 2006; Riha et al  ., 2005; Slater et 
al  2008). Understanding how different microenvironmental factors can regulate the fate 
of MSCs during in vitro culture and after implantation in vivo, is crucial for successful 
tissue regeneration therapies. In this chapter, three dimensional culture in vitro using 
Matrigel was shown to promote further MSC differentiation towards an EC fate by 
inducing VEGFR2 expression and significantly enhancing VE-cadherin expression 
throughout the network assemblies. It must however be noted that the high density 
MSCs in the middle of the network may be undergoing apoptosis so in this case the 
western blot is more convincing. Furthermore, implanted endothelialised MSCs in the 
pro-angiogenic environment of the chick CAM, expressed cell surface VE-cadherin, 
formed enhanced network assemblies and stimulated growth of the underlying chick 
vasculature. 
 
Matrigel promotes many cell types to adopt a more mature phenotype, as well as the 
outgrowth of differentiated cells from tissue explants (Bradham et al ., 1995; Hadley et al 
., 1995; Hoffman et al ., 1986; Kibbey et al ., 1992; Kleinman et al ., 1987; Li et al., 1987 
2005; Oliver et al ., 1987; Sawada et al ., 1987; Schuetz et al ., 1988; Vukicevic et al ., 
1990). Matrigel significantly reduces the proliferative capacity of many cell lines, which in 
many cases results in the morphology and gene expression profile reflecting a more 
differentiated phenotype. Epithelial cells, become more columnar when cultured on top 
of Matrigel, but form ducts, ductules and large glandular-like structures with a lumen 
when cultured in three-dimension within the matrix (Li et al ., 1987) In contrast, 
chondrocytes form cartilaginous nodules when cultured on the surface of the Matrigel 
(Bradham et al ., 1995). ECs cultured within Matrigel rapidly attach and align then form 
capillary-like structures with a lumen (Kubota et al ., 1988), whilst salivary gland cells 
form acinar-like structures and produce amylase when cultured on Matrigel (Hoffman et 
al ., 1996).  
Basement membrane components are the first ECMs synthesised in the developing 
embryo, with laminin expressed at the two-cell stage and a basement membrane 
apparent at gastrulation (Kleinman et al ., 2005). Since basement membranes are the 
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first ECMs that stem cells contact, it would be expected that such matrices would have a 
profound effect on regulating their differentiation.  
The multiple responses observed when cells are cultured in Matrigel are not well 
understood but undoubtedly involve a variety of mechanisms. Cells cultured within the 
three dimensional environment of Matrigel rapidly associate and become polarised. 
Thus, MSCs within Matrigel will have cell-cell contacts which are more representative of 
in vivo tissues. Matrigel, as well as being composed of basement membrane 
components, contains a rich store of angiogenic growth factors. In addition, fragments of 
laminin-1, collagen IV, and other matrix proteins have been shown to contribute 
angiogenic- and growth-promoting signals (Engbring et al ., 2003). For example, certain 
peptide sequences in laminin-1 have been shown to increase angiogenesis, protease 
activity, and/or tumor growth and metastasis via integrin receptors αvβ3 and α5β1. 
(Enbring et al ., 2003; Markwald et al, 1987; Ponce et al ., 1999; Stack et al ., 1993; 
Frisch et al ., 1996).   
As previously discussed, VEGFR2 plays a key role in regulating angiogenesis, therefore 
an environment such as Matrigel that is conducive to network formation or blood vessel 
development may well be expected to induce VEGFR2 expression (Smadja et al., 
2007).However, it must be noted that VEGFR2 only shows weak localisation by 
immunofluorescence analysis and low expression levels by western analysis. Regulation 
of VEGFR2 is an important mechanism during blood vessel formation, therefore it would 
be interesting to determine the components in Matrigel that are responsible for inducing 
this critical gene. RT-PCR analysis (Figure 4.11) showed that exogenous VEGF-A is not 
capable of inducing VEGFR2 in MSCs cultured at high density on tissue culture plastic. 
Previous studies have implicated BMP4, fibroblast growth factor 8 and Wnt-signalling 
pathways (Nimmagadda et al ., 2007) In addition, TNF-α known to be involved in 
inducing VCAM-1 expression, has also been shown to up-regulate VEGFR2 expression 
and function in a dose- and time-dependent manner, as well as the expression of its co-
receptor neuropilin-1 in human endothelium (Giraudo et al ., 1998).  
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The aforementioned potential induction of VEGFR2 may contribute to the enhanced 
networks formed by endothelialised MSCs (Smadja et al., 2007). In addition, it may 
explain why endothelialised MSCs were detected within the CAM blood vessels, whilst 
MSCs pre-cultured in standard culture conditions could not be detected in these vessels. 
VEGFR2-positive endothelialised MSCs may have adopted a more migratory phenotype 
in response to paracrine stimulation. Molecular blockade of VEGFR2 has been shown to 
inhibit several critical steps involved in angiogenesis. VEGFR2 blockade attenuated EC 
proliferation, reduced migration, and disrupted differentiation and formation of capillary-
like networks (Li et al., 2005; Koolwijk et al., 2001).  Interestingly, both PECAM-1 and 
PDGFR signalling was shown to decrease in endothelialised MSCs cultured on Matrigel. 
A number of previous studies have demonstrated that PECAM-1 can be downregulated 
during angiogenesis in HUVECs (Romero et al., 1997; Berger et al ., 1993; Delisser et al 
., 1997). In this study, PDGFRα signalling has been shown to regulate PECAM-1 
(Chapter 4 Results; section 4.56) and may explain the observed decrease in PECAM-1 
expression. 
 
 
The implanted endothelialised MSCs resulted in enhanced CAM blood vessel growth. 
This enhanced growth may be attributed to the MSCs providing increased paracrine 
angiogenic stimulation and/or to direct integration of the endothelialised MSCs within the 
CAM vasculature.  Endothelialised MSCs were found to incorporate in vitro into 
preformed endothelial networks and were distributed in vivo around CAM blood vessels 
suggesting endothelialised MSCs may incorporate into the pre-existing CAM 
vasculature, although longer time periods would be needed to fully assess functional 
incorporation as well as improved confocal microscopy techniques. The endothelialised 
MSCs may also result in enhanced blood vessel growth by providing an increased 
source of angiogenic factors. Bone marrow MSCs have been shown in a number of 
studies to secrete differential levels of numerous cytokines including EGF, keratinocyte 
growth factor, insulin like growth factor  1, VEGF-A and PDGF-BB (Burchfield et al ., 
2008; Tang et al., 2005b). Indeed, this study has shown that VEGF-A is significantly 
enhanced in endothelialised MSCs. It would therefore be interesting to determine if 
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knockdown of VEGF-A in endothelialised MSCs, reduced the pronounced blood vessel 
growth.  
 
5.5. Summary 
• In vitro Matrigel culture induced endothelialised MSCs to express low levels of 
VEGFR2, enhanced VE-cadherin but decreased PECAM-1 expression  
• Endothelialised MSCs formed enhanced network assemblies in vitro expressing 
vWF, PECAM-1, VE-cadherin and possible VEGFR2  
• Endothelialised MSCs formed enhanced networks in ovo  
• Endothelialised MSCs in ovo increased expression of  vWF, PECAM1 and 
VEGFR2 and VE-cadherin was promoted to the cell surface 
• Endothelialised MSCs enhanced CAM blood vessel growth and localised to the 
surface of blood vessels 
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CHAPTER 6. FINAL DISCUSSION 
 
6.1. Potential therapeutic strategies 
 
Therapeutic angiogenesis/vasculogenesis is a promising option for treating peripheral 
artery diseases, ischaemic heart diseases, and cerebral ischaemia. Clinical trials have 
confirmed that autologous cell therapies using BM-derived or circulating blood-derived 
progenitor cells are safe and provide beneficial effects (Li et al., 2009a; Iba et al., 2002; 
Tateishi-Yuyama et al., 2002; Huang et al ., 2004; Riha et al., 2005). Interestingly, it has 
been shown that highly differentiated cells may lose their therapeutic potential, as adult 
ECs provide no benefits to postnatal neovascularisation (Yang et al., 2004; Sone et al., 
2007). The vascular regenerative potential of EPCs is limited, due to their sparse 
numbers in the bone marrow and peripheral circulation, low ex vivo expansion potential, 
as well as a number of coronary artery disease risk factors, including age, smoking, 
diabetes and hypercholesterolemia which all reduce EPC number, migration and 
function (Ball et al ., 2010b; Rodriguez et al .,2009).  
 
6.2. Stem cell therapy 
 
The majority of studies documenting stem cell therapy for vascular disorders have 
utilised undifferentiated stem cells, particularly ESCs. However major risks associated 
with the use of ESCs are the possibility of teratoma formation following transplantation, 
immune rejection and uncontrolled neovascularisation, which contributes to 
tumorigenesis and diabetic and age-related retinopathies (Blum et al ., 2008; Li et al ., 
2009b; Nussbaum et al ., 2007; Swijnenburg et al ., 2005; Xu et al ., 2001). It is vital 
therefore to identify, characterise, and isolate progenitor populations that will not form 
teratomas, but yet are capable of proliferation and continual differentiation into functional 
ECs for cell therapy and the development of functional vascular grafts.  
 
MSCs can be readily isolated from a variety of different tissue locations, are easily 
expanded ex vivo, are largely non-immunogenic and can differentiate towards ECs 
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during neovascularisation (Caplan et al, 2009; Devine et al ., 2003; Phinney et al ., 
2007a; Silva et al ., 2005; Tomita et al ., 2002). In addition, a number of studies have 
shown how MSCs transplanted directly into tissues, by local intravascular administration 
or by systemic delivery, can enhance neovascularisation by direct integration into blood 
vessel walls or by acting as a source of angiogenic factors, such as VEGF-A (Li et al ., 
2009a; Sasaki et al ., 2008; Shoji et al ., 2010; Xu et al ., 2010; Wakabayashi et al., 
2010; Zhang et al., 2010).  These properties make MSCs remarkably appealing for 
vascular regenerative or vascular graft applications.  Furthermore, ex vivo expansion 
and manipulation of MSCs prior to transplantation may increase the opportunities to 
improve vascular regenerative therapy. 
 
A major challenge of stem cell based vascular regeneration has been the production of 
sufficient numbers of differentiated ECs. The efficiency of endothelial differentiation from 
ESCs is typically low, ranging from 1% to 3% (Levenberg et al ., 2002; Li et al ., 2009b). 
However, one study demonstrated that 10% CD34+ progenitor cells were present by 
monolayer culturing of hESCs on murine embryonic fibroblast feeder layer for 10 days 
(Wang et al., 2007b). In addition, a further study introduced a different two-step method 
by attaching day 9 embryoid bodies to dishes, culturing them for 7–9 days, then 
mechanically isolating the center region, eventually yielding 40% cells that were positive 
for vWF (Cho et al ., 2007). Compared to ESCs, work presented in this thesis has 
demonstrated that MSC differentiation to ECs yields much higher numbers of 
differentiated ECs, with 100% of differentiated cells expressing vWF and 50% positive 
for ac-LDL uptake. Furthermore, differentiated MSCs exhibited moderately stable 
commitment to an EC lineage, limiting the possibility of dysregulated stem cell 
differentiation.  
 
Moreover, recent research on hESC-based therapy showed poor long-term engraftment 
of human ESC-derived ECs and poor cell survival by serial bioluminescence imaging (Li 
et al., 2008b). However, preliminary investigations in this study revealed that 
endothelialised MSCs are present on the surface of the CAM suggesting that they may 
  
 - 185 - 
integrate into preformed endothelial networks over longer periods of time. However to 
understand more fully the beneficial effects of MSC therapy using endothelialised MSCs, 
it will be necessary to either perform histological analysis to determine viable 
engraftment of the transplanted MSCs, or track transplanted MSCs in animal models 
over time to monitor functional engraftment. 
 
6.3. Therapeutic manipulation  
 
Defining the critical mechanisms which regulate the initiation of MSC differentiation 
towards an EC fate is crucial for the effective therapeutic manipulation of MSCs within in 
vivo environments, potentially enabling targeted modulation of neovascularisation during 
ischemia, wound healing and tumourigenesis. This study has identified Notch signalling 
as a primary mechanism regulating density dependent differentiation to ECs. Notch 
signalling is sufficient to initiate MSC commitment to ECs, by stimulating VEGFR1 and 
vWF expression and VEGF-A secretion. In addition, to consolidate further the EC fate, 
Notch-activated VEGF-A stimulated the adhesion molecules VE-cadherin and PECAM-
1, mediated through differential VEGFR1 and PDGFRα signalling respectively. Targeted 
regulation of Notch signalling could therapeutically be used to modulate MSC 
differentiation towards ECs during postnatal neovascularisation events. MicroRNAs are 
a family of small, non-coding single stranded RNAs of 19-25 nucleotides in length that 
base pair with target mRNAs invoking post-transcriptional gene silencing through mRNA 
cleavage or translational repression (He et al., 2004; Kim et al., 2005c). In this respect, 
microRNAs mimetics could be applied to potentially stimulate gene translation and 
enhance MSC endothelialisation at sites of ischemic injury or vascular injury. In contrast, 
miRNAs could be identified to repress Notch receptor translation and prevent MSC 
differentiation events and subsequent neovascularisation in pathological situation such 
as in tumorigenesis. However a single miRNA can have multiple targets, each target can 
be regulated by several miRNAs, and the effects of a specific miRNA are variable 
depending a cell context, therefore this approach is likely to be challenging. 
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An alternative approach is to modify genetically MSCs overexpressing a particular Notch 
receptor or ligand to stimulate Notch signalling, to enable controlled recruitment, 
differentiation and functional incorporation into blood vessel walls. Similarly, MSCs 
engineered to overexpress truncated Notch receptors or ligands may also enable 
repression of MSC differentiation. Recent studies have investigated the use of MSCs for 
gene therapy, including transplantation of MSCs transiently expressing VEGF for the 
improvement of heart function in myocardial rat infarction models (Kumar et al ., 2008; 
Tang et al ., 2006) MSCs expressing BMP2 to promote bone formation and MSCs as a 
vehicle for interferon-β delivery into tumors in mice have also been reported (Studeny et 
al ., 2002). In addition, genetically modified MSCs have been used in several therapeutic 
applications in pre-clinical models of human diseases (Kumar et al ., 2008). However 
concerns regarding the exposure to viral vectors and foreign genetic material have to be 
considered. 
 
6.4. Notch regulation of stem cell differentiation 
 
It should be noted that a number of previous studies have demonstrated that Notch 
signalling is an important mechanism involved in regulating stem cell differentiation to 
chondrocytes (Oldershaw et al ., 2008) cardiomyocytes (Li et al ., 2006) and neurons 
(Dezawa et al ., 2004). In studies inducing chondrogenic differentiation, aggregates were 
cultured in serum free medium containing a chondrogenic differentiation supplement for 
up to 14 days. Notch signalling was shown to be necessary to initiate chondrogenesis, 
but had to be switched off for chondrogenesis to proceed to completion (Oldershaw et al 
., 2008). In addition, MSCs transfected with the intracellular domain of the Notch 
receptor (NICD) stimulated with neural differentiation factors, efficiently induced MSCs 
with neuronal characteristics (Dezawa et al ., 2004). However in both these studies, it is 
unclear whether Notch signalling in MSCs cultured without differentiation supplements 
would be sufficient to induce differentiation. In this thesis, high MSC density and 
subsequent Notch signalling did not result in the induction of the chondrogenic gene 
Col2A1 or Col9A2, suggesting that Notch signalling alone in two dimensional culture is 
not sufficient to initiate chondrogenesis. However, Notch signalling alone has been 
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shown to be sufficient to stimulate the differentiation of MSCs to cardiomyocytes when 
MSCs and cardiomyocytes were co-cultured together (Li et al ., 2006). The overall 
effects of Notch signalling activation are therefore likely to be dependent on the specific 
Notch ligands and receptors involved, the cell type being stimulated and the timing of the 
activation.  
 
6.5. MSCs as a vascular progenitor cell 
 
Recently it has been shown that Notch signalling alone, stimulated by using immobilised 
Jagged-1, transfected with the intracellular domain of the Notch receptor or following co-
culture with fibroblasts overexpressing the Notch ligand DLL1, was sufficient to induce 
the vSMC markers SM-MHC-1 and myocardin in MSCs (Kurpinski et al ., 2010). Our 
preliminary studies have also detected a significant up-regulation of vSMC markers, 
including SM-MHC-1 after MSCs were cultured at high density for 24 hours, suggesting 
that at this early time point MSCs are forming a vascular progenitor cell with the 
capability of differentiating towards an EC or vSMC fate. Moreover, the vSMC markers 
were markedly decreased with time as the EC fate was consolidated. Thus, 
understanding the mechanisms driving density differentiation to ECs may enable 
manipulation of this differentiation pathway to generate vSMCs. However, it must be 
noted that the appearance of vSMC markers alone is not sufficient to identify MSC to 
vSMC differentiation. Functional responses of differentiated MSCs must be assessed, 
including intracellular responses to calcium signalling agonists (Hill et al ., 2010) and 
contractility (Davis et al ., 1992). Interestingly, recently studies have suggested that 
MSCs can adopt both a vSMC-like and an EC-like state simultaneously (Lozito et al ., 
2009 a, b). Direct co-culture of MSCs with HUVECs increased mRNA expression of both 
αSMA and PECAM-1. However, since MSCs express high levels of αSMA 
endogenously, differentiation to vSMCs can only be suggested by the expression of late 
vSMC markers including SM-MHC-1 and desmin.  
 
6.6. Density dependent differentiation of MSCs to ECs in vivo 
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It is important to consider whether high MSC density is potentially representative of an in 
vivo situation, such that the in vitro Notch signalling identified in this study would also 
occur in vivo, either at a wound site, during neovascularisation of a tumour or in 
ischaemia. As previously discussed, BM-derived MSCs have the capacity to leave the 
BM, circulate in the blood and home to injured tissues. Studies have shown that when, 
1x106 MSCs were administered, 7.4x102 MSCs were detected in wounded murine 
dermis (Sasaki et al ., 2008). In addition, another study documented that when mice 
were injected with 1x106 MSCs, approximately 9x102 MSCs were detected in 1cm2 of 
wounded murine skin (Wu et al ., 2007). Thus, using these murine models only a limited 
proportion of injected MSCs reached sites of neovascularisation. However, studies 
determining the number of detected MSCs reaching sites of active vascular remodelling 
or neovascularisation, such as during ischaemia or tumourigenesis are limited. To 
increase the abundance of MSCs reaching sites of neovascularisation and reaching a 
critical density to initiate Notch signalling, more specific targeting of MSCs to sites of 
repair and regeneration is required.  It is likely that MSCs residing in blood vessel walls 
will rapidly respond to minor vascular injuries, however it is not known whether their 
numbers will be sufficient to reach high density. Major vascular damage or pathological 
neovascularisation will require a greater number of MSCs, however the chemotactic 
stimulus mediated in part by hypoxia will induce a greater number of MSCs to be 
recruited to these sites.  
 
This study demonstrates that a high density of MSCs in vitro is required to initiate Notch 
signalling and induce EC differentiation events (Figure 6.1). However, a significantly 
lower number of MSCs might be sufficient in vivo to promote EC differentiation due to 
the three dimensional environment: Irrespective of whether the high MSC density is 
attained in vivo, this study has shown that MSCs can be induced to differentiate towards 
an EC lineage in vitro and has identified an important in vitro culture method to pre-
condition MSCs towards an EC fate prior to therapeutic utilisation in vivo. Thus 
optimised culture methods could be developed to accelerate the MSC-to-EC 
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differentiation event, enabling the endothelialised MSCs to be rapidly administered in 
vivo for vascular repair or regeneration therapies.  
 
The work presented in this thesis demonstrates not only a novel density dependent 
mechanism for differentiation of MSCs to ECs, which advances our current 
understanding of this crucial differentiation event during vascular wall regeneration, but 
also provides a potentially unrecognised opportunity to regulate MSCs contribution to  
postnatal neovascularisation.  
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Figure 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Model of how Notch signalling initiates MSCs to EC commitment  
(I) Schematic model of cell density dependent regulation of VEGFR1 and vWF expression by 
MSCs. In MSC-L, Notch signalling is low and VEGFR1 is not expressed. In MSC-H, cell-cell 
contact enhances Notch receptor activation which induces expression of VEGFR1, enhances 
autocrine VEGF-A expression, and induces punctuate perinuclear vWF immunostaining. By 24 
hours, newly synthesized VEGFR1 is mainly in the Golgi, with low levels of VEGFR1signalling at 
the cell surface. VEGF-A, through PDGFRs, induces PECAM-1. Subsequently, Notch and VEGF-
A signalling induce VE-cadherin cell-cell contacts (not shown). (II) Co-ordinated pathways of MSC 
differentiation to ECs. Notch signals stimulate expression of VEGFR1, VEGF-A, VE-cadherin and 
vWF, and induce EC morphology. Upregulated VEGF-A further activates Notch, and stimulates 
PECAM-1 and VE-cadherin expression and EC commitment 
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6.7. Summary 
 
This study provides evidence that MSC density is an important microenvironmental 
factor in regulating the in vitro differentiation of MSCs to ECs and also demonstrates that 
a proportion of MSCs can be differentiated to a functional EC under these conditions. 
Notch signalling was the primary stimulus initiating MSC commitment to an EC lineage, 
whilst VEGF-A stimulation was required to consolidate the EC fate. This study has 
identified a novel approach for generating ECs from MSCs and isolating and expanding 
these endothelialised MSCs may provide new opportunities for in vitro engineering of 
artificial vascularised tissues based on endothelialised MSCs. The mechanisms 
identified could be utilised to pre-condition MSCs prior to in vivo implantation, to improve 
vascular repair or regeneration events such as in ischaemia or wound healing. 
Conversely, they could provide therapeutic targets to inhibit in vivo neovascularisation 
events, such as during tumourigenesis. Taken together, this study demonstrates the 
potential of MSCs to differentiate to a functional EC, their prospective therapeutic role 
during postnatal neovascularisation, and conveys potential pharmacologic targeting to 
regulate MSC derived vascularisation.  
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